UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~September~~March 3031, ~~2024~~2025

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-39580

Immunome, Inc.

(Exact name of registrant as specified in its charter)

Delaware	77-0694340
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

18702 N. Creek Parkway, Suite 100 Bothell, WA	98011
(Address of principal executive offices)	(Zip Code)

(425) 939-7410

(Registrant’s telephone number, including area code)

Not applicable.

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value		IMNM		The Nasdaq Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒	Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

There were 6287,~~416~~012,~~845~~328 shares of the registrant’s common stock outstanding as of ~~November~~May 87, ~~2024~~2025.

Table of Contents

TABLE OF CONTENTS

		Page
	PART I – FINANCIAL INFORMATION

Item 1.	Financial Statements (Unaudited)
	- Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023	3
	- Condensed Consolidated Balance Sheets as of March 31, 2025 and December 31, 2024	3
	- Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended September 30, 2024 and 2023	4
	- Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three Months Ended March 31, 2025 and 2024	4
	- Condensed Consolidated Statements of Changes in Stockholders’ Equity for the Three and Nine Months Ended September 30, 2024 and 2023	5
	- Condensed Consolidated Statements of Changes in Stockholders’ Equity for the Three Months Ended March 31, 2025 and 2024	5
	- Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2024 and 2023	7
	- Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2025 and 2024	6
	- Notes to Condensed Consolidated Financial Statements	98

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations.	2320
Item 3.	Quantitative and Qualitative Disclosures about Market Risk.	3529
Item 4.	Controls and Procedures.	3529

	PART II – OTHER INFORMATION

Item 1.	Legal Proceedings.	3629
Item 1A.	Risk Factors.	3629
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds.	9589
Item 3.	Defaults Upon Senior Securities.	9589
Item 4.	Mine and Safety Disclosures.	9589
Item 5.	Other Information.	9589
Item 6.	Exhibits.	9690

	SIGNATURES

Table of Contents

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements.

IMMUNOME, INC.

Condensed Consolidated Balance Sheets

(Inin thousands, except share and per share ~~data~~amounts)

(unaudited)


	March 31, 2025		December 31, 2024
	September 30, 2024		December 31, 2023
Assets
Current assets:
Cash and cash equivalents	$	~~155~~257,~~568~~613	$	98143,~~679~~351
Marketable securities		8459,~~562~~710		3973,~~463~~952
Prepaid expenses and other current assets		35,~~910~~807		64,~~561~~036
Total current assets		~~244~~323,~~040~~130		~~144~~221,~~703~~339
Property and equipment, net		710,~~172~~953		210,~~073~~113
Operating right-of-use assets		24,~~388~~163		14,~~564~~278
Restricted cash		100		100
Other long-term assets		34,~~198~~347		~~100~~4,411
Total assets	$	~~256~~342,~~898~~693	$	~~148~~240,~~540~~241
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	39,~~518~~126	$	314,~~311~~189
Accrued expenses and other current liabilities		2617,~~331~~656		833,~~025~~177
Deferred revenue, current		94,~~679~~015		106,~~493~~941
Total current liabilities		3930,~~528~~797		2154,~~829~~307
Deferred revenue, non-current		—		5,489
Operating lease liabilities, net of current portion		4,770		4,769
Operating lease liabilities, net of current portion		2,464		1,340
Total liabilities		35,567		59,076
Total liabilities		41,992		28,658
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued or outstanding at September 30, 2024 and December 31, 2023		—		—
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued or outstanding at March 31, 2025 and December 31, 2024		—		—
Common stock, $0.0001 par value; 300,000,000 shares authorized at September 30, 2024 and December 31, 2023; 60,422,062 and 43,251,778 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively		6		4
Common stock, $0.0001 par value; 300,000,000 shares authorized at March 31, 2025 and December 31, 2024; 86,955,855 and 64,460,829 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively		9		6
Additional paid-in capital		~~650~~864,~~351~~530		~~342~~696,~~663~~872
Accumulated other comprehensive income		70		22
Accumulated other comprehensive (loss) income		(3)		57
Accumulated deficit		(~~435~~557,~~521~~410)		(~~222~~515,~~807~~770)
Total stockholders’ equity		~~214~~307,~~906~~126		~~119~~181,~~882~~165
Total liabilities and stockholders’ equity	$	~~256~~342,~~898~~693	$	~~148~~240,~~540~~241

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

IMMUNOME, INC.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Inin thousands, except share and per share ~~data~~amounts)

(unaudited)

Three Months Ended ~~September~~March 3031,

~~Nine Months Ended September 30,~~

~~2024~~2025

~~2023~~2024

~~2024~~

~~2023~~

Collaboration revenue

2,~~910~~926

31,~~565~~029

~~6,303~~

~~10,192~~

Operating expenses:

In-process research and development

~~6,706~~—

—111,954

~~124,972~~

—

Research and development

3736,~~200~~872

315,~~823~~369

~~81,652~~

~~13,452~~

General and administrative

910,~~526~~690

46,~~375~~005

~~22,509~~

~~11,617~~

Total operating expenses

5347,~~432~~562

8133,~~198~~328

~~229,133~~

~~25,069~~

Loss from operations

(5044,~~522~~636)

(4132,~~633~~299)

~~(222,830)~~

~~(14,877)~~

Interest income

32,~~422~~996

~~288~~2,807

~~10,116~~

~~705~~

Net loss

(4741,~~100~~640)

(4129,~~345~~492)

~~(212,714)~~

~~(14,172)~~

Net loss per share, basic and diluted

(0.7852)

(02.3651)

~~(3.72)~~

~~(1.16)~~

Weighted-average shares outstanding, basic and diluted

6079,~~205~~410,~~327~~354

1251,~~202~~544,~~335~~383

~~57,239,668~~

~~12,194,277~~

Comprehensive loss:

Net loss

(4741,~~100~~640)

(4129,~~345~~492)

~~(212,714)~~

~~(14,172)~~

Unrealized gain on marketable securities

—

Unrealized loss on marketable securities

(60)

(18)

Comprehensive loss

(4741,~~032~~700)

(4129,~~345~~510)

~~(212,666)~~

~~(14,172)~~

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

IMMUNOME, INC.

Condensed Consolidated Statements of Changes in Stockholders’ Equity

(Inin thousands, except share ~~data~~amounts)

(unaudited)


						Accumulated
				Additional		Other				Total
	Common Stock			Paid-in		Comprehensive		Accumulated		Stockholders'
	Shares	Amount		Capital		Income (Loss)		Deficit		Equity
Balance at December 31, 2023	43,251,778	$	4	$	342,663	$	22	$	(222,807)	$	119,882
Balance at December 31, 2024	64,460,829	$	6	$	696,872	$	57	$	(515,770)	$	181,165
Share-based compensation expense	—		—		25,~~159~~703		—		—		25,~~159~~703
Issuance of common stock under Zentalis License Agreement	2,298,586		—		23,388		—		—		23,388
Issuance of common stock for public offering, net of commissions and offering costs of $10,755	22,258,064		3		161,742		—		—		161,745
Issuance of common stock under the Ayala Asset Purchase Agreement	2,175,489		—		50,645		—		—		50,645
Exercise of stock options	236,962		—		213		—		—		213
Issuance of common stock for public offering, net of commissions and offering costs of $14,592	11,500,000		2		215,408		—		—		215,410
Unrealized loss on marketable securities	—		—		—		(60)		—		(60)
Exercise of stock options	125,704		—		171		—		—		171
Net loss	—		—		—		—		(41,640)		(41,640)
Exercise of common stock warrants	342,686		—		3,427		—		—		3,427
Balance at March 31, 2025	86,955,855	$	9	$	864,530	$	(3)	$	(557,410)	$	307,126
Unrealized loss on marketable securities	—		—		—		(18)		—		(18)
Net loss	—		—		—		—		(129,492)		(129,492)
Balance at March 31, 2024	59,694,243		6		637,861		4		(352,299)		285,572
Share-based compensation expense	—		—		3,227		—		—		3,227
Exercise of stock options	289,041		—		859		—		—		859
Exercise of common stock warrants	30,371		—		304		—		—		304
Unrealized loss on marketable securities	—		—		—		(2)		—		(2)
Net loss	—		—		—		—		(36,122)		(36,122)
Balance at June 30, 2024	60,013,655		6		642,251		2		(388,421)		253,838
Share-based compensation expense	—		—		4,892		—		—		4,892
Issuance of common stock in connection with BMS License Agreement Amendment	230,415		—		2,699		—		—		2,699
Exercise of stock options	177,992		—		509		—		—		509
Unrealized gain on marketable securities	—		—		—		68		—		68
Net loss	—		—		—		—		(47,100)		(47,100)
Balance at September 30, 2024	60,422,062	$	6	$	650,351	$	70	$	(435,521)	$	214,906


						Accumulated
				Additional		Other				Total
	Common Stock			Paid-in		Comprehensive		Accumulated		Stockholders'
	Shares	Amount		Capital		Income		Deficit		Equity
Balance at December 31, 2023	43,251,778	$	4	$	342,663	$	22	$	(222,807)	$	119,882
Share-based compensation expense	—		—		2,159		—		—		2,159
Issuance of common stock under Zentalis License Agreement	2,298,586		—		23,388		—		—		23,388
Issuance of common stock under the Ayala Asset Purchase Agreement	2,175,489		—		50,645		—		—		50,645
Issuance of common stock for public offering, net of commissions and offering costs of $14,592	11,500,000		2		215,408		—		—		215,410
Exercise of stock options	125,704		—		171		—		—		171
Exercise of common stock warrants	342,686		—		3,427		—		—		3,427
Unrealized loss on marketable securities	—		—		—		(18)		—		(18)
Net loss	—		—		—		—		(129,492)		(129,492)
Balance at March 31, 2024	59,694,243	$	6	$	637,861	$	4	$	(352,299)	$	285,572

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

IMMUNOME, INC.

Condensed Consolidated Statements of Changes in Stockholders’ Equity

(In thousands, except share data)

(unaudited)


				Additional				Total
	Common Stock			Paid-in		Accumulated		Stockholders'
	Shares	Amount		Capital		Deficit		Equity
Balance at December 31, 2022	12,128,843	$	1	$	132,653	$	(116,001)	$	16,653
Share-based compensation expense	—		—		1,200		—		1,200
Issuance of common stock under prior ATM, net of $1 of issuance costs	5,925		—		34		—		34
Issuance of common stock	55,250		—		221		—		221
Vesting of restricted stock awards	4,166		—		24		—		24
Net loss	—		—		—		(4,270)		(4,270)
Balance at March 31, 2023	12,194,184		1		134,132		(120,271)		13,862
Share-based compensation expense	—		—		998		—		998
Vesting of restricted stock awards	6,249		—		35		—		35
Net loss	—		—		—		(5,557)		(5,557)
Balance at June 30, 2023	12,200,433		1		135,165		(125,828)		9,338
Share-based compensation expense	—		—		1,072		—		1,072
Vesting of restricted stock awards	2,083		—		11		—		11
Net loss	—		—		—		(4,345)		(4,345)
Balance at September 30, 2023	12,202,516	$	1	$	136,248	$	(130,173)	$	6,076

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

IMMUNOME, INC.

Condensed Consolidated Statements of Cash Flows

(Inin thousands)

(unaudited)


	~~Nine~~Three Months Ended ~~September~~March 3031,
	~~2024~~2025		~~2023~~2024
Cash flows from operating activities:
Net loss	$	(~~212~~41,~~714~~640)	$	(14129,~~172~~492)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		~~1,117~~611		~~306~~157
Amortization of right-of-use asset		~~390~~115		~~165~~106
Accretion of discounts on marketable securities		(~~2,363~~818)		~~332~~(538)
Share-based compensation expense		105,~~278~~703		32,~~340~~159
Charge for purchase of in-process research and development assets		~~124,972~~—		—111,954
Changes in operating assets and liabilities:
Prepaid expenses and other assets		2(1,~~269~~707)		12,~~553~~473
Accounts payable		~~256~~(3,810)		712,396
Accrued expenses and other current liabilities		13(8,~~507~~521)		~~(1,452)~~669
Deferred revenue		(62,~~303~~926)		19(1,~~808~~029)
Operating lease liabilities		(~~143~~62)		(6025)
Net cash (used in) provided by operating activities		(68,734)		9,891
Net cash used in operating activities		(53,055)		(11,170)
Cash flows from investing activities:
Purchases of in-process research and development assets		(466,~~086~~246)		—(35,067)
Purchases of marketable securities		(112,688)		—
Maturities of marketable securities		15,000		—
Maturities of marketable securities		70,000		—
Purchases of property and equipment		(3,665)		(2,164)
Purchases of property and equipment		(6,047)		(482)
Net cash provided by (used in) investing activities		5,089		(37,231)
Net cash used in investing activities		(94,821)		(482)
Cash flows from financing activities:
Proceeds from public offering		~~230~~172,~~002~~500		—230,002
Payment of offering costs		(1410,~~828~~485)		(~~125~~14,155)
Prepayments from PIPE transaction recorded as deposit liability		—		61,000
Proceeds from exercise of stock options		213		171
Proceeds from exercise of stock options		1,539		—
Proceeds from exercise of common stock warrants		—		3,427
Proceeds from exercise of common stock warrants		3,731		—
Net cash provided by financing activities		162,228		219,445
Proceeds from issuance of common stock under prior ATM, net		—		34
Net increase in cash and cash equivalents and restricted cash		114,262		171,044
Net cash provided by financing activities		220,444		60,909
Cash and cash equivalents and restricted cash at beginning of period		143,451		98,779
Net increase in cash and cash equivalents and restricted cash		56,889		70,318
Cash and cash equivalents and restricted cash at end of period	$	257,713	$	269,823
Cash and cash equivalents and restricted cash at beginning of period		98,779		20,423
Cash and cash equivalents and restricted cash at end of period	$	155,668	$	90,741
Reconciliation of cash and cash equivalents and restricted cash:
Cash and cash equivalents	$	~~155~~257,~~568~~613	$	90269,~~641~~723
Restricted cash		100		100
Total cash, cash equivalents, and restricted cash	$	~~155~~257,~~668~~713	$	90269,~~741~~823

Table of Contents

IMMUNOME, INC.

Condensed Consolidated Statements of Cash Flows

(Inin thousands)

(unaudited)


	~~Nine~~Three Months Ended ~~September~~March 3031,
	~~2024~~2025		~~2023~~2024
Supplemental disclosures of non-cash investing and financing activities:
Issuance of common stock in exchange for in-process research and development assets	$	~~76,732~~—	$	—74,033
Net liabilities assumed from purchases of in-process research and development assets	$	~~2,041~~—	$	—2,041
Purchase of in-process research and development assets in accounts payable	$	113	$	—
Purchase of in-process research and development assets in accounts payable and accrued expenses	$	—	$	813
Right-of-use assets obtained in exchange for operating lease liabilities	$	1,189	$	—
Offering costs in accounts payable	$	270	$	437
Remeasurement of operating right-of-use asset and lease liability due to lease extension	$	—	$	226
Purchases of property and equipment in accounts payable and accrued expenses and other current liabilities	$	592	$	594
Issuance of common stock to certain board of directors in lieu of accrued compensation	$	—	$	221
Offering costs in accounts payable and accrued expenses and other current liabilities	$	—	$	5
Purchases of property and equipment in accounts payable and accrued expenses and other current liabilities	$	541	$	315

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

IMMUNOME, INC.

Notes to Condensed Consolidated Financial Statements

(~~Unaudited~~unaudited)

1. Nature of the business

Organization

Immunome, Inc., or the Company or Immunome, is a ~~biotechnology~~clinical-stage targeted oncology company ~~focused~~committed onto ~~the~~developing ~~development~~first-in-class ofand best-in-class targeted ~~oncology~~ therapies designed to improve outcomes for cancer patients. ~~The~~Since its inception, the Company ~~believes~~has ~~that~~devoted ~~the~~substantially ~~pursuit~~all ofits ~~novel~~resources orto ~~underexplored~~research ~~targets~~and ~~will~~development, beraising ~~central~~capital, tobuilding ~~the~~its ~~next~~management ~~generation~~team, ofextending ~~transformative~~its ~~therapies~~intellectual property portfolio, and itexecuting strategic partnerships and transactions. The Company is ~~dedicated~~subject to ~~developing~~risks ~~targeted~~and ~~cancer~~uncertainties ~~therapies~~common ~~with~~to ~~first~~early-~~in-class~~stage ~~and~~companies ~~best-~~in~~-class~~ ~~potential.~~the ~~The~~biotechnology ~~Company’s~~industry ~~goal~~including, isbut not limited to, ~~establish~~risks aassociated ~~broad~~with ~~pipeline~~research, development, and manufacturing activities, uncertain results of preclinical and clinical ~~assets~~testing, ~~and~~development ~~develop~~of ~~these~~new ~~assets~~technological ~~into~~innovations ~~approved~~and products ~~for~~by ~~commercialization.~~competitors, Todependence ~~support~~on ~~that~~key ~~goal~~personnel, ~~the~~partners ~~Company~~and ~~invests~~third-party ~~heavily~~vendors, inprotection ~~both~~of ~~business~~proprietary ~~development~~technology, compliance with government regulations, regulatory approval of products and ~~internal~~the ~~discovery~~ability ~~programs.~~to secure additional capital to fund operations.

Immunome is advancing a pipeline comprising one clinical and two preclinical assets. The clinical asset is AL102, an investigational gamma secretase inhibitor, or GSI, currently under evaluation in a Phase 3 trial for the treatment of desmoid tumors. AL102 was acquired from Ayala Pharmaceuticals, Inc. on March 25, 2024. The preclinical assets are IM-1021, a receptor tyrosine kinase-like orphan receptor 1, or ROR1, antibody-drug conjugate, or ADC, and IM-3050, a fibroblast activation protein, or FAP, targeted radioligand therapy, or RLT.

On October 2, 2023, the Company completed its merger with Morphimmune Inc., or Morphimmune, a preclinical biotechnology company focused on developing targeted oncology therapies, and Morphimmune became a wholly owned subsidiary of Immunome.

Liquidity

The Company has incurred significant operating losses since inception and expects to continue to incur losses from operations for the foreseeable future as it pursues development of its therapeutic candidates and other programs. As of ~~September~~March 3031, ~~2024~~2025, the Company had an accumulated deficit of $~~435~~557.54 million, cash and cash equivalents of $~~155~~257.6 million, and marketable securities of $8459.67 million. The Company has not generated any product revenue to date and does not expect to generate product revenue until it successfully completes development and obtains regulatory approval for at least one of its product candidates.

Through ~~September~~March 3031, ~~2024~~2025, the Company has funded its operations primarily through sales of equity securities ~~and strategic partnerships and transactions as well as expense reimbursements from a government contract that ended in 2022~~. The Company expects that its existing cash, cash equivalents and marketable securities at ~~September~~March 3031, ~~2024~~2025 ~~are~~will be sufficient to fund its current and planned operating expenses and capital expenditures for at least 12 months from the filing date of this Quarterly Report on Form 10-Q. Beyond that date, the Company may need to raise additional capital through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements to achieve its longer-term business objectives.

Table of Contents

2. Summary of significant accounting policies

Basis of presentation

The accompanying unaudited interim financial statements have been prepared in accordance with the accounting principles generally accepted in the United States, or GAAP, and following the requirements of the Securities and Exchange Commission, or the SEC, for interim reporting. Certain information and disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted. Accordingly, these unaudited condensed consolidated financial statements and accompanying notes should be read in conjunction with the Company’s annual financial statements and related notes included in the Company’s Annual Report on Form 10-K filed with the SEC on March 2819, ~~2024~~2025, which provide a more complete discussion of the Company’s accounting policies and certain other information. The December 31, ~~2023~~2024 condensed consolidated balance sheet has been derived from the Company’s annual financial statements. These unaudited condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and include all adjustments that management believes to be necessary for a fair presentation of the Company’s financial information. Interim results are not necessarily indicative of results for a full year or any future interim period.

Table of Contents

Principles of consolidation

The condensed consolidated financial statements include the accounts of the Company and its wholly owned ~~subsidiaries~~subsidiary. All intercompany accounts and transactions have been eliminated in consolidation.

Use of estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the unaudited condensed consolidated financial statements and the accompanying notes. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates. The Company’s significant accounting estimates include, but are not necessarily limited to, revenue recognition, the estimated fair value of share-based awards, accrued research and development expenses and the fair value of acquired in-process research and development assets.

Segment and geographic information

Operating segments are defined as components of an entity about which separate discrete information is available and regularly reviewed by the chief operating decision maker, ~~its~~or ~~Chief Executive Officer~~CODM, in deciding how to allocate resources and in assessing performance. The Company’s ~~has~~CODM ~~determined~~is ~~that~~its itChief ~~operates~~Executive Officer. The CODM views the Company’s operations and manages its business as one operating and reporting segment, which is the business of development of targeted oncology therapies exclusively in the United States.

Concentration of credit risk

Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents and marketable securities. The Company maintains deposits in a financial institution in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company’s deposits are held at a financial institution that management believes to be of high credit quality and the Company has not experienced any losses on these deposits. Management also believes that the Company is not exposed to significant credit risk as it relates to marketable securities because the Company only invests in U.S government securities.

Restricted cash

Restricted cash represents collateral provided for a letter of credit issued as a security deposit in connection with one of the Company’s leased facilities. Cash will be released from restriction upon termination of the lease and satisfaction of any applicable termination conditions. Restricted cash was $0.1 million at both ~~September~~March 3031, ~~2024~~2025 and December 31, ~~2023~~2024.

Table of Contents

Asset acquisitions

Acquisitions of assets or a group of assets that do not meet the definition of a business are accounted for as asset acquisitions, with a cost accumulation model used to determine the cost of the acquisition. Common stock issued as consideration in an acquisition of assets is generally measured based on the acquisition date fair value of the equity interests issued. Direct transaction costs are recognized as part of the cost of an acquisition of assets. Intangible assets that are acquired in an asset acquisition for use in research and development activities that have an alternative future use are capitalized as in-process research and development, or IPR&D. Acquired IPR&D that has no alternative future use is expensed immediately as a component of in-process research and development expense in the condensed consolidated statements of operations and comprehensive loss.

In addition to upfront consideration, acquisitions of assets may also include contingent consideration payments to be made for future milestone events or royalties on net sales of future products. The Company assesses whether such contingent consideration is subject to liability classification and fair value measurement or meets the definition of a derivative. Contingent consideration payments in an acquisition of assets not required to be accounted for as a liability at fair value are recognized when the contingency is resolved and the consideration is paid or becomes payable. Contingent consideration payments made prior to regulatory approval are expensed as incurred.

Research and development expenses

Research and development costs consist of costs incurred in performing research and development activities, including salaries and bonuses, share-based compensation, employee benefits, facilities costs, laboratory supplies, depreciation and amortization, and preclinical and clinical development expenses, including process development, validation, and the manufacture of drug supplies, costs to conduct clinical trials, and amounts incurred under license agreements, consulting agreements and other contracted services. Research and development costs are expensed as incurred. Non-refundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized as prepaid expenses until the related goods are delivered or services are performed. Such payments are evaluated for current or long-term classification based on when such services are expected to be received.

The Company estimates preclinical, clinical trial, and other research and development expenses based on the services performed pursuant to contracts with research institutions, contract manufacturing organizations, and third-party service providers that conduct and manage preclinical studies and clinical trials and perform research services on its behalf. The Company records these costs of research and development activities based on the estimated services provided but not yet invoiced and includes these costs in accrued expenses and other current liabilities in the consolidated balance sheets and in research and development expense in the consolidated statements of operations.

The Company accrues these costs based on factors such as estimates of the work completed in accordance with agreements established with its third-party service providers, actual levels of patient enrollment and reported activities at clinical trial sites. The Company makes judgments and estimates in determining the accrued expenses balance. As actual costs become known, the Company adjusts its accrued expenses. The Company has not experienced any material differences between accrued costs and actual costs incurred. However, the status and timing of actual services performed may vary from the Company’s estimates, resulting in adjustments to expenses in future periods. Changes in these estimates that result in material changes to the Company’s accrued expenses could materially affect the Company’s results of operations.

Net loss per share

Basic net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding for the period, including the effect of dilutive securities.

11As the Company was in a net loss position for the three months ended March 31, 2025 and 2024, diluted net loss per share is the same as basic net loss per share because the effects of potentially dilutive securities are antidilutive.

Table of Contents

As the Company was in a net loss position for the three and nine months ended September 30, 2024 and 2023, diluted net loss per share is the same as basic net loss per share because the effects of potentially dilutive securities are antidilutive.

The following potentially dilutive securities have been excluded from the computation of diluted net loss per share for the periods presented because including them would have been anti-dilutive (on an as-converted basis):


	~~September~~March 3031,
	~~2024~~2025	~~2023~~2024
Stock options outstanding	11,~~451~~498,~~856~~848	38,~~024~~531,~~419~~683
Common stock warrants	—	~~500~~157,~~000~~314
	11,~~451~~498,~~856~~848	38,~~524~~688,~~419~~997

Recently adopted accounting standards

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280) – Improvements to Reportable Segment Disclosures. ASU 2023-07 requires disclosure of incremental segment information on an interim and annual basis and provides new segment disclosure requirements for entities with a single reportable segment. ASU 2023-07 is effective for all public companies for fiscal years beginning after December 15, 2023, and interim periods within fiscal periods beginning after December 15, 2024, and requires retrospective application to all prior periods presented in the financial statements. The Company adopted annual requirements under ASU 2023-07 on January 1, 2024 and adopted interim requirements under ASU 2023-07 on January 1, 2025. There was no impact on the Company’s reportable segments identified and additional required disclosures have been included in Note 11.

In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which updates income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This update also includes certain other amendments to improve the effectiveness of income tax disclosures. The amendments in this update are effective for annual periods beginning after December 15, 2024. The Company adopted ASU 2023-09 on January 1, 2025. The adoption of this ASU did not have a material impact on the condensed consolidated financial statements.

Recent accounting standards not yet adopted

In ~~December~~November ~~2023~~2024, the ~~Financial Accounting Standards Board, or~~ FASB, issued ~~Accounting~~ASU ~~Standards Update~~2024-03, orIncome ~~ASU,~~Statement ~~2023-09,~~– ~~Improvements~~Reporting toComprehensive Income ~~Tax~~– Expense Disaggregation Disclosures, ~~which~~(Subtopic ~~updates~~220-40): ~~income~~Disaggregation ~~tax~~of ~~disclosures~~Income ~~primarily~~Statement ~~related~~Expenses. toASU ~~the~~2024-03 ~~rate~~requires ~~reconciliation~~disclosure ~~and~~about ~~income~~the ~~taxes~~types ~~paid~~of ~~information.~~costs ~~This~~and ~~update~~expenses ~~also~~included ~~includes~~in certain ~~other~~expense ~~amendments~~captions topresented ~~improve~~on the ~~effectiveness of~~ income ~~tax disclosures~~statement. ~~The~~This ~~amendments~~guidance inis ~~this update are~~ effective for annual periods beginning after December 15, ~~2024.~~2026 ~~Early~~and ~~adoption~~interim isperiods ~~permitted~~beginning ~~for~~after ~~annual~~December ~~financial~~15, ~~statements~~2027. ~~that~~Early ~~have~~adoption ~~not~~is ~~yet been issued or made available for issuance~~permitted. The Company is ~~still~~currently inevaluating the ~~process~~impact of ~~determining the effect~~ this ~~ASU~~guidance ~~will have~~ on ~~the~~its condensed consolidated financial statements.

In November 2023, the FASB issued ASU 2023-07, Segment Reporting—Improvements to Reportable Segment Disclosures. ASU 2023-07 requires disclosure of incremental segment information on an interim and annual basis and provides new segment disclosure requirements for entities with a single reportable segment. ASU 2023-07 is effective for all public companies for fiscal years beginning after December 15, 2023, and interim periods within fiscal periods beginning after December 15, 2024, and requires retrospective application to all prior periods presented in the financial statements. The Company adopted annual requirements under ASU 2023-07 on January 1, 2024 and plans to adopt interim requirements under ASU 2023-07 on January 1, 2025. The Company will begin including financial statement disclosures in accordance with ASU 2023-07 in its Annual Report on Form 10-K for the year ended December 31, 2024.

3. Fair value measurement

The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:

Level 1 – Quoted prices in active markets for identical assets or liabilities.

Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

1210

Table of Contents

The following tables summarize the Company’s financial assets measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):


	~~September~~March 3031, ~~2024~~2025
	Level	Amortized Cost		Unrealized Gain		Unrealized Loss		Fair Value
Cash equivalents:
Money market funds	1	$	72255,~~878~~939	$	—	$	—	$	72255,~~878~~939
U.S. treasury securities	2		79,760		20		—		79,780
Marketable securities:
U.S. treasury securities	2		8459,~~512~~713		50—		—(3)		8459,~~562~~710
Total financial assets		$	~~237~~315,~~150~~652	$	70—	$	—(3)	$	~~237~~315,~~220~~649

	December 31, ~~2023~~2024
	Level	Amortized Cost		Unrealized Gain		Unrealized Loss		Fair Value
Cash equivalents:
Money market funds	1	$	7346,~~988~~987	$	—	$	—	$	7346,~~988~~987
U.S. treasury securities	2		2294,~~993~~379		—40		—		2294,~~993~~419
Marketable securities:
U.S. treasury securities	2		3973,~~441~~935		2217		—		3973,~~463~~952
Total financial assets		$	~~136~~215,~~422~~301	$	2257	$	—	$	~~136~~215,~~444~~358

The Company’s marketable securities consist of U.S. treasury debt securities with a contractual maturity date of up to 6 months.

4. Collaboration agreement with AbbVie

In January 2023, the Company entered into a Collaboration and Option Agreement, or the Collaboration Agreement, with AbbVie Global Enterprises Ltd., or AbbVie, pursuant to which the Company is using its discovery platform to discover and validate targets derived from patients with three specified tumor types, and antibodies that bind to such targets, which may be the subject of further development and commercialization by AbbVie. Pursuant to the terms of the Collaboration Agreement, the Company granted AbbVie an exclusive option to purchase all rights to each novel target-antibody pair, or a Validated Target Pair or VTP, that the Company generates that meets certain mutually agreed criteria, up to a maximum of 10 in total, for all human and non-human diagnostic, prophylactic and therapeutic uses throughout the world, including the development and commercialization of certain products, or Products, derived from the assigned VTP.

AbbVie paid the Company a nonrefundable upfront payment of $30.0 million in January 2023 and will be required to pay certain additional platform access payments of up to $70.0 million in aggregate based on the Company’s use of its discovery platform in connection with activities under each stage of the research plan and delivery of VTPs to AbbVie. If AbbVie exercises its option to purchase a VTP, then AbbVie will be required to pay an option exercise fee in the low single-digit millions for each of up to 10 VTPs for which it exercises an option. For each Product, the Company is eligible to receive development and commercial based milestones of up to $120.0 million in the aggregate and sales milestones of up to $150.0 million in the aggregate for the achievement of specified levels of annual net sales. The Company is also eligible to receive tiered royalties at percentage rates in the low single digits on annual net sales of any Products that are commercialized by AbbVie.

AbbVie’s obligation to pay royalties will terminate, on a Product-by-Product and country-by-country basis, upon the earlier of (a) the later of (i) 10 years following the first commercial sale for such Product in such country, or (ii) expiration of all valid claims of patent rights covering the Product in such country, and (b) the expiration of all applicable regulatory exclusivities for such Product in such country. AbbVie may terminate the Collaboration Agreement at any time for convenience upon a specified period of prior written notice.

1311

Table of Contents

The Company determined that the Collaboration Agreement represents a contract with a customer and consists of one performance obligation to provide research and development services, or R&D services, to AbbVie. The Company evaluated the options to continue the R&D services and options to purchase licenses to each VTP and concluded that these options did not represent material rights.

The Company determined the initial transaction price of the single performance obligation to be $30.0 million, as the variable consideration for additional R&D services, option exercise payments and development milestone payments are all subject to constraint at contract inception. At each reporting period, the Company will reevaluate the variable consideration subject to constraint and, if necessary, will adjust its estimate of the overall transaction price. For the sales-based royalties, the Company will recognize revenue when the related sales occur.

Revenue from the Collaboration Agreement will be recognized over the estimated performance of the R&D services using the cost-to-cost input method which the Company believes best depicts the transfer of control to the customer. Under the cost-to-cost input method, the extent of progress towards completion is measured based on the ratio of actual costs incurred to the total estimated costs expected upon satisfying the performance obligation. The Company recognized collaboration revenue of $2.9 million and $31.60 million for the three months ended ~~September~~March 3031, ~~2024~~2025 and ~~2023, respectively, and $6.3 million and $10.2 million for the nine months ended September 30,~~ 2024 ~~and 2023~~, respectively.

The following table summarizes the change in deferred revenue (in thousands):


	~~Nine~~Three Months Ended ~~September~~March 3031, ~~2024~~2025
Beginning balance	$	156,~~982~~941
Deferral of revenue		—
Recognition of revenue		(62,~~303~~926)
Balance at the end of the period	$	94,~~679~~015

As of ~~September~~March 3031, ~~2024~~2025, the Company expects to recognize the deferred revenue associated with the non-refundable upfront fee over the estimated remaining research and development period of approximately 0.7525 years.

5. Balance sheet components

Accrued expenses and other current liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):


	~~September~~March 3031, ~~2024~~2025		December 31, ~~2023~~2024
Research and development	$	1812,~~076~~456	$	124,~~794~~185
Compensation and related benefits		32,~~312~~993		25,~~734~~861
Severance accruals		824		1,436
Professional services and consulting		997		933
Professional services and consulting		2,871		1,019
Operating lease liabilities, current portion		—		63
Operating lease liabilities, current portion		257		310
Other		1,210		2,135
Other		991		732
Total accrued expenses and other current liabilities	$	17,656	$	33,177
Total accrued expenses and other current liabilities	$	26,331	$	8,025

Table of Contents

6. Employee benefit plan

The Company maintains a defined-contribution plan under Section 401(k) of the Internal Revenue Code, or the 401(k) Plan. The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. The Company assumes all administrative costs of the 401(k) Plan and makes matching contributions as defined in the 401(k) Plan document. The Company made matching contributions ~~to the 401(k) Plan~~ of $0.12 million and $0.31 million ~~for~~to the ~~three~~401(k) ~~and~~Plan ~~nine months ended September 30, 2024, respectively, and $0.1 million and $0.2 million~~ for the three ~~and nine~~ months ended ~~September~~March 3031, ~~2023~~2025 and 2024, respectively.

~~7. Asset acquisitions~~12

~~Atreca~~Table of Contents

On May 17, 2024, the Company and Atreca, Inc., or Atreca, completed an Asset Purchase Agreement, or the Atreca Purchase Agreement, initially entered into in December 2023, pursuant to which the Company acquired certain antibody-related assets and materials. No liabilities were assumed under the Atreca Purchase Agreement as of the acquisition date. The Company accounted for the transaction as an asset acquisition as substantially all of the fair value of the gross assets acquired was concentrated in a group of similar identifiable IPR&D assets. The total cost of the acquisition of $5.7 ~~million, which consisted of an upfront payment of $5~~.5 ~~million~~Strategic ~~and~~transactions ~~direct transaction costs of $0.2 million, was immediately expensed in the Company’s condensed consolidated statements of operations~~ and ~~comprehensive loss for the nine months ended September 30, 2024 since the acquired IPR&D had no alternative future use.~~ agreements

Under the Atreca Purchase Agreement, the Company will be required to pay Atreca up to $7.0 million in the aggregate upon the achievement of certain clinical development milestone events. Any potential future milestone payment amounts will be accrued when the related contingency is resolved and the milestone consideration becomes payable.

Ayala Pharmaceuticals

On March 25, 2024, the Company and Ayala Pharmaceuticals, Inc., or Ayala, completed an Asset Purchase Agreement, or the Ayala Purchase Agreement, that was entered into in February 2024, pursuant to which the Company acquired Ayala’s AL101 and varegacestat (then known as AL102) programs and assumed certain liabilities associated with the acquired assets. The upfront consideration included (i) payment of approximately $20.0 million in cash, and (ii) the issuance of 2,175,489 unregistered shares of the Company’s common stock at an aggregate fair value of $50.6 million on the acquisition date. The fair value of the shares issued to Ayala was based on the closing stock price of the Company’s common stock on March 25, 2024 of $24.00 per share less a discount of 3.0% related to unregistered share restrictions.

The Company accounted for the transaction as an asset acquisition as substantially all of the fair value of the gross assets acquired was concentrated in two programs that were grouped as a single identifiable IPR&D asset. The assets acquired in the transaction were measured based on the estimated fair value of the consideration paid of $71.3 million, which included direct transaction costs of $0.7 million.

Table of Contents

The consideration paid and the relative fair values of the assets acquired and liabilities assumed were as follows (in thousands):


	Amount
Common stock issued to Ayala	$	50,645
Upfront consideration paid to Ayala		20,039
Transaction costs		657
Consideration paid	$	71,341

Assets acquired:
In-process research and development	$	73,382
Other long-term assets		2,480
Total assets acquired	$	75,862
Liabilities assumed:
Accrued expenses	$	4,521
Total liabilities assumed	$	4,521
Net assets acquired	$	71,341

The cost attributable to the IPR&D was expensed in the Company’s condensed consolidated statements of operations and comprehensive loss for the ~~nine~~three months ended ~~September~~March 3031, 2024 since the acquired IPR&D had no alternative future use.

Under the Ayala Purchase Agreement, the Company will be required to pay Ayala up to $37.5 million in the aggregate upon the achievement of certain development, regulatory and commercial milestone events. Any potential future milestone payment amounts will be accrued when the related contingency is resolved and the milestone consideration becomes payable.

~~Morphimmune~~Zentalis Pharmaceuticals

On ~~October~~January 25, ~~2023~~2024, the Company ~~completed~~entered ~~its~~into ~~merger~~a ~~with~~license ~~Morphimmune,~~agreement orwith ~~the~~Zentalis ~~Merger~~Pharmaceuticals, ~~and acquired all of the outstanding equity interests of Morphimmune in exchange for 8~~Inc.,~~835,710~~ ~~shares~~or of the ~~Company's~~Zentalis ~~common~~License ~~stock~~Agreement, ~~based~~pursuant ~~upon~~to anwhich ~~exchange ratio of 0.3042 shares of~~ the Company’s ~~common~~received ~~stock~~an ~~for~~exclusive, ~~each~~worldwide, ~~outstanding~~royalty-bearing, ~~share~~sublicensable oflicense ~~Morphimmune~~under ~~capital~~certain ~~stock.~~intellectual ~~Under~~property ~~the~~relating ~~terms~~to ofZentalis’ ~~the~~proprietary ~~Agreement~~ADC ~~and~~platform ~~Plan of Merger and Reorganization dated as of June 28~~technology, ~~2023,~~ROR1 ~~the~~antibodies ~~Company assumed Morphimmune’s 2020 Equity Incentive Plan~~ and ~~all~~ADCs ~~outstanding~~targeting ~~options~~ROR1 to ~~purchase~~exploit ~~shares~~products ofcovered ~~Morphimmune~~by ~~capital~~or ~~stock~~incorporating ~~were converted into 2,472,563 options to purchase shares of~~ the ~~Company’s~~licensed ~~common~~intellectual ~~stock~~property ~~with~~rights, ~~a weighted average exercise price of $1.29 per share. All other terms and conditions associated with these options~~or, ~~including vesting and exercisability~~collectively, ~~are governed by~~ the ~~original~~Zentalis ~~terms~~Licensed ~~and conditions of the Morphimmune 2020 Equity Incentive Plan~~Assets.

The Company accounted for the acquisition of Morphimmune as an asset acquisition as substantially all of the fair value of the gross assets acquired was concentrated in two programs that were grouped as a single identifiable IPR&D asset. The assets acquired in the transaction were measured based on the estimated fair value of the consideration paid of $88.0 million, which included direct transaction costs of $0.8 million. The consideration paid consisted of $72.5 million of the Company’s common stock based on the closing stock price on October 2, 2023 of $8.20 per share and $14.7 million related to the value of Morphimmune’s share-based awards assumed by Immunome as of the same date. The cost of the acquisition allocated to the acquired IPR&D of $80.8 million was expensed since the acquired IPR&D had no alternative future use.13

Table of Contents

As upfront consideration for the license, the Company paid to Zentalis $15.0 million in cash and issued to Zentalis 2,298,586 unregistered shares of its common stock at an aggregate fair value of $23.4 million. The fair value of the common stock issued to Zentalis was based on the closing stock price of the Company’s common stock on January 5, 2024 of $11.12 per share less a discount of 8.5% ~~Licensing~~related ~~arrangements~~to unregistered share restrictions. The Company accounted for the transaction as an asset acquisition as substantially all of the fair value of the gross assets acquired was concentrated in a single identifiable IPR&D asset. The consideration paid to acquire the license and intellectual property rights, which included transaction costs of $0.2 million, was immediately recognized as IPR&D expense in the Company’s condensed consolidated statement of operations and comprehensive loss for the three months ended March 31, 2024 since the acquired IPR&D had no alternative future use.

As consideration for the Zentalis Asset Purchase, the Company issued to Zentalis 1,805,502 unregistered shares of its common stock at an aggregate fair value of $21.0 million. The fair value of the common stock issued to Zentalis was based on the closing stock price of the Company’s common stock on October 25, 2024 of $12.11 per share less a discount of 4.0% related to unregistered share restrictions. The consideration paid to Zentalis for the Zentalis Asset Purchase was immediately recognized as IPR&D expense.

The Company was also obligated to pay Zentalis a one-time payment of $5.0 million in cash upon the achievement of a developmental milestone, which was achieved in December 2024 and paid during the three months ended March 31, 2025. The related liability was accrued within accrued expenses and other current liabilities on the condensed consolidated balance sheet as of December 31, 2024.

Bristol-Myers Squibb

In connection with the closing of the Ayala Purchase Agreement in March 2024, the Company assumed a license agreement, the BMS License Agreement, with Bristol-Myers Squibb Company, or BMS, pursuant to which the Company obtained a worldwide, non-transferable, royalty-bearing, exclusive, sublicensable, license under certain patent rights and know-how of BMS to research, discover, develop, make, have made, use, sell, offer to sell, export, import and commercialize AL101 and ~~AL102~~varegacestat, or the BMS Licensed Compounds, and products containing AL101 or ~~AL102~~varegacestat, or the BMS Licensed Products, for all uses including the prevention, treatment or control of any human or animal disease, disorder or condition.

Under the BMS License Agreement, the Company is obligated to use commercially reasonable efforts to develop at least one BMS Licensed Product. The Company is also required to use commercially reasonable efforts to obtain regulatory approvals in certain major market countries for at least one BMS Licensed Product, as well as to affect the first commercial sale of and commercialize each BMS Licensed Product after obtaining such regulatory approval.

The Company is required to pay BMS up to approximately $142.0 million in the aggregate upon the achievement of certain clinical development or regulatory milestones for AL101 and ~~AL102~~varegacestat across multiple indications. In addition, the Company is required to pay BMS up to $50.0 million in the aggregate upon the achievement of certain commercial milestones for each BMS Licensed Product. Any potential future milestone payment amounts will be accrued when the related contingency is resolved and the milestone consideration becomes payable. BMS is also eligible to receive tiered royalties ranging from a high single-digit to a low teen percentage on annual worldwide net sales of any BMS Licensed Products. Royalty payments will be expensed in the period in which the underlying revenues are earned.

BMS has the right to terminate the BMS License Agreement in its entirety if the Company fails to fulfill its development and commercialization obligations within a defined period of time following written notice by BMS. The Company has the right to terminate the BMS License Agreement for convenience upon prior written notice to BMS. Upon termination of the BMS License Agreement by the Company for convenience or by BMS, the Company will grant an exclusive, non-transferable, sublicensable, worldwide license to BMS for certain patent rights that are necessary to develop, manufacture or commercialize the BMS Licensed Compounds or BMS Licensed Products. In exchange for such license, BMS will be obligated to pay the Company a low single-digit percentage royalty on net sales of the BMS Licensed Compounds and/or BMS Licensed Products by it or its affiliates, licensees or sublicensees, provided that the termination occurred after a specified developmental milestone for such BMS Licensed Compounds and/or BMS Licensed Products.14

Following the closing of the Ayala Purchase Agreement, on August 7, 2024, the Company and BMS entered into Amendment No. 2 to the BMS License Agreement, or the BMS License Agreement Amendment. As consideration to BMS for entering into the BMS License Agreement Amendment, the Company issued BMS 230,415 unregistered shares of its common stock at an aggregate fair value of $2.7 million. The fair value of the common stock issued to BMS was based on the closing stock price of the Company’s common stock on August 7, 2024 of $12.46 per share less a discount of 6.0% related to unregistered share restrictions. The consideration paid to BMS to amend the BMS License Agreement was immediately recognized as IPR&D expense in the Company’s condensed consolidated statement of operations and comprehensive loss for the three and nine months ended September 30, 2024. The shares issued to BMS were subsequently registered for resale on a Form S-3 filed with the SEC in October 2024.

Zentalis Pharmaceuticals

On January 5, 2024, the Company entered into a license agreement with Zentalis Pharmaceuticals, Inc., or the Zentalis License Agreement, pursuant to which the Company received an exclusive, worldwide, royalty-bearing, sublicensable license under certain intellectual property relating to Zentalis’ proprietary antibody-drug conjugate, or ADC, platform technology, ROR1 antibodies and ADCs targeting ROR1 to exploit products covered by or incorporating the licensed intellectual property rights, or, collectively, the Zentalis Licensed Assets.

Table of Contents

AsBMS ~~upfront~~has ~~consideration~~the ~~for~~right ~~the~~to ~~license,~~terminate the ~~Company~~BMS ~~paid~~License toAgreement ~~Zentalis~~in ~~$15.0~~its ~~million~~entirety inif ~~cash~~the ~~and~~Company ~~issued~~fails to ~~Zentalis~~fulfill ~~2,298,586~~its ~~unregistered~~development ~~shares~~and ofcommercialization ~~its~~obligations ~~common~~within ~~stock~~a atdefined anperiod ~~aggregate~~of ~~fair~~time ~~value~~following ofwritten ~~$23.4~~notice ~~million~~by BMS. The ~~fair~~Company ~~value~~has ofthe right to terminate the ~~common~~BMS ~~stock~~License ~~issued~~Agreement tofor ~~Zentalis~~convenience ~~was~~upon ~~based~~prior onwritten ~~the~~notice ~~closing~~to ~~stock~~BMS. ~~price~~Upon termination of the ~~Company’s~~BMS ~~common~~License ~~stock~~Agreement onby ~~January~~the 5,Company ~~2024~~for ofconvenience ~~$11.12~~or ~~per~~by ~~share~~BMS, ~~less~~the aCompany ~~discount~~will ofgrant ~~8.5%~~an ~~related~~exclusive, tonon-transferable, ~~unregistered~~sublicensable, ~~share~~worldwide ~~restrictions.~~license ~~The~~to ~~Company~~BMS ~~accounted~~ for ~~the~~certain ~~transaction~~patent asrights anthat ~~asset~~are ~~acquisition~~necessary asto ~~substantially~~develop, ~~all~~manufacture ofor commercialize the ~~fair~~BMS ~~value~~Licensed ofCompounds ~~the~~or ~~gross~~BMS ~~assets~~Licensed ~~acquired~~Products. ~~was~~In ~~concentrated~~exchange infor asuch ~~single~~license, ~~identifiable~~BMS ~~IPR&D~~will ~~asset.~~be ~~The~~obligated ~~consideration paid~~ to ~~acquire~~pay the ~~license~~Company ~~and~~a ~~intellectual~~low ~~property~~single-digit ~~rights,~~percentage ~~which~~royalty ~~included~~on ~~transaction~~net ~~costs~~sales of ~~$0.2~~the ~~million,~~BMS ~~was~~Licensed ~~immediately~~Compounds ~~recognized~~and/or asBMS ~~IPR&D~~Licensed ~~expense~~Products inby ~~the~~it ~~Company’s~~or ~~condensed~~its ~~consolidated~~affiliates, ~~statement~~licensees ofor ~~operations~~sublicensees, ~~and~~provided ~~comprehensive~~that ~~loss~~the ~~for~~termination ~~the~~occurred ~~nine~~after ~~months~~a ~~ended~~specified ~~September 30, 2024~~developmental ~~since~~milestone ~~the~~for ~~acquired~~such ~~IPR&D~~BMS ~~had~~Licensed noCompounds ~~alternative~~and/or ~~future~~BMS ~~use~~Licensed Products.

OnFollowing ~~October~~the ~~25,~~closing ~~2024~~of the Ayala Purchase Agreement, inon ~~conjunction~~August 7, ~~with~~2024, the Company’s ~~purchase~~and ofBMS entered into Amendment No. 2 to the ~~Zentalis~~BMS ~~Licensed~~License ~~Assets~~Agreement, ~~Immunome~~or ~~and~~the ~~Zentalis~~BMS ~~agreed~~License Agreement Amendment. As consideration to ~~terminate~~BMS for entering into the ~~Zentalis~~BMS License Agreement inAmendment, ~~its~~the ~~entirety~~Company issued BMS 230,415 ~~including~~unregistered ~~the~~shares ~~termination~~of its common stock at an aggregate fair value of ~~all~~$2.7 million. The fair value of the common stock issued to BMS was based on the closing stock price of the Company’s ~~contingent~~common ~~milestone~~stock ~~and~~on ~~royalty~~August ~~payment~~7, ~~obligations~~2024 of $12.46 ~~See~~per ~~Note~~share ~~12,~~less ~~Subsequent~~a ~~Events,~~discount ~~for~~of ~~more~~6.0% ~~information~~related to unregistered share restrictions. The consideration paid to BMS to amend the BMS License Agreement was immediately recognized as IPR&D expense.

~~Purdue~~Other ~~Research~~asset ~~Foundation~~acquisitions and license agreements

~~Upon~~The ~~closing of the Merger, the~~ Company ~~assumed~~has ~~certain license agreements that Morphimmune had~~ entered into ~~prior~~various toother ~~the~~asset ~~Merger.~~purchase Inand ~~January 2022,~~license ~~Morphimmune~~agreements ~~entered~~to ~~into~~further ~~a Master License Agreement~~acquire, ~~or the Purdue License Agreement~~discover, ~~with~~develop ~~Purdue~~and ~~Research~~commercialize ~~Foundation,~~certain ortechnologies ~~PRF~~and treatments. ~~Under~~There ~~the~~was ~~Purdue~~no ~~License~~IPR&D ~~Agreement,~~expense ~~PRF granted Morphimmune a royalty-bearing, transferable, worldwide, exclusive license, sublicensable through multiple tiers,~~ under ~~certain~~these ~~intellectual~~agreements ~~property~~for ~~owned~~the bythree ~~PRF~~months toended ~~research,~~March ~~develop~~31, 2025 ~~manufacture~~ and ~~commercialize the licensed products in all fields of use with limited exceptions~~2024.

Under the Purdue License Agreement, the Company is obligated to pay PRF a low single-digit royalty on gross receipts from the sale of licensed products, and beginning with the first sale of a licensed product, a tiered minimum annual royalty from the low to mid six-digit figure range less the unit royalties due for the annual period. In addition, the Company is obligated to pay PRF up to $3.8 million in the aggregate upon the achievement of specified development and commercialization milestones. The Company is also required to pay PRF an annual maintenance fee ranging from a low five-digit figure to a low six-digit figure prior to first sale of a licensed product and a low double-digit percentage of sublicense income received for sublicenses of licensed intellectual property, the percentage depending upon the timing of execution of the sublicense.

The Purdue License Agreement expires on a licensed product-by-licensed product and country-by-country basis, upon expiration of the royalty term for such licensed product for the applicable country. The Company may terminate the Purdue License Agreement upon at least one month’s prior written notice to PRF. PRF may terminate the Purdue License Agreement and the licenses granted thereunder if the Company fails to cure a payment default or other material breach of the Purdue License Agreement after written notice from PRF, or if the Company becomes insolvent.

Other License Agreements

The Company has entered into various other license agreements to further discover, develop and commercialize certain technologies and treatments. During the three and nine months ended September 30, 2024, the Company incurred upfront fees of $4.0 million and $4.6 million, respectively, under these license agreements which were recognized as IPR&D expense in the Company’s condensed consolidated statement of operations and comprehensive loss since the acquired IPR&D had no alternative future use. There was no IPR&D expense under these agreements for the three and nine months ended September 30, 2023.

Under the terms of these agreements, the Company may need to pay certain development, regulatory, and commercial milestones payments and royalties on product sales, if any. Any potential future milestone payment amounts will be accrued when the related contingency is resolved and the milestone consideration becomes payable. Royalty payments will be expensed in the period in which the underlying revenues are earned.

18As of December 31, 2024, the Company accrued $1.2 million within accrued expenses and other current liabilities on the condensed consolidated balance sheet related to upfront license fees and the achievement of certain milestones under these agreements. These amounts were subsequently settled during the three months ended March 31, 2025.

8. Leases

The Company currently leases approximately 39,000 square feet of office and laboratory space in Bothell, Washington. In December 2024, the Company was granted a one-time tenant improvement allowance of $3.5 million which was considered payable by the lessor at the commencement date. The Bothell lease also includes an expansion option to lease approximately 13,000 additional square feet of office and laboratory space with a $4.7 million tenant improvement allowance. The Bothell lease expires on March 31, 2033, and includes two five-year renewal options that are not included in the lease term as it is not reasonably certain that they will be exercised.

The Company also leased approximately 11,000 square feet of office and laboratory space in Exton, Pennsylvania. The Exton lease expired on March 31, 2025.

Table of Contents

9. Leases

The Company currently leases approximately 29,000 square feet of office and laboratory space in Bothell, Washington, including 15,000 square feet of space that was added in May 2024 under an amended lease agreement, and approximately 11,000 square feet of office and laboratory space in Exton, Pennsylvania. The Bothell lease expires on January 31, 2029, and includes two five-year renewal options that are not included in the lease term as it is not reasonably certain that they will be exercised. The Exton lease expires on March 31, 2025.

Supplemental balance sheet information related to leases was as follows (in thousands):


		~~September~~March 3031, ~~2024~~2025			December 31, ~~2023~~2024
Operating leases:
Operating lease right-of-use assets	$	~~2,388~~$	4,163	$	~~1,564~~$	4,278

Operating lease liabilities, current portion	$	~~257~~$	—	$	~~310~~$	63
Operating lease liabilities, net of current portion		~~2,464~~	4,770		~~1,340~~	4,769
Total operating lease liabilities	$	~~2,721~~$	4,770	$	~~1,650~~$	4,832

Operating lease liabilities, current portion is included in accrued expenses and other current liabilities in the accompanying condensed consolidated balance sheets.

The Company recorded operating lease expense of $0.23 million and $0.51 million for the three ~~and nine~~ months ended ~~September~~March 3031, ~~2024,~~2025 ~~respectively,~~ and ~~$0.1 million and $0.2 million for the three and nine months ended September 30~~2024, ~~2023,~~ respectively. Under the terms of the lease agreements, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. The Company did not incur significant variable lease costs for the three ~~and nine~~ months ended ~~September~~March 3031, ~~2024~~2025 and ~~2023~~2024.

Other information related to the Company’s operating leases was as follows:


	~~September~~March 3031, ~~2024~~2025		December 31, ~~2023~~2024
Weighted-average remaining lease term (in years)	~~4.16~~	8.00	~~4.81~~	8.15
Weighted-average discount rate	~~9.0%~~	9.6%	~~8.3%~~	9.5%

Supplemental cash flow information related to the Company’s operating leases was as follows (in thousands):


	~~Nine Months Ended September 30,~~	Three Months Ended March 31,
	~~2024~~	2025		~~2023~~	2024
Cash paid for operating lease liabilities	$	~~301~~$	264	$	~~184~~$	63

The Company’s future minimum lease payments were as follows as of ~~September~~March 3031, ~~2024~~2025 (in thousands):


Years ending December 31,	Amount
2024 (represents remaining three months in 2024)	$	180
2025 (represents remaining nine months in 2025)	$	665
2025		881
2026		1,304
2026		841
2027		1,577
2027		862
2028		1,616
2028 and thereafter		958
2029 and thereafter		7,333
Total lease payments		312,~~722~~495
Less: Imputed interest		(633)
Less: imputed interest		(4,000)
Less: Tenant improvement allowance not yet received		(368)
Less: tenant improvement allowance not yet received		(3,725)
Present value of operating lease liabilities	$	24,~~721~~770

9. Common stock

Table of Contents

10. Common stock

Common stock

The holders of common stock are entitled to one vote for each share of common stock. The holders of common stock are entitled to receive dividends out of funds legally available if and when declared by the Company’s board of directors. In the event of any voluntary or involuntary liquidation, dissolution, or winding up of the Company, the holders of common stock are entitled to share ratably in the remaining assets of the Company available for distribution.

Table of Contents

The Company has reserved the following shares of common stock for issuance, on an as-converted basis, as follows:


	~~September 30, 2024~~	March 31, 2025	~~December 31, 2023~~	December 31, 2024
Stock options issued and outstanding under the Plans	~~11,451,856~~	11,498,848	~~7,978,291~~	11,990,781
Common stock warrants outstanding	—		500,000
Remaining shares available for issuance under the Plans		5,445,680		2,631,369
Remaining shares available for issuance under the Plans	2,018,277		4,250,303
Remaining shares available for issuance under the ESPP		1,550,859		906,251
Remaining shares available for issuance under the ESPP	906,251		473,733
Total reserved common stock		18,495,387		15,528,401
Total reserved common stock	14,376,384		13,202,327

~~Follow-on~~2025 ~~public~~Public ~~offering~~Offering

In ~~February~~January ~~2024~~2025, the Company completed a ~~follow-on~~ public offering and issued 1122,~~500~~258,~~000~~064 shares of its common stock at a price of $207.0075 per share, for net proceeds of $~~215~~161.47 million, after deducting underwriting discounts and commissions and offering expenses.

2024 ATM Agreement

On May 14, 2024, the Company entered into an “at the market” sales agreement, or the 2024 ATM Agreement, with TD Securities (USA) LLC, or TD Cowen, as sales agent, pursuant to which the Company may offer and sell from time to time shares of its common stock having an aggregate offering price of up to $200.0 million, or the ATM Shares. The Company has agreed to pay TD Cowen a commission of up to 3.0% of the aggregate gross proceeds from any ATM Shares sold through the 2024 ATM Agreement. NoAs of March 31, 2025, the Company had sold an aggregate of 2,030,431 shares of common stock ~~have~~under ~~been~~the 2024 ATM Agreement for gross proceeds of $20.0 million and net proceeds of approximately $19.6 million, with approximately $180.0 million remaining available for future offerings. No shares of common stock were sold under the 2024 ATM Agreement asduring ofthe ~~September 30~~three months ended March 31, ~~2024.~~ 2025.

~~Warrants~~10. toShare-based ~~acquire shares of common stock~~compensation

The Company had 500,000 issued and outstanding common stock warrants as of December 31, 2023 with an exercise price of $10.00 per share and an expiration date of April 28, 2024. During the nine months ended September 30, 2024, warrants to purchase 373,057 shares of common stock were exercised for proceeds of $3.7 million and the remaining 126,943 common stock warrants expired unexercised. No warrants were exercised during the three months ended September 30, 2024 or the three and nine months ended September 30, 2023. No warrants were issued and outstanding as of September 30, 2024.

11. Share-based compensation

2020 Equity Incentive Plan

In September 2020, the Company adopted the 2020 Equity Incentive Plan, or the 2020 Plan, which supersedes all prior equity incentive plans. No further awards will be granted under the 2018 Equity Incentive Plan, or 2018 Plan. Awards forfeited, cancelled, or repurchased from the above plans are returned to the pool of shares of common stock available for issuance under the 2020 Plan. On January 1, ~~2024~~2025, the ~~shares~~number of ~~common~~shares ~~stock~~available ~~authorized~~ for future issuance under the 2020 Plan increased by 12,~~730~~578,~~071~~433 shares. As of ~~September~~March 3031, ~~2024~~2025, there were 14,~~077~~475,~~406~~485 shares available for issuance under the 2020 Plan.

20In October 2023, the Company completed its merger with Morphimmune, Inc. and assumed the Morphimmune 2020 Equity Incentive Plan, or the Morphimmune Plan. There were 555,895 shares available for issuance under the Morphimmune Plan as of March 31, 2025.

2024 Inducement Plan

In October 2024, the Company adopted the 2024 Inducement Plan, or the 2024 Plan, to reserve 2,000,000 shares of the Company’s common stock to be used exclusively for grants of equity awards to individuals that were not previously employees or directors of the Company, as an inducement material to the individual’s entry into employment with the Company. The terms and conditions of the 2024 Plan are substantially similar to the Company’s 2020 Plan. As of March 31, 2025, there were 414,300 shares available for issuance under the 2024 Plan.

Stock options granted for Chief Executive Officer

On June 28, 2023, Clay Siegall was granted 2,137,080 options to purchase shares of the Company’s common stock at an initial exercise price of $5.91 per share, or the Inducement Grant. The options vest over time during Dr. Siegall’s continued employment with the Company, which commenced on October 2, 2023. 25% of the options granted vest after one year of employment with the Company, and the remaining 75% vest monthly over the 36 months immediately following the one-year anniversary.

Table of Contents

OnThe ~~October~~Inducement 2Grant, ~~2023,~~ the Morphimmune ~~2020 Equity Incentive~~ Plan, or the ~~Morphimmune~~2024 Plan, ~~was~~and ~~assumed by~~ the ~~Company~~2020 inPlan ~~conjunction~~are ~~with~~collectively ~~the~~referred ~~Merger~~to ~~(Note~~as ~~7). There were 940,871 shares available for issuance under~~ the ~~Morphimmune Plan as of September 30, 2024~~Plans.

Stock Options Granted for Chief Executive Officer

On June 28, 2023, Clay Siegall was granted 2,137,080 options to purchase shares of the Company’s common stock at an initial exercise price of $5.91 per share, or the Inducement Grant. The options vest over time during Dr. Siegall’s continued employment, which commenced on October 2, 2023, in connection with the closing of the Merger. 25% of the options granted vest after one year of employment with the Company, and the remaining 75% vest monthly over the 36 months immediately following the one-year anniversary. The Inducement Grant, the Morphimmune Plan and the 2020 Plan are collectively referred to as the Plans.

2020 Employee Stock Purchase Plan

The Company adopted the 2020 Employee Stock Purchase Plan, or ESPP, in September 2020. On January 1, ~~2024~~2025, the shares of common stock authorized for issuance under the ESPP increased by ~~432~~664,~~518~~608 shares. As of ~~September~~March 3031, ~~2024~~2025, there were ~~906~~1,~~251~~550,859 shares available for issuance under the ESPP. No shares of common stock have been issued under the ESPP as of ~~September~~March 3031, ~~2024~~2025.

Stock options

A summary of option activity under the Plans during the ~~nine~~three months ended ~~September~~March 3031, ~~2024~~2025 is as follows:


				Weighted
		Weighted		average	Aggregate
		average		remaining	Intrinsic
	Number of	exercise price		contractual	Value
	shares	per share		term (years)	(in thousands)
Outstanding at December 31, 2023	7,978,291	$	6.15	8.62	$	45,360
Outstanding at December 31, 2024	11,990,781	$	10.02	8.69	$	34,209
Granted	5224,~~172,469~~000		1510.1210
Exercised	(~~566~~256,~~548~~055)		31.1352
Forfeited	(~~895~~348,~~548~~748)		86.1813
Expired	(~~236~~111,~~808~~130)		2420.4227
Outstanding at September 30, 2024	11,451,856	$	9.81	8.75	$	65,609
Outstanding at March 31, 2025	11,498,848	$	10.21	8.64	$	12,063
Exercisable at September 30, 2024	2,813,140	$	4.91	6.89	$	29,667
Exercisable at March 31, 2025	3,563,637	$	6.26	7.60	$	10,228

Aggregate intrinsic value in the above table is calculated as the difference between the exercise price of the options and the Company’s fair value of its common stock as of period end.

The weighted-average grant date fair value of stock options granted during the ~~nine~~three months ended ~~September~~March 3031, ~~2024~~2025 and ~~2023~~2024 was $117.4776 and $314.6762 per share, respectively. The aggregate intrinsic value of options exercised during the ~~nine~~three months ended ~~September~~March 3031, ~~2024~~2025 and ~~2023~~2024 was $82.1 million and $02.15 million, respectively.

Table of Contents

The weighted average assumptions used in the Black-Scholes option-pricing model for stock options granted were:


	~~Nine~~Three Months Ended ~~September~~March 3031,
	~~2024~~2025			~~2023~~2024
Expected volatility		8990.84	%		8884.51	%
Risk-free interest rate		4.03	%		34.81	%
Expected term (in years)		6.0608			6.0306
Expected dividend yield		—	%		—	%

Share-based compensation expense recorded in the condensed consolidated statements of operations and comprehensive loss is as follows (in thousands):

Three Months Ended ~~September~~March 3031,

~~Nine Months Ended September 30,~~

~~2024~~2025

~~2023~~2024

~~2024~~

~~2023~~

Research and development

12,~~820~~434

~~466~~383

~~3,244~~

~~1,323~~

General and administrative

3,~~072~~269

~~617~~1,776

~~7,034~~

~~2,017~~

Total share-based compensation expense

45,~~892~~703

12,~~083~~159

~~10,278~~

~~3,340~~

Unrecognized share-based compensation related to stock options was $7268.2 million as of ~~September~~March 3031, ~~2024~~2025 and is expected to be recognized over a weighted average period of 3.51 years.

~~12. Subsequent Events~~18

~~Zentalis~~Table ~~Purchase~~of ~~Agreement~~Contents

On October 25, 2024, the Company and Zentalis entered into an asset purchase agreement, or the Zentalis Purchase Agreement, pursuant to which the Company purchased the Zentalis Licensed Assets that were licensed to the Company under the then-existing Zentalis License Agreement dated January 5, 2024, together with all the customary rights and obligations of a sole owner, or the Zentalis Asset Purchase11. ~~Upon~~Segment the closing of the Zentalis Asset Purchase, the Zentalis License Agreement was terminated in its entirety, including the termination of all of the Company’s contingent milestone and royalty payment obligations. Certain accrued rights and obligations of the parties survive the closing of the Zentalis Asset Purchase. As consideration for the Zentalis Asset Purchase, the Company issued to Zentalis 1,805,502 unregistered shares of its common stock. The Company is also obligated to pay Zentalis a one-time payment of $5.0 million in cash upon the achievement of a developmental milestone that was previously a milestone under the Zentalis License Agreement. The Company has agreed to use commercially reasonable efforts to achieve the developmental milestone.information

The Company has one operating and reportable segment related to the development of targeted oncology therapies. The segment derives its current revenues from research and development collaborations.

The CODM assesses performance for the segment based on net loss, which is reported on the condensed consolidated statements of operations and comprehensive loss as net loss. The measure of segment assets is reported on the condensed consolidated balance sheets as total assets. When evaluating the Company’s financial performance, the CODM regularly reviews total revenues, total expenses and research and development expenses by program.

The table below is a summary of the segment net loss, including significant segment expense categories (in thousands):


	Three Months Ended March 31,
	2025		2024
Collaboration revenue	$	2,926	$	1,029
Less:
In-process research and development		—		(111,954)
Direct research and development expenses⁽¹⁾
Varegacestat		(14,387)		(250)
IM-1021		(3,067)		(2,724)
IM-3050		(1,033)		(1,972)
Other product candidates		(6,843)		(6,295)
Indirect research and development⁽²⁾		(11,542)		(4,128)
General and administrative⁽³⁾		(10,690)		(6,005)
Total operating expenses		(47,562)		(133,328)
Loss from operations		(44,636)		(132,299)
Interest income		2,996		2,807
Net loss	$	(41,640)	$	(129,492)

(1)

Direct research and development expenses include external costs, such as costs related to manufacturing, outsourced research, product development, and clinical trial costs, including fees paid to investigators, consultants, central laboratories and CROs to specific product candidates.

(2)

Indirect research and development expenses include personnel salary, benefit and share-based compensation costs, depreciation and amortization, laboratory materials and services, and certain overhead expenses.

(3)

General and administrative expenses include personnel salary, benefit and share-based compensation costs, legal fees, professional fees for accounting, auditing, tax and consulting services, insurance costs, travel, depreciation and amortization, and certain overhead expenses.

2219

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations together with our condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q and our audited financial statements and notes thereto and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, ~~2023~~2024. Unless otherwise indicated, all references in this Quarterly Report on Form 10-Q to “Immunome,” the “company,” “we,” “our,” “us” or similar terms refer to Immunome, Inc. and its subsidiary.

Forward-Looking Statements

In addition to historical financial information, this discussion contains forward-looking statements based upon current expectations that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in the section titled “Risk Factors” under Part II, Item 1A below. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potentially,” “predict,” “should,” “will” or the negative of these terms or other similar expressions.

~~In addition~~Furthermore, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report on Form 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements.

Overview

We are a ~~biotechnology~~clinical-stage targeted oncology company ~~focused~~committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge targeted ~~oncology~~cancer therapies, including antibody-drug conjugate therapies, or ADCs. We believe that the pursuit of novel or underexplored targets will be central to the next generation of transformative therapies ~~and we are dedicated to developing targeted cancer therapies with first-in-class and best-in-class potential~~. Our goal is to establish a broad pipeline of preclinical and clinical assets and develop these assets into approved products for commercialization. ~~To support that goal, we pair business development activity with significant investment in our internal discovery programs.~~

We are advancing a pipeline ~~comprising~~that ~~one~~includes three clinical assets and ~~two~~three preclinical assets. ~~The~~Varegacestat, ~~clinical~~formerly ~~asset is~~ AL102, is an investigational gamma secretase inhibitor, or GSI, currently under evaluation in a Phase 3 clinical trial for the treatment of desmoid tumors. ~~The preclinical assets are~~ IM-1021, a receptor tyrosine kinase-like orphan receptor 1, or ROR1, antibody-drug conjugate, received investigational new drug, or ~~ADC~~IND, clearance in December 2024, and the Phase 1 trial is ongoing with the first patient dosed in February 2025. IM-3050, a fibroblast activation protein, or FAP, targeted radioligand therapy, or RLT, received IND clearance in April 2025 and we expect to initiate a Phase 1 trial in the second half of 2025. Our preclinical assets include three solid tumor ADC drug candidates: IM-1617, IM-1340, and IM-1335, all of which are undergoing IND-enabling activities. In addition, we have multiple ADCs currently undergoing lead optimization in advance of future development decisions.

OnAt ~~October~~present, 2our internal discovery efforts center on designing ADCs against novel or underexplored targets. We believe that pursuing differentiated targets provides a path to significant clinical benefit and meaningful market opportunities. This strategy is supported by HC74, ~~2023~~the differentiated, wenovel ~~completed~~topoisomerase ~~our~~1 ~~merger~~inhibitor, ~~with~~or ~~Morphimmune~~TOP1i, payload we purchased from Zentalis Pharmaceuticals, Inc., or ~~Morphimmune~~Zentalis, ain ~~preclinical~~October ~~biotechnology~~2024. ~~company~~We ~~focused~~have onefforts ~~developing~~underway ~~targeted~~to ~~oncology~~develop ~~therapies,~~additional linkers and ~~Morphimmune~~payloads ~~became~~and believe that a ~~wholly~~broad ~~owned~~toolbox ~~subsidiary~~of linkers and payloads supports our mission to design and develop a diverse pipeline of ~~Immunome~~ADCs.

~~Our~~To ~~current~~expand ~~programs~~and advance our innovative portfolio of therapeutics, we draw on leadership that previously played key roles in the design, development, and commercialization of cutting-edge targeted cancer therapies, including the first ADCs commercialized for Hodgkin and T-cell lymphoma, urothelial cancer and cervical cancer.

~~AL-102 (Gamma Secretase Inhibitor)~~20

Our clinical asset is AL102, an investigational GSI that we acquired from Ayala Pharmaceuticals, Inc., or Ayala, on March 25, 2024 pursuant to an Asset Purchase Agreement, or the Ayala Purchase Agreement. AL102 is currently under evaluation in a Phase 3 trial for the treatment of desmoid tumors.

Table of Contents

~~AL102~~Our ~~clinical~~current activity was observed in two prior clinical trials that enrolled adult desmoid tumor patients. A Phase 1 dose-escalation clinical trial was conducted by Bristol-Myers Squibb, or BMS, in patients with solid tumors before the asset was licensed from BMS by Ayala. In this trial, one patient with desmoid fibromatosis was enrolled. This patient demonstrated tumor shrinkage of 16.5% while on study. Based on these data and responses demonstrated with other GSIs, Ayala designed a seamless Phase 2/3 study called RINGSIDE to specifically evaluate the activity of AL102 in patients with progressing desmoid tumors who required therapy. RINGSIDE Part A enrolled 42 patients at three different dosing regimens of AL102: 2 mg once a day for two days every week, 4 mg once a day for two days every week or 1.2 mg once a day daily. Overall, the ORR in evaluable patients as measured by RECIST v1.1 by an independent radiologist was 61% for all doses tested. The 1.2 mg daily dosing cohort had an ORR of 75% in the evaluable population. AL102 was well tolerated overall with a safety profile consistent with that reported with other GSIs. These data were reported at ESMO in 2023.programs

~~Based~~Varegacestat upon the clinical activity observed in RINGSIDE Part A at the dose of 1.2 mg given once daily, and following consultation with the U.S. Food and Drug Administration, or FDA, the Phase 3 randomized registration trial, RINGSIDE Part B (~~NCT04871282)~~formerly ~~was initiated by Ayala in November 2022. Enrollment was completed in February 2024.~~AL102)

~~RINGSIDE~~Our ~~Part~~lead Bclinical asset is ~~a registrational Phase 3~~varegacestat, ~~global,~~an ~~double-blind~~oral, ~~randomized,~~once ~~placebo-controlled~~daily ~~clinical~~GSI ~~trial,~~that ~~conducted~~is atbeing 61evaluated ~~clinical~~for ~~sites in North America, Europe, Asia and Australia. The study is evaluating~~ the ~~efficacy,~~treatment ~~safety and tolerability~~ of ~~AL102 compared to placebo in patients with progressing~~ desmoid tumors. ~~One~~In ~~hundred~~the ~~fifty-six~~Phase ~~patients~~2 ~~with~~RINGSIDE ~~histologically~~study ~~confirmed~~Part ~~desmoid~~A, ~~tumors~~varegacestat ~~with~~demonstrated ~~progressive~~objective ~~disease~~response ~~(defined~~rates, asor ~~tumor~~ORR, ~~growth~~ of ~~at least 20~~75% ~~within~~of ~~the~~evaluable ~~past~~patients 12and ~~months~~64% asin ~~measured~~the ~~by RECIST v1.1) were enrolled. Patients were either treatment~~intent-~~naïve~~to-treat ~~with~~population; ~~desmoid~~median ~~tumors~~reduction ~~not~~in ~~amenable~~tumor tovolume ~~surgery~~of or88%; ~~had~~and ~~refractory~~an or85% ~~recurrent~~reduction ~~disease~~in ~~after~~T2 atimaging, ~~least~~which ~~one~~is ~~line~~suggestive of ~~therapy.~~a ~~Patients~~reduction in ~~the~~cellularity. ~~study~~The ~~were~~Phase ~~randomized~~2 todata ~~receive~~also ~~either~~show ~~AL102 at~~ a ~~dose~~safety ofprofile ~~1.2~~consistent mgwith ~~given~~the ~~once~~GSI ~~daily~~class. orEnrollment ~~placebo~~in ~~and~~a ~~evaluated~~Phase ~~for~~3 ~~tumor~~registrational ~~progression~~trial ~~using~~was ~~RECIST~~completed ~~v1.1.~~in ~~Patients~~February ~~who~~2024, ~~progress~~and ~~while~~we onexpect ~~study are eligible~~ to ~~enter~~report antopline ~~open-label~~data ~~extension~~from ~~whereby~~this ~~they~~trial ~~may~~in ~~receive~~the ~~AL102~~second athalf ~~a dose~~ of 12025.2 mgWe ~~once~~acquired ~~daily~~varegacestat ~~until~~from ~~disease~~Ayala ~~progression~~Pharmaceuticals, ~~or unacceptable toxicity~~Inc., ~~The~~or ~~primary endpoint of RINGSIDE Part B is progression free survival with secondary endpoints of ORR~~Ayala, ~~duration~~in ofMarch ~~response and specific patient-reported outcomes~~2024.

WeIM-1021 ~~expect~~(Solid toTumor ~~publish~~and ~~topline data for RINGSIDE Part~~ B-Cell inLymphoma ~~the second half of 2025. In parallel, we are evaluating and performing the additional manufacturing and pharmacology work required to support a new drug application, or NDA, submission.~~ADC)

IM-1021 (is a ROR1 ADC) that incorporates HC74, our proprietary TOP1i payload. ROR1 is expressed in both hematologic malignancies and solid tumors with limited normal tissue expression, and previous ADCs targeting ROR1 have demonstrated clinical activity. In preclinical studies, IM-1021 showed sustained tumor regression in preclinical models, including a mouse model of triple-negative breast cancer, or TNBC, and a mouse model of mantle cell lymphoma, or MCL. We believe that IM-1021 may provide improved therapeutic index as compared to other ROR1-targeted ADCs in development. IM-1021 received IND clearance in December 2024, and the Phase 1 clinical trial is ongoing with a starting dose of 2 mg/kg of adjusted ideal body weight. We expect dose escalation to include patients both with solid tumors and with B-cell lymphomas.

We are developing IM-1021, a preclinical stage ADC targeting ROR1 that we exclusively licensed from Zentalis Pharmaceuticals, Inc., or Zentalis, in January 2024, and acquired from Zentalis in October 2024 in connection with the Zentalis Asset Purchase.

In preclinical studies, IM-1021 showed sustained tumor regression in a mouse model of triple-negative breast cancer. In this model, IM-1021 dosed weekly for three weeks at 2.5 mg/kg or 5.0 mg/kg demonstrated superior reductions in tumor volume compared with the same respective dose of a competitor, vedotin payload ROR1 ADC, with no meaningful weight loss observed.

Subject to obtaining an IND, our IM-1021 clinical strategy is designed to efficiently evaluate dose escalation in patients with solid tumors or lymphoma, followed by potential expansion of the solid tumor clinical program into targeted indications, which may include any or all of the following: non-small cell lung cancer, breast, prostate, pancreatic and gastric cancer, and potential expansion of the lymphoma program into diffuse large B-cell lymphoma, mantle cell lymphoma, or other indications that are deemed to be appropriate. Concurrent with the dose escalation and expansion studies, we plan to conduct non-clinical studies evaluating IM-1021 in combination with other therapies and to evaluate and develop potential companion diagnostics that could help identify patients most likely to respond to IM-1021. Our strategy is to pursue pivotal clinical studies in indications that have shown compelling clinical outcomes in earlier-stage trials, present significant commercial opportunities, have the potential for enhanced outcomes using a companion diagnostic and offer potential for accelerated approval. We expect to submit an IND for the IM-1021 program to the FDA in the first quarter of 2025.

Table of Contents

IM-3050 (FAP Radioligand Therapy)

IM-3050 is a FAP-targeted lutetium-177, Lu-177 or 177Lu, RLT product candidate for the treatment of solid tumors. FAP is a cell surface protease that serves as a tumor-specific marker due to its broad expression on cancer associated fibroblasts, the most common tumor stromal cell. FAP is expressed in 75% of solid tumors. IM-3050 is designed to deliver radioactive 177Lu directly to FAP- expressing cells, where the “bystander” effect of the radiation may damage or kill nearby tumor cells. We believe this RLT approach could overcome the limitations, such as poor internalization and low expression on tumor cells, that make FAP an unsuitable target for ADCs. In vivo data show single dose antitumor activity and tolerability. We received IND clearance for this program in April 2025 and expect to initiate a Phase 1 clinical trial in the second half of 2025.

~~We are developing~~ IM-~~3050,~~1617 a(Solid ~~FAP-targeted~~Tumor Lu-177 RLT development candidate for the treatment of solid tumors. FAP is expressed in approximately 75% of solid tumors. FAP is predominantly expressed by cancer-associated fibroblasts, the most common tumor stromal cell. IM-3050 is designed to deliver radioactive Lu-177 directly to FAP-expressing cells, where the “bystander” effect of the radiation may damage or kill nearby tumor cells. We believe this RLT approach could overcome the limitations, such as poor internalization and low expression on tumor cells, that make FAP an unsuitable target for ADCs. ADC)

IM-1617 is a potential first-in-class ADC that targets an undisclosed receptor that is preferentially expressed in a broad array of solid tumors, including colorectal cancer, or CRC, non-small cell lung cancer, or NSCLC, and breast and ovarian cancers. The target is a receptor tyrosine kinase that promotes tumor cell survival and mediates immune cell exclusion, providing potential for a secondary mechanism of action. IND-enabling work for IM-1617 was initiated in the fourth quarter of 2024.

IM-~~3050~~1340 ~~has~~(Solid ~~four~~Tumor functional domains: A small molecule FAP-specific ligand; a linker tuned to drive tumor-specific uptake; an albumin-binding domain to improve tumor retention; and a chelator to deliver the radionuclide.ADC)

IM-1340 is a potential first-in-class ADC for the treatment of multiple solid tumors. The target of IM-1340 is underexplored and non-obvious in cancer and, to our knowledge, there are no ADCs or other therapeutic modalities in development against it. It has a unique expression profile that spans neuroendocrine tumors, or NETs, and other carcinomas, including lung and prostate tumors, with limited expression in normal tissue. IND-enabling work for IM-1340 was initiated in the fourth quarter of 2024.

~~We expect to submit an IND for the IM-3050 program to the FDA in the first quarter of 2025.~~21

Table of Contents

IM-1335 (Solid Tumor ADC)

IM-1335 is being developed for the treatment of solid tumor indications. It shares a target with a competitor’s now-discontinued investigational ADC that showed clinical activity prior to discontinuation. Our goal in designing IM-1335 was to optimize the safety and efficacy through a deep understanding of target biology and ADC optimization. We identified limitations that we expect contributed to the failure of the prior ADC against this target, and we believe that IM-1335 overcomes these limitations. IND-enabling work for IM-1335 was initiated in the fourth quarter of 2024.

Other Programs and Platforms

In addition to the already described current programs, we expect to continue to invest in discovery efforts intended to expand our pipeline. Additional ADC programs are the primary focus of these efforts. We believe that ~~quality~~our ~~antibodies~~team’s ~~against~~ADC ~~novel~~expertise orpositions ~~underexplored~~us ~~targets,~~to ~~whether~~develop ~~generated~~the bynext ~~our~~generation ~~proprietary~~of ~~platform~~transformative orADCs. ~~acquired~~This ~~through~~expertise ~~business~~comprises ~~development,~~executive ~~are~~leadership ~~the~~with ~~starting~~a ~~point~~proven ~~for~~record ~~differentiated~~of ~~therapies.~~success, Byan ~~pairing~~ADC-focused ~~these~~discovery ~~antibodies~~team with ~~linkers~~deep experience in ADC design, and ~~payloads~~a ~~that~~seasoned ~~are~~development ~~suitable~~team ~~for~~whose members spearheaded the ~~biology~~development of ~~each~~multiple ~~target,~~FDA-approved weADCs. ~~believe~~We wepair ~~can~~our ~~ultimately~~portfolio ~~develop~~of ~~therapies~~antibodies ~~that~~to ~~bring~~potential ~~substantial~~first-in-class ~~benefit~~ADC totargets ~~patients.~~with Werigorous ~~expect~~target toselection ~~add~~based ~~several~~on ~~such~~a ~~candidates~~deep tounderstanding ~~our~~of ~~pipeline~~target inbiology. ~~the~~That ~~future.~~target-driven Weapproach ~~may~~is ~~also~~complemented ~~choose~~by toHC74, ~~acquire~~our ~~additional~~differentiated, ~~clinical-stage~~proprietary ~~programs~~TOP1i payload and our optimized, proprietary linkers.

Additionally, we plan to expand our intellectual property estate and the infrastructure needed to discover and advance our platform and programs. We may continue to in-license or acquire complementary intellectual property as needed or required and we may continue to build our know-how and trade secrets. As an example, we may design and evaluate proprietary ADC components with the potential for use across multiple programs. We believe that establishing a broad toolbox of ADC-related technologies supports the development of potential first-in-class or best-in-class oncology therapies.

Components of our results of operations

Collaboration revenue

We have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products for the foreseeable future. To date, we have generated our revenue through a Collaboration and Option Agreement, or the Collaboration Agreement, with AbbVie Global Enterprises Ltd., or AbbVie. Our collaboration revenue to date consists of payments from AbbVie that we recognize over the expected performance period under this agreement. We expect that revenues for the foreseeable future will be derived primarily from this agreement and any additional collaborations into which we may enter. We have not received any royalties under the Collaboration Agreement ~~with AbbVie~~ to date.

In-process research and development ~~expense~~expenses

Intangible assets acquired in an asset acquisition for use in research and development activities which have no alternative future use are expensed as in-process research and development, or IPR&D, expense on the acquisition date. IPR&D expense for the nine months ended September 30, 2024 primarily relate to the acquisition of our license pursuant to the Zentalis License Agreement and the acquisition of certain assets from Ayala and Atreca.

Table of Contents

Research and development expenses

Research and development expenses consist of costs incurred in performing research and development activities, which include:

●

personnel-related expenses, including salaries, bonuses, benefits and share-based compensation for employees engaged in research and development functions;

● expenses incurred in connection with the advancement of our programs and product candidates, including under agreements with consultants, contractors, contract research organizations, or CROs, and other third-party vendors and suppliers;

● expenses incurred in connection with the advancement of our programs and development candidates, including under agreements with consultants, contractors, contract research organizations, or CROs, and other third-party vendors and suppliers;

●

expenses to conduct clinical trials including regulatory and quality assurance;

●

the cost of process development, validation, and the manufacturing of drug supplies for use in our preclinical studies and clinical trials;

Table of Contents

●

laboratory supplies and research materials and other infrastructure-related expenses; and

●

facilities, depreciation and amortization and other expenses which include direct and allocated expenses.

We expense research and development costs as incurred. Advance payments that we make for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the benefits are consumed.

Research and development activities are central to our business model. We expect that our research and development expenses will increase substantially in connection with the continuation of our activities and new agreements.

General and administrative expenses

General and administrative expenses consist primarily of salaries and other related costs, including share-based compensation for personnel in our executive, business development, and administrative functions. General and administrative expenses also include legal fees relating to intellectual property and corporate matters, professional fees for accounting, auditing, tax and consulting services, insurance costs, travel, direct and allocated facility related expenses and other operating costs.

We anticipate that our general and administrative expenses will increase in the future to support increased and progressed research and development activities and to operate as a public company.

Interest income

Interest income consists of interest earned on our marketable securities and on our cash and cash equivalent balances held with financial institutions.

Table of Contents

Results of operations

Comparison of the three months ended ~~September~~March 3031, ~~2024~~2025 and ~~2023~~2024

The following table summarizes our results of operations for the periods presented (in thousands):


	Three Months Ended ~~September~~March 3031,
	~~2024~~2025		~~2023~~2024		Change
Collaboration revenue	$	2,~~910~~926	$	31,~~565~~029	$	~~(655)~~1,897
Operating expenses:
In-process research and development		~~6,706~~—		—111,954		6(111,~~706~~954)
Research and development(1)		3736,~~200~~872		315,~~823~~369		3321,~~377~~503
General and administrative(1)		910,~~526~~690		46,~~375~~005		54,~~151~~685
Total operating expenses		5347,~~432~~562		8133,~~198~~328		45(85,~~234~~766)
Loss from operations		(5044,~~522~~636)		(4132,~~633~~299)		~~(45~~87,~~889)~~663
Interest income		32,~~422~~996		~~288~~2,807		~~3,134~~189
Net loss	$	(4741,~~100~~640)	$	(4129,~~345~~492)	$	~~(42~~87,~~755)~~852

(1) Amounts include non-cash share-based compensation expense as follows (in thousands):


	Three Months Ended September 30,
	2024		2023		Change
Research and development	$	1,820	$	466	$	1,354
General and administrative		3,072		617		2,455
Total share-based compensation expense	$	4,892	$	1,083	$	3,809

Collaboration revenue

Collaboration revenue decreased by $0.7 million, from $3.6 million for the three months ended September 30, 2023 to $2.9 million for the three months ended September 30, 2024. The decrease was primarily due to a decrease in certain research and development activities allocated to AbbVie during the three months ended September 30, 2024 compared to the same period in 2023.

In-process research and development expense

IPR&D expense for the three months ended September 30, 2024 related to $4.0 million for the write-off of acquired IPR&D assets that were determined to have no alternative future use and $2.7 million for the issuance of unregistered shares of our common stock in connection with the BMS License Agreement Amendment. There was no IPR&D expense for the three months ended September 30, 2023.

Research and development expenses

Research and development expenses increased by $33.4 million, from $3.8 million for the three months ended September 30, 2023 to $37.2 million for the three months ended September 30, 2024.

We record direct research and development expenses, consisting principally of external costs, such as costs related to manufacturing, costs related to specific product development, and clinical trial costs including fees paid to investigators, consultants, central laboratories and CROs, to specific product development and clinical programs. We do not allocate costs related to purchasing laboratory materials, employee-related costs and costs associated with our facility expenses, including depreciation or other indirect costs, to specific product candidates and clinical programs because these costs support multiple product programs.

Table of Contents

The table below shows our research and development expenses incurred with respect to each active program.


	Three Months Ended September 30,
	2024		2023		Change
AL102 (1)	$	9,621	$	—	$	9,621
Preclinical programs (2)		8,581		42		8,539
Other research and development activities (3)		10,872		727		10,145
Indirect research and development (4)		8,126		3,054		5,072
Total	$	37,200	$	3,823	$	33,377


	(1)	The increase for the three months ended September 30, 2024 compared to the three months ended September 30, 2023 was primarily due to manufacturing activities and clinical trial activities related to AL102.


	(2)	The increase for the three months ended September 30, 2024 compared to the three months ended September 30, 2023 was due primarily to increased outsourced research and manufacturing activities pertaining to IM-1021 and IM-3050.


	(3)	The increase for the three months ended September 30, 2024 compared to the three months ended September 30, 2023 was due primarily to increased ADC discovery activities.

(4) The increase for the three months ended September 30, 2024 compared to the three months ended September 30, 2023 was due primarily to an increase in personnel and personnel-related costs associated with supporting a larger development pipeline and performing increased discovery work.

General and administrative expenses

General and administrative expenses increased by $5.2 million, from $4.4 million for the three months ended September 30, 2023 to $9.5 million for the three months ended September 30, 2024. The increase was primarily a result of a $4.1 million increase in personnel-related costs from an increase in headcount, including a $2.5 million increase in share-based compensation.

Interest income

Interest income increased by $3.1 million from $0.3 million for the three months ended September 30, 2023 to $3.4 million for the three months ended September 30, 2024. The increase was primarily a result of higher cash and cash equivalent and marketable security balances.

Table of Contents

Comparison of the nine months ended September 30, 2024 and 2023

The following table summarizes our results of operations for the periods presented (in thousands):


	Nine Months Ended September 30,
	2024		2023		Change
Collaboration revenue	$	6,303	$	10,192	$	(3,889)
Operating expenses:
In-process research and development		124,972		—		124,972
Research and development(1)		81,652		13,452		68,200
General and administrative(1)		22,509		11,617		10,892
Total operating expenses		229,133		25,069		204,064
Loss from operations		(222,830)		(14,877)		(207,953)
Interest income		10,116		705		9,411
Net loss	$	(212,714)	$	(14,172)	$	(198,542)

(1)

Amounts include non-cash share-based compensation expense as follows (in thousands):


	~~Nine~~Three Months Ended ~~September~~March 3031,
	~~2024~~2025		~~2023~~2024		Change
Research and development	$	32,~~244~~434	$	~~1,323~~383	$	12,~~921~~051
General and administrative		73,~~034~~269		21,~~017~~776		51,~~017~~493
Total share-based compensation expense	$	105,~~278~~703	$	32,~~340~~159	$	63,~~938~~544

Table of Contents

Collaboration revenue

Collaboration revenue ~~decreased~~increased by $31.9 million, from $101.20 million for the ~~nine~~three months ended ~~September~~March 3031, ~~2023~~2024 to $62.39 million for the ~~nine~~three months ended ~~September~~March 3031, ~~2024~~2025. The ~~decrease~~increase was primarily due to aan ~~decrease~~increase in certain research and development activities allocated to AbbVie during the ~~nine~~three months ended ~~September~~March 3031, ~~2024~~2025 compared to the same period in ~~2023~~2024.

In-process research and development expense

There was no IPR&D expense for the ~~nine~~three months ended ~~September~~March 3031, 2025. IPR&D expense for the three months ended March 31, 2024 was ~~primarily~~ related to the write-off of ~~acquired~~ IPR&D assets that were acquired from Zentalis and Ayala and determined to have no alternative future use. ~~There was no IPR&D expense for the nine months ended September 30, 2023.~~

Research and development expenses

Research and development expenses increased by $6821.25 million, from $1315.54 million for the ~~nine~~three months ended ~~September~~March 3031, ~~2023~~2024 to $8136.79 million for the ~~nine~~three months ended ~~September~~March 3031, ~~2024~~2025.

29The table below shows our research and development expenses incurred with respect to each active program (in thousands):

Table of Contents


	Three Months Ended March 31,
	2025		2024		Change
Varegacestat ⁽¹⁾	$	14,387	$	250	$	14,137
IM-1021 ⁽²⁾		3,067		2,724		343
IM-3050 ⁽³⁾		1,033		1,972		(939)
Other product candidates ⁽⁴⁾		6,843		6,295		548
Indirect research and development ⁽⁵⁾		11,542		4,128		7,414
Total	$	36,872	$	15,369	$	21,503

(1) The ~~table~~increase ~~below~~for ~~shows~~the ~~our~~three ~~research~~months ~~and~~ended ~~development~~March ~~expenses~~31, ~~incurred~~2025 ~~with~~compared ~~respect~~to the three months ended March 31, 2024 was due primarily to ~~each~~manufacturing ~~active~~and ~~program~~clinical trial activities related to varegacestat, which we acquired from Ayala in March 2024.


	Nine Months Ended September 30,
	2024		2023		Change
AL102 (1)	$	14,397	$	—	$	14,397
Preclinical programs (2)		24,743		1,618		23,125
Other research and development activities (3)		24,774		3,891		20,883
Indirect research and development (4)		17,738		7,943		9,795
Total	$	81,652	$	13,452	$	68,200

(2)

The increase for the three months ended March 31, 2025 compared to the three months ended March 31, 2024 was due primarily to increased clinical trial activities as we initiated our Phase 1 trial in February 2025.

(3)

The decrease for the three months ended March 31, 2025 compared to the three months ended March 31, 2024 was due primarily to the timing of outsourced research, manufacturing and IND-enabling activities. We received IND clearance for this program in April 2025.

(4)

The increase for the three months ended March 31, 2025 compared to the three months ended March 31, 2024 was due primarily to increased ADC discovery activities.

(5)

The increase for the three months ended March 31, 2025 compared to the three months ended March 31, 2024 was due primarily to an increase in personnel and personnel-related costs in support of varegacestat, IM-1021, IM-3050 and other development and discovery programs.


	(1)	The increase for the nine months ended September 30, 2024 compared to the nine months ended September 30, 2023 was primarily due to manufacturing activities and clinical trial activities related to AL102, which was acquired from Ayala in March 2024.

Table of Contents


	(2)	The increase for the nine months ended September 30, 2024 compared to the nine months ended September 30, 2023 was due primarily to increased outsourced research and manufacturing activities pertaining to IM-1021 and IM-3050.


	(3)	The increase for the nine months ended September 30, 2024 compared to the nine months ended September 30, 2023 was due primarily to increased ADC discovery activities.

(4) The increase for the nine months ended September 30, 2024 compared to the nine months ended September 30, 2023 was due primarily to an increase in personnel and personnel-related costs associated with supporting a larger development pipeline and performing increased discovery work.

General and administrative expenses

General and administrative expenses increased by $104.97 million, from $~~11.~~6.0 million for the ~~nine~~three months ended ~~September~~March 3031, ~~2023~~2024 to $2210.57 million for the ~~nine~~three months ended ~~September~~March 3031, ~~2024~~2025. The increase was primarily a result of a $83.43 million increase in personnel-related costs from an increase in headcount, including a $51.05 million increase in share-based compensation. ~~In addition, fees related to accounting, legal and patent fees and other overhead related costs increased by $2.5 million.~~

Interest income

Interest income increased by $90.42 million from $02.78 million for the ~~nine~~three months ended ~~September~~March 3031, ~~2023~~2024 to $103.10 million for the ~~nine~~three months ended ~~September~~March 3031, ~~2024~~2025. The increase was primarily a result of ~~increased~~higher marketable security balances, partially offset by lower interest rates ~~and~~during ~~higher~~the ~~cash~~three ~~and~~months ~~cash~~ended ~~equivalent~~March ~~and~~31, ~~marketable~~2025 ~~security~~compared ~~balances~~to the three months ended March 31, 2024.

Liquidity and capital resources

Sources of liquidity

Since our inception in 2006, we have devoted substantially all our resources to research and development, raising capital, building our management team, building our intellectual property portfolio and entering and executing on collaborations and strategic transactions. To date, we have financed our operations primarily through sales of our equity securities~~, collaboration arrangements, strategic partnerships and transactions and to a lesser extent, through expense reimbursements received from a governmental contract that ended in 2022~~.

30To date, we have not generated any revenue from commercial sale of products and do not expect to generate revenue from commercial sales for the foreseeable future. Since inception, we have incurred significant operating losses and negative cash flows from operations. Our net losses were $41.6 million and $129.5 million for the three months ended March 31, 2025 and 2024, respectively. As of March 31, 2025, we had cash, cash equivalents and marketable securities of $317.3 million and an accumulated deficit of $557.4 million.

~~Table~~In January 2025, we issued 22,258,064 shares of ~~Contents~~our common stock at $7.75 per share for net proceeds of $161.7 million, after deducting underwriting discounts and commissions and offering expenses payable by us, or the 2025 Financing.

ToIn ~~date~~May 2024, we ~~have~~entered ~~not~~into ~~generated~~an ~~any~~“at ~~revenue~~the ~~from~~market” ~~commercial~~sales ~~sale~~agreement, ofor ~~products~~the ~~and~~2024 doATM ~~not~~Agreement, ~~expect~~with toTD ~~generate~~Securities ~~revenue~~(USA) ~~from~~LLC, ~~commercial~~or ~~sales~~TD ~~for~~Cowen, ~~the~~as ~~foreseeable~~sales ~~future.~~agent, ~~Since~~pursuant ~~inception,~~to which we ~~have~~may ~~incurred~~offer ~~significant~~and ~~operating~~sell ~~losses~~from ~~and~~time ~~negative~~to ~~cash~~time ~~flows~~shares ~~from~~of ~~operations.~~our ~~Our~~common ~~net~~stock ~~losses~~having ~~were~~an ~~$47.1~~aggregate ~~million~~offering ~~and~~price of up to $4200.30 million, ~~for~~or the ~~three~~ATM ~~months~~Shares. ~~ended~~We ~~September 30, 2024~~have ~~and~~agreed ~~2023,~~to ~~respectively,~~pay ~~and~~TD ~~$212.7~~Cowen ~~million~~a ~~and~~commission ~~$14.2~~of ~~million~~up ~~for~~to 3.0% of the ~~nine~~aggregate ~~months~~gross ~~ended~~proceeds ~~September 30, 2024~~from ~~and~~any ~~2023,~~ATM ~~respectively~~Shares sold through the 2024 ATM Agreement. As of ~~September 30~~March 31, ~~2024~~ 2025, we had ~~cash~~sold an aggregate of 2,030,431 ~~cash~~shares ~~equivalents~~of ~~and~~common ~~marketable~~stock ~~securities~~under the 2024 ATM Agreement for gross proceeds of $~~240~~20.10 million and annet ~~accumulated~~proceeds ~~deficit~~ of approximately $~~435~~19.56 million, with approximately $180. 0 million remaining available for future offerings. No shares of common stock were sold under the 2024 ATM Agreement during the three months ended March 31, 2025.

In February 2024, we completed a follow-on public offering and issued 11,500,000 shares of our common stock at $20.00 per share for net proceeds of $215.4 million, after deducting underwriting discounts and commissions and offering expenses payable by us, or the 2024 Financing.

In May 2024, we entered into an “at the market” sales agreement, or the 2024 ATM Agreement, with TD Securities (USA) LLC, or TD Cowen, as sales agent, pursuant to which we may offer and sell from time to time shares of our common stock having an aggregate offering price of up to $200.0 million, or the ATM Shares. We have agreed to pay TD Cowen a commission of up to 3.0% of the aggregate gross proceeds from any ATM Shares sold through the 2024 ATM Agreement. We have not yet sold any ATM Shares under the 2024 ATM Agreement.

Cash flows

The following table summarizes our sources and uses of cash for the ~~nine~~three months ended ~~September~~March 3031, ~~2024~~2025 and ~~2023~~2024 (in thousands):


	~~Nine~~Three Months Ended ~~September~~March 3031,
	~~2024~~2025		~~2023~~2024
Cash (used in) provided by operating activities	$	(68,734)	$	9,891
Cash used in operating activities	$	(53,055)	$	(11,170)
Cash used in investing activities		(94,821)		(482)
Cash provided by (used in) investing activities		5,089		(37,231)
Cash provided by financing activities		~~220~~162,~~444~~228		60219,~~909~~445
Net increase in cash and cash equivalents and restricted cash	$	56114,~~889~~262	$	70171,~~318~~044

Table of Contents

Operating activities

Net cash used in operating activities for the ~~nine~~three months ended ~~September~~March 3031, ~~2024~~2025 was $6853.71 million, consisting primarily of our net loss of $~~212~~41.76 million, ~~partially offset by noncash charges of $134.4 million~~ and a net change in operating assets and liabilities of $917.60 million., ~~The~~partially offset by noncash charges ~~primarily consisted~~ of $~~125~~5.06 million. ofThe ~~in-process~~noncash ~~research~~charges ~~and~~primarily ~~development~~consisted ~~assets~~of ~~acquired without alternative future use and~~ $105.37 million of share-based compensation. The change in operating assets and liabilities primarily consisted of ana ~~increase~~decrease in accrued expenses and other current liabilities of $138.5 million, ana ~~increase~~decrease in accounts payable of $0.3.8 million, ~~and~~ a decrease in ~~prepaid~~deferred ~~expenses~~revenue ~~and other assets~~ of $2.39 million, ~~partially~~and ~~offset~~an byincrease ain ~~decrease~~prepaid inexpenses ~~deferred~~and ~~revenue~~other assets of $61.37 million.

Net cash ~~provided~~used byin operating activities for the ~~nine~~three months ended ~~September 30~~March 31, ~~2023~~ 2024 was $911.92 million, consisting primarily of our net loss of $14129.25 million, partially offset by noncash charges of $4113.18 million and a net change in operating assets and liabilities of $194.95 million. The noncash charges primarily consisted of $3112.30 million of IPR&D assets acquired without alternative future use and $2.2 million of share-based compensation ~~expense~~. The change in operating assets and liabilities primarily consisted of a decrease in prepaid expense and other current assets of $2.5 million, an increase in ~~deferred~~accounts ~~revenue~~payable of $192.84 million, and aan ~~decrease~~increase in ~~prepaid~~accrued expenses and other ~~assets~~current liabilities of $10.67 million, partially offset by a decrease in ~~accrued~~deferred ~~expenses~~revenue ~~and other current liabilities~~ of $1.50 million.

Investing activities

Net cash ~~used~~provided inby investing activities for the ~~nine~~three months ended ~~September~~March 3031, ~~2024~~2025 was $945.81 million, consisting ~~primarily~~ of $~~112~~15.70 million offrom ~~purchases~~maturities of marketable securities, partially offset by $466.12 million of ~~purchases~~upfront ofand milestone payments related to IPR&D assets and $63.07 million of purchases of property and equipment~~, partially offset by $70~~.0 ~~million from maturities of marketable securities.~~

Net cash used in investing activities for the three ~~nine~~ months ended ~~September~~March 3031, ~~2023~~ 2024 was $037.5 2 million, consisting of $35.1 million in IPR&D assets acquired from Zentalis and Ayala and $2.2 million of purchases of property and equipment.

Table of Contents

Financing activities

Net cash provided by financing activities for the ~~nine~~three months ended ~~September~~March 3031, ~~2024~~2025 was $~~220~~162.42 million, consisting of gross proceeds of $~~230~~172.05 million from the ~~2024~~2025 Financing and $50.32 million from the exercise of options ~~and common stock warrants~~, partially offset by offering costs of $1410.85 million from ~~our~~the ~~2024~~2025 Financing ~~and 2024 ATM Agreement~~.

Net cash provided by financing activities for the ~~nine~~three months ended ~~September 30~~March 31, ~~2023~~ 2024 was $60219.94 million, consisting ~~primarily~~of gross proceeds of $61230.0 million ~~in gross proceeds~~ from ~~prepayments~~our ~~received~~issuance inof ~~relation~~11,500,000 toshares ~~the PIPE transaction associated with the closing~~ of ~~the~~our ~~Merger~~common instock ~~October~~at ~~2023~~$20.00 ~~The~~per ~~Company~~share ~~received~~in ~~these funds prior to the closing of the Merger and recorded this transaction as~~ a ~~deposit~~public ~~liability~~offering, inor the ~~accompanying~~2024 ~~condensed balance sheets as of September 30~~Financing, ~~2023.~~and ~~Financing activities also provided~~ $~~34,000~~3.6 ~~net~~million ~~proceeds~~ from the ~~sales~~exercise of options and common stock ~~under~~warrants, ~~our~~partially ~~prior~~offset ~~ATM~~by ~~sales~~offering ~~agreement~~costs ~~that~~of ~~we terminated in November 2023, offset by~~ $014.12 million infrom ~~payments of deferred offering costs associated with~~ the ~~PIPE~~2024 ~~transaction~~Financing.

Funding requirements

We expect our expenses to increase substantially in connection with our ongoing and future activities, particularly as we advance and expand our clinical development of ~~AL102~~varegacestat, seek regulatory approval for ~~AL102~~varegacestat, ~~continue~~advance the ~~preclinical and potential~~ clinical development of IM-1021 and IM-3050, ~~and~~continue ~~any~~the development of our other current product candidates and any future product candidates, and continue to pursue our business development strategy. We expect that our primary uses of capital will be for clinical development services, non-clinical research, strategic transactions, manufacturing, legal and other regulatory compliance expenses, compensation and related expenses, risk management and general overhead costs.

We expect that our existing cash, cash equivalents and marketable securities as of ~~September~~March 3031, ~~2024~~2025 will ~~enable~~be ussufficient to fund our current and planned operating expenses and capital expenditures for at least 12 months from the filing date of this Quarterly Report on Form 10-Q. We will need additional financing to support our continuing operations and pursue our research and development strategy. We have based these estimates on assumptions that may prove to be imprecise, and we may exhaust our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated with the development of our programs, we are unable to estimate the amounts of increased capital outlays and operating expenses associated with completing the research and development of our programs and ~~development~~product candidates.

Table of Contents

Our future funding requirements will depend on many factors including:

●

the scope, progress, results and costs of discovery, preclinical development, manufacturing and clinical trials for programs and product candidates that we currently own and those that we may discover or acquire rights to in the future;

●

the extent to which we acquire or in-license products, intellectual property and other technologies and the terms on which we acquire or in-license those assets;

● the scope, progress, results and costs of discovery, preclinical development, manufacturing and clinical trials for programs and development candidates that we currently own and those that we may acquire rights to in the future;

● the costs of continuing to operate and advance our discovery and ADC platforms;

●

the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property and proprietary rights, and defending intellectual property-related claims and the success of our intellectual property portfolio;

● the costs, timing and outcome of regulatory review of the programs and ~~development~~product candidates we may develop;

● the costs of future activities, including product sales, medical affairs, marketing, manufacturing, distribution, coverage and reimbursement for any programs or ~~development~~product candidates for which we receive regulatory approval;

Table of Contents

●

the success of our existing and any future license agreements, collaborations and other strategic transactions and the achievement of milestones or occurrence of other developments that trigger payments to or from us under any such agreements and transactions; and

●

the costs of operating as a public company.

Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, including pursuant to the 2024 ATM Agreement, debt financings, collaborations, strategic alliances and licensing arrangements. As a result of the war between Russia and Ukraine, ~~conflict~~conflicts in the Middle East, trade wars, bank failures, inflationary pressures on the economy and monetary policy responses taken by government agencies and other macroeconomic and political factors, the global credit and financial markets have experienced extreme volatility, including diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth and uncertainty about economic stability. There can be no assurance that deterioration in credit and financial markets and confidence in economic conditions will not occur. If equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult to obtain, more costly and/or more dilutive. To the extent that we raise additional capital through the sale of equity, including pursuant to the 2024 ATM Agreement, or convertible debt securities, the ownership interest of any purchaser will be or could be diluted and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or drug candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, limit, reduce or terminate our research, product development or future commercialization efforts, or grant rights to develop and market programs and ~~development~~product candidates that we would otherwise prefer to develop and market ourselves. If we cannot obtain the necessary funding to support these activities on favorable terms, or at all, we will need to delay, scale back or eliminate some or all of our research and development programs, including our clinical and preclinical development of our product candidates.

Table of Contents

Contractual obligations and contingencies

We have no material non-cancelable purchase commitments with service providers, as we have generally contracted on a cancelable, purchase order basis. Our expected material cash requirements do not include potential contingent payments that we may be required to pay upon the achievement of development, regulatory or commercial milestones pursuant to asset acquisitions and license agreements to which we are a party, nor do they include potential contingent payments upon the achievement of development, regulatory and commercial milestones or royalty payments that we may be required to make under license agreements we have entered into or may enter into with various entities pursuant to which we have in-licensed certain intellectual property. For further details on the potential contingent payments related to asset acquisitions and license agreements, see ~~Notes~~Note 7 ~~and 8~~ to our condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.

Critical accounting policies and estimates

~~Management’s~~There ~~discussion~~have ~~and~~been ~~analysis~~no ofmaterial changes in our ~~financial~~critical ~~condition~~accounting policies and ~~results~~estimates offrom ~~operations~~those isdisclosed ~~based~~in on our ~~financial~~Form ~~statements,~~10-K ~~which~~for ~~have~~the ~~been~~fiscal ~~prepared~~year inended ~~accordance~~December ~~with~~31, U2024.S. ~~generally~~For ~~accepted~~a ~~accounting~~discussion ~~principles. The preparation~~ of ~~these~~our ~~financial~~critical ~~statements~~accounting ~~requires~~policies usand ~~to make~~ estimates, ~~and~~refer ~~assumptions~~to ~~that~~“Management’s ~~affect~~Discussion ~~the reported amounts of assets~~ and ~~liabilities~~Analysis ~~and the disclosure~~ of ~~contingent~~Financial ~~assets~~Condition and ~~liabilities~~Results ~~at the date~~ of ~~the~~Operations ~~financial~~– ~~statements,~~Critical asaccounting ~~well~~policies asand ~~the reported expenses incurred during the reporting periods. Our~~ estimates” ~~are~~in ~~based~~Part ~~on our historical experience and on various other factors that we believe are reasonable under the circumstances~~II, ~~the~~Item ~~results~~7 of ~~which~~our ~~form~~Form ~~the~~10-K ~~basis~~ for ~~making judgments about~~ the ~~carrying~~fiscal ~~value~~year ofended ~~assets~~December ~~and~~31, ~~liabilities that are not readily apparent from other sources~~2024. ~~Actual results may differ from these estimates under different assumptions or conditions and any such differences may be material.~~

Table of Contents

While our significant accounting policies are described in Note 2 to our condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q, we believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas that involve a significant level of estimation uncertainty and have had or are reasonably likely to have a material impact on our financial condition or results of operations.

Research and development expenses and accruals

As part of preparing our financial statements, we are required to estimate and accrue expenses. We estimate preclinical, clinical trial and other research and development expenses based on the services performed pursuant to contracts with research institutions, contract manufacturing organizations and third-party service providers that conduct and manage preclinical studies and clinical trials and perform research services on our behalf. We record these costs of research and development activities based upon the estimated services provided but not yet invoiced and include these costs in accrued expenses and other current liabilities in our consolidated balance sheets and in research and development expense in our consolidated statements of operations. We make significant judgments and estimates in determining the accrued balance in each reporting period. As actual costs become known, we adjust our accrued estimates. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed may vary from our estimates and could result in us reporting amounts that are too high or too low in any particular period. Our accrued expenses are dependent, in part, upon the receipt of timely and accurate reporting from external third-party service providers. Amounts ultimately incurred in relation to amounts accrued for these services at a reporting date may be substantially higher or lower than our estimates.

We execute all our clinical trials with support from CROs and other vendors and we accrue costs for clinical trial activities performed by these third parties based upon the estimated amount of work completed on each trial. The significant factors used in estimating accruals include the number of patients enrolled, the activities to be performed for each patient, the number of active clinical sites, and the duration for which the patients will be enrolled in the trial. We monitor patient enrollment levels and related activities to the extent possible through internal reviews, correspondence with CROs and review of contractual terms. We base our estimates on the best information available at the time. However, additional information may become available to us, which may allow us to make a more accurate estimate in future periods. If we do not identify costs that we have begun to incur or if we underestimate or overestimate the level of services performed or the costs of these services, our actual expenses could differ from our estimates.

Other than research and development expenses and accruals as disclosed above, there have been no material changes in our critical accounting policies and estimates from those disclosed in our Form 10-K for the fiscal year ended December 31, 2023. For a discussion of our critical accounting policies and estimates, refer to “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Critical accounting policies and significant judgments” in Part II, Item 7 of our Form 10-K for the fiscal year ended December 31, 2023.

Recent accounting pronouncements

See Note 2, Summary of significant accounting policies, to our condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q for more information regarding recently issued accounting pronouncements.

Table of Contents

JOBS Act

We qualify as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. As an emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies, including reduced disclosure about our executive compensation arrangements, exemption from the requirements to hold non-binding advisory votes on executive compensation and golden parachute payments and exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting.

We may take advantage of these exemptions until the last day of the fiscal year following the fifth anniversary of our initial public offering (i.e., December 31, 2025) or such earlier time that we are no longer an emerging growth company. We would cease to be an emerging growth company earlier if we have more than $1.235 billion in annual revenue during our most recently completed fiscal year, we have more than $700.0 million in market value of our stock held by non-affiliates as of the last business day of our most recently completed second fiscal quarter, or we issue more than $1.0 billion of non-convertible debt securities over a three-year period. For so long as we remain an emerging growth company, we are permitted, and intend, to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. We may choose to take advantage of some, but not all, of the available exemptions. In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected not to “opt out” of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we will adopt the new or revised standard at the time private companies adopt the new or revised standard and will do so until such time that we either (i) irrevocably elect to “opt out” of such extended transition period or (ii) no longer qualify as an emerging growth company. Therefore, the reported results of operations contained in our financial statements may not be directly comparable to those of other public companies.

Table of Contents

Item 3. Quantitative and Qualitative Disclosures About Market Risk

The information under this item is not required to be provided by smaller reporting companies.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Quarterly Report. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost benefit relationship of possible controls and procedures. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, ~~as of September 30, 2024,~~ our disclosure controls and procedures, as of March 31, 2025, were effective toat ~~ensure~~ the ~~timely~~reasonable ~~disclosure~~assurance ~~of required information in our SEC filings~~level.

Changes in Internal Control Over Financial Reporting

No changes in our internal control over financial reporting occurred during the quarter ended ~~September~~March 3031, ~~2024~~2025 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II — OTHER INFORMATION

Item 1. Legal Proceedings

We are not currently a party to any material legal proceedings. From time to time, we may become involved in legal proceedings arising in the ordinary course of our business.

Item 1A. Risk Factors

RISK FACTOR SUMMARY

Below is a summary of the principal factors that make an investment in our common stock speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, can be found below under the heading “Risk Factors” and should be carefully considered, together with other information in this Quarterly Report and our other filings with the SEC before making investment decisions regarding our common stock.

●

We are a biopharmaceutical company with a history of losses. We expect to continue to incur significant losses for the foreseeable future and may never achieve or maintain profitability.

●

We have a limited operating history, which may make it difficult to evaluate our drug development capabilities and predict our future performance.

● We have not yet demonstrated successful completion of clinical development, submitted a New Drug Application, or NDA, or Biologics License Application, or BLA, obtained FDA approval for marketing, or successfully commercialized a ~~drug~~ product, and we may be unable to do so. Furthermore, ~~AL102~~varegacestat, which we recently acquired, is currently in Phase 3 clinical development, but such acquisition and prior clinical success is not indicative of our ability to obtain ~~new drug application, or~~ NDA, approval or successfully commercialize ~~AL102~~varegacestat.

● We may ~~not~~ be ~~successful~~unable into advance any of our ~~efforts~~product tocandidates ~~use~~into and ~~expand~~through ~~our~~clinical ~~discovery~~development, obtain regulatory approvals and ~~ADC~~ultimately ~~platforms~~commercialize tothem, ~~build~~or ~~and~~we ~~progress~~could aexperience ~~pipeline~~significant delays in doing so.

● We may not be ~~unable~~successful toin ~~advance any of~~ our ~~development~~efforts ~~candidates~~to ~~into~~use and ~~through~~expand ~~clinical~~our ~~development,~~ADC ~~obtain~~platform ~~regulatory~~to ~~approvals~~build and ~~ultimately~~progress ~~commercialize~~a ~~them, or we could experience significant delays in doing so~~pipeline.

~~● We may pursue particular programs or development candidates over others; these decisions may prove to be wrong and may adversely impact our business.~~29

● We may fail to realize the business benefits anticipated as a result of completed or pending strategic transactions.

● Clinical trials are expensive, time-consuming and difficult to design and implement.

● If we or others identify undesirable side effects caused by a development candidate undergoing clinical trials, our ability to market and derive revenue from the program or development candidate could be compromised.

● If third parties on which we intend to rely to conduct our current and future preclinical and clinical studies do not perform as contractually required, fail to satisfy regulatory or legal requirements or miss expected deadlines, our programs could be delayed with material and adverse impacts on our business and financial condition.

● Because we may rely on third parties for manufacturing, supply and testing, some of which may be sole source vendors, for preclinical and clinical development materials and commercial supplies, our supply may become limited or interrupted or may not be of satisfactory quantity or quality.

Table of Contents

●

We may pursue particular programs or product candidates over others; these decisions may prove to be wrong and may adversely impact our business.

●

We may fail to realize the business benefits anticipated as a result of completed or future strategic transactions.

●

As a targeted radioligand therapy, our IM-3050 program may face additional and potentially unpredictable challenges.

●

Clinical trials are expensive, time-consuming and difficult to design and implement.

●

Preliminary results from our preclinical studies and clinical trials that we announce or publish from time to time may change as more data become available and as the data undergo audit and verification procedures. Furthermore, clinical development has an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results and generally could be impacted by other factors beyond our reasonable control.

●

If we encounter difficulties enrolling participants in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.

●

We may experience delays in completion of our clinical trials based on study design.

●

We face substantial competition, which may result in others discovering, developing or commercializing products more quickly or marketing them more successfully than us. Additionally, if their product candidates are shown to be safer or more effective than ours, then our commercial opportunity will be reduced or eliminated.

●

If we or others identify undesirable side effects caused by any of our current or future product candidates undergoing clinical trials, our ability to market and derive revenue from the product candidate could be compromised.

●

If third parties on which we rely to conduct our current and future preclinical studies and clinical trials do not perform as contractually required, fail to satisfy regulatory or legal requirements or miss expected deadlines, our programs could be delayed with material and adverse impacts on our business and financial condition.

●

Because we rely on third parties for manufacturing, supply and testing, some of which may be sole source vendors, for preclinical and clinical development materials and commercial supplies, our supply may become limited or interrupted or may not be of satisfactory quantity or quality.

●

It is difficult and costly to protect our intellectual property and our proprietary technologies, and we may not be able to ensure their protection.

● Others may challenge inventorship or claim an ownership interest in our intellectual property which could expose us to litigation and have a significant adverse effect on our prospects.

●

If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.

●

Any inability to attract and retain qualified key management, technical personnel and employees would impair our ability to implement our business plan. In addition, prior successes of our personnel may not be indicative of our future success.

●

The market price of our common stock is expected to be volatile, and purchasers of our common stock could incur substantial losses.

● Unfavorable global economic and political conditions, including tariffs and trade barriers, could adversely affect our business, financial condition or results of operations.

Table of Contents

RISK FACTORS

As noted throughout this Quarterly Report on Form 10-Q, or this Quarterly Report, we are subject to a number of risks and uncertainties. You should consider and read carefully all the risks and uncertainties described below, as well as other information included in this Quarterly Report, including our condensed consolidated financial statements and related notes appearing elsewhere in this Quarterly Report and our “Management’s Discussion and Analysis of Financial Conditions and Results of Operations.” The risks and uncertainties described below are not the only ones we face. The occurrence of any of the following risks or additional risks and uncertainties not presently known to us or that we currently believe to be immaterial could materially and adversely affect our business, financial condition or results of operations. In such case, the trading price of our common stock could decline, and you may lose all or part of your investment. This Quarterly Report also contains forward-looking statements and estimates. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of specific factors, including the risks and uncertainties described below. We have marked with an asterisk (*) those risk factors that were not included as separate risk factors in, or reflect changes from the similarly titled risk factors included in, Item 1A of our Annual Report on Form 10-K, filed with the SEC on March 2819, ~~2024~~2025. References to “we,” “us,” and “our” in this section refer to Immunome and its subsidiaries.

Risks Related to Our Business

We are a biopharmaceutical company with a history of losses. We expect to continue to incur significant losses for the foreseeable future and may never achieve or maintain profitability.*

We are a biotechnology company with a history of losses. Since our inception, we have devoted substantially all of our resources to research and development, raising capital, pursuing strategic transactions, building our management team and building our intellectual property portfolio, and we have incurred significant operating losses. As of ~~September~~March 3031, ~~2024~~2025, we had an accumulated deficit of $~~435~~557.54 million. Our net loss for the year ended December 31, ~~2023~~2024 was $~~106~~293.80 million and $~~212~~41.76 million for the ~~nine~~three months ended ~~September~~March 3031, ~~2024~~2025. To date, we have not generated any revenue from product sales, and we have not identified or sought or obtained regulatory approval for the marketing or sale of any product. Furthermore, we may not generate any revenue from product sales for the foreseeable future, and we expect to continue to incur significant operating losses for the foreseeable future due to the cost of research and development activities and the regulatory approval process for our ~~development~~programs and product candidates.

We expect our net losses to increase substantially as we continue our operations; however, the amount of our future losses is uncertain. Our ability to achieve or sustain profitability, if ever, will depend on, among other things, successfully identifying and developing our ~~development~~programs and product candidates, obtaining regulatory approvals for marketing and commercialization, manufacturing on commercially reasonable terms, performance as anticipated by our vendors, entering into additional potential future strategic partnerships and performing and meeting milestones on strategic partnerships, establishing a sales and marketing organization or suitable third-party alternatives for any approved product and raising sufficient funds to finance business activities. If we, or our present or potential future partners, are unable to commercialize one or more of our programs or ~~development~~product candidates, or if sales revenue from any program or ~~development~~product candidate that receives approval is insufficient, we will not achieve or sustain profitability, which could have a material and adverse effect on our business, financial condition, results of operations and prospects.

Table of Contents

We have a limited operating history, which may make it difficult to evaluate our drug development capabilities and predict our future performance.

Other than our recent acquisition of ~~AL102~~varegacestat, a product candidate in late-stage clinical trials, and initiation of the Phase 1 clinical trial for IM-1021 in February 2025, we have not ~~initiated~~undertaken clinical trials for any of our drug candidates. We have no drugs approved for commercial sale and have not generated any revenue from drug sales. Our ability to generate drug revenue, which may not occur for the foreseeable future, if ever, will depend on the successful development and eventual commercialization of our drug candidates, which may never occur. We may never be able to develop or commercialize a marketable drug.

Table of Contents

Our current and future drug candidates require additional discovery research, preclinical development, clinical development, regulatory approval in multiple jurisdictions to market, manufacturing validation, obtaining current good manufacturing practice, or cGMP, manufacturing supply, capacity and expertise, building of a commercial and distribution organization, substantial investment and significant marketing efforts before we generate any revenue from drug sales.

Our ~~limited operating history may make it difficult to evaluate our drug candidates and predict our future performance. Our~~ short history as an operating company makes any assessment of our future success or viability subject to significant uncertainty. We will encounter risks and difficulties frequently experienced by early clinical-stage companies in evolving fields. If we do not address these risks successfully, our business will suffer. Similarly, we expect that our financial condition and operating results will fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. As a result, our stockholders should not rely upon the results of any quarterly or annual period as an indicator of future operating performance.

In addition, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown circumstances. As we advance our drug candidates, ~~including AL102,~~ we will need to transition from a company with a research focus to a company capable of supporting clinical development and, if successful, commercial activities. We may not be successful in such a transition.

38We have not yet demonstrated successful completion of clinical development, submitted a New Drug Application or NDA, or Biologics License Application, or BLA, obtained FDA approval for marketing, or successfully commercialized a product, and we may be unable to do so. Furthermore, varegacestat, which we recently acquired, is currently in Phase 3 clinical development, but such acquisition and prior clinical success is not indicative of our ability to obtain NDA approval or successfully commercialize varegacestat.

As an organization, we have not yet demonstrated an ability to successfully complete clinical development, obtain regulatory approvals for marketing, manufacture a commercial-scale product, conduct sales and marketing activities necessary for successful commercialization, or arrange for a third party to do any of the foregoing on our behalf. Prior to obtaining approval to commercialize a product candidate in the United States or elsewhere, we must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA or comparable foreign regulatory authorities, that such product candidates are safe and effective for their intended uses. We have not previously completed any clinical trials for any of our current product candidates. We also have limited experience as a company in preparing and submitting marketing applications and have not previously submitted an NDA, a BLA, or other comparable foreign regulatory submission for any product candidate. In addition, we have had limited interactions with the FDA or other comparable foreign regulatory authorities and cannot be certain how many additional clinical trials of our product candidates will be required or how such additional trials should be designed. Consequently, we may be unable to successfully and efficiently execute and complete necessary clinical trials in a way that leads to submission of an application for and obtaining regulatory approval of any of our product candidates. Notably, varegacestat’s prior development was not conducted by us. As a result, our assumptions about varegacestat’s development potential are based in large part on the data generated from clinical trials conducted by Ayala and we may observe materially and adversely different results in ongoing or future clinical trials. In addition, results from nonclinical studies and clinical trials can be interpreted in different ways. Further, even if we believe the nonclinical or clinical data for our product candidates is promising, compliance or data integrity issues may later arise and even if not, the data may not be sufficient to support approval by the FDA or comparable foreign regulatory authorities. Marketing approval or any other applications that we may submit may be delayed by several years or may require us to expend significantly more resources than we have available.

In addition, even if we were to obtain marketing approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may impose significant limitations in the form of narrow indications, warnings, or a post-marketing risk management strategy such as a Risk Evaluation and Mitigation Strategy, or REMS, or the equivalent in another jurisdiction. Regulatory authorities may grant approval contingent on the performance of costly post-marketing clinical trials or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our current and future product candidates.

Table of Contents

We ~~have~~will ~~not~~need ~~yet~~to ~~demonstrated~~raise ~~successful~~substantial ~~completion~~additional offunds ~~clinical~~to advance development, ~~submitted~~of aour ~~New~~product ~~Drug~~candidates ~~Application,~~and ~~obtained~~our ~~FDA~~ADC ~~approval for marketing~~platform, ~~or successfully commercialized a drug product,~~ and we ~~may~~cannot beguarantee ~~unable~~that ~~to do so. Furthermore, AL102, which~~ we ~~recently~~will ~~acquired,~~have issufficient ~~currently~~funds available in ~~Phase~~the 3future ~~development,~~to ~~but~~develop ~~such acquisition~~ and ~~prior~~commercialize ~~clinical~~any ~~success is not indicative~~ of our ~~ability~~product ~~to obtain new drug application, or NDA, approval or successfully commercialize AL102~~candidates.*

AsThe anresearch ~~organization,~~and ~~we have not yet demonstrated an ability to successfully complete clinical~~ development, ~~obtain~~of ~~regulatory~~biotechnology ~~approvals,~~products ~~manufacture~~is ~~a commercial~~capital-~~scale~~intensive. ~~product,~~If ~~conduct sales and marketing activities necessary for successful commercialization, or arrange for a third party to do any of the foregoing on~~ our ~~behalf.~~product ~~Prior~~candidates tocontinue ~~obtaining approval~~ to ~~commercialize~~advance athrough ~~product~~preclinical ~~candidate~~studies inand ~~the~~clinical ~~United States or elsewhere~~trials, we orwill ~~our~~need ~~collaborators must demonstrate with~~ substantial ~~evidence~~additional ~~from~~funds ~~well-controlled clinical trials, and~~ to ~~the~~expand ~~satisfaction~~our ofdevelopment, ~~the FDA or comparable foreign~~ regulatory, ~~authorities~~manufacturing, ~~that~~marketing ~~such product candidates are safe~~ and ~~effective~~sales ~~for their intended uses~~capabilities. InWe ~~2022,~~have weused ~~advanced~~substantial ~~IMM-BCP-01~~funds ~~into Phase 1 clinical trials for the treatment of SARS-CoV-2, but we since decided~~ to ~~cease~~develop ~~further~~and ~~development~~acquire ~~of IMM-BCP-01. As such, AL102 is currently~~ our ~~only~~product ~~clinical~~candidates ~~trial candidate. We acquired this asset~~ and ~~have~~will ~~not~~require ~~yet~~significant ~~conducted~~funds orto ~~completed~~continue ~~any~~to ~~clinical~~advance ~~trials for any of~~ our ~~other~~ADC ~~current~~platform ~~development candidates. We also have limited experience as a company in preparing~~ and ~~submitting~~conduct ~~marketing~~further ~~applications~~research and ~~have not previously submitted an NDA or other comparable foreign regulatory submission for any product candidate. In addition~~development, weincluding ~~have~~preclinical ~~had~~studies ~~limited interactions with the FDA or other comparable foreign regulatory authorities~~ and ~~cannot be certain how many additional~~ clinical trials ~~of our development candidates will be required or how such additional trials should be designed. Consequently~~, ~~we may be unable~~ to ~~successfully~~seek ~~and~~regulatory ~~efficiently~~approvals ~~execute~~ and ~~complete necessary clinical trials in a way that leads~~ to ~~submission~~manufacture ~~of an application for~~ and ~~obtaining~~market ~~regulatory~~products, ~~approval~~if of any ~~of our development candidates. Notably~~, ~~AL102's~~that ~~prior development was not conducted by us. As a result, our assumptions about AL102's development potential~~ are ~~based~~approved infor ~~large~~commercial ~~part on the data generated from clinical trials conducted by Ayala and we may observe materially and adversely different results in ongoing or future clinical trials~~sale. In addition, ~~results from nonclinical studies and clinical trials can be interpreted in different ways. Even if~~ we ~~believe~~incur ~~the~~additional ~~nonclinical~~costs orassociated ~~clinical~~with ~~data~~operating ~~for~~as ~~AL102~~a ispublic ~~promising, compliance or data integrity issues may later arise and even if not, the data may not be sufficient to support approval by the FDA or comparable foreign regulatory authorities~~company. ~~Marketing approval of AL102 or any other applications that we may submit may be delayed by several years or may require us to expend significantly more resources than we have available.~~

InBased ~~addition,~~on ~~even~~our ifcurrent operating plan, we ~~were~~expect tothat ~~obtain~~our ~~marketing~~existing ~~approval~~cash, ~~regulatory~~cash ~~authorities~~equivalents ~~may~~and ~~approve~~marketable ~~any~~securities as of ~~our~~March 31, 2025 ~~product~~will ~~candidates~~be ~~for~~sufficient ~~fewer~~to orfund ~~more~~our ~~limited~~current ~~indications~~and ~~than~~planned weoperating ~~request,~~expenses ~~may~~and ~~impose~~capital ~~significant~~expenditures ~~limitations~~for inat ~~the~~least ~~form~~12 ofmonths ~~narrow~~from ~~indications,~~the ~~warnings,~~filing ordate aof ~~post-marketing~~this ~~risk~~Quarterly ~~management~~Report ~~strategy~~on ~~such~~Form as10-Q. aOur ~~Risk~~future ~~Evaluation~~capital requirements and ~~Mitigation~~the ~~Strategy,~~period orfor ~~REMS,~~which orwe ~~the~~expect ~~equivalent~~our inexisting ~~another~~resources ~~jurisdiction.~~to ~~Regulatory~~support ~~authorities~~our operations may ~~grant~~vary ~~approval~~significantly ~~contingent~~from onwhat ~~the~~we ~~performance~~expect. ofOur ~~costly~~monthly ~~post-marketing~~spending ~~clinical~~levels ~~trials~~vary orbased ~~may~~on ~~approve~~new aand ~~product~~ongoing ~~candidate~~research ~~with~~and adevelopment ~~label~~and ~~that~~other ~~does~~corporate ~~not~~activities. ~~include~~Because the ~~labeling~~length ~~claims~~of ~~necessary~~time orand ~~desirable~~activities ~~for~~associated ~~the~~with successful ~~commercialization~~research ofand ~~that~~development ~~product~~of ~~candidate.~~biotechnology ~~Any~~products ofis ~~the~~highly ~~foregoing~~uncertain, ~~scenarios~~we ~~could~~are ~~materially~~unable ~~harm~~to estimate the ~~commercial~~actual ~~prospects~~funds we will require for ~~AL102~~development orand ~~our~~any ~~earlier-stage~~approved ~~product~~marketing ~~candidates~~and commercialization activities.

WeAny ~~will~~additional ~~need~~capital-raising efforts may divert our management from their day-to-day ~~raise~~activities, ~~substantial~~which ~~additional~~may ~~funds~~adversely affect our ability to ~~advance~~develop ~~development~~and, ofif approved, commercialize our ~~development~~current and any future programs or product candidates. Additional funding may not be available on acceptable terms, or at all. As a result of the war between Russia and ~~our~~Ukraine, ~~discovery~~conflict in the Middle East, bank failures, inflationary pressures on the economy and ~~ADC~~monetary ~~platforms~~policy responses taken by government agencies, including tariffs and wethe ~~cannot~~prospects ~~guarantee~~of ~~that~~trade wewars, ~~will~~and other macroeconomic and political factors, the global credit and financial markets have ~~sufficient~~experienced ~~funds~~and ~~available~~may in the future toexperience ~~develop~~extreme volatility and ~~commercialize~~disruptions, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, and uncertainty about economic stability. If the equity and credit markets deteriorate, it may make any ofnecessary ~~our~~debt ~~development~~or ~~candidates~~equity financing more difficult to obtain in a timely manner on favorable terms or at all.*

The research and development of biotechnology products is capital-intensive. If our development candidates continue to advance through preclinical studies and clinical trials, we will need substantial additional funds to expand our development, regulatory, manufacturing, marketing and sales capabilities. We have used substantial funds to develop and acquire our development candidates and will require significant funds to continue to advance our discovery and ADC platforms and conduct further research and development, including preclinical studies and clinical trials, to seek regulatory approvals and to manufacture and market products, if any, that are approved for commercial sale. In addition, we incur additional costs associated with operating as a public company.

Table of Contents

Based on our current operating plan, we expect that our existing cash, cash equivalents and marketable securities as of September 30, 2024 will enable us to fund our current and planned operating expenses and capital expenditures for at least 12 months from the filing date of this Quarterly Report on Form 10-Q. Our future capital requirements and the period for which we expect our existing resources to support our operations may vary significantly from what we expect. Our monthly spending levels vary based on new and ongoing research and development and other corporate activities. Because the length of time and activities associated with successful research and development of biotechnology products is highly uncertain, we are unable to estimate the actual funds we will require for development and any approved marketing and commercialization activities.

Any additional capital-raising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and, if approved, commercialize our current and any future development candidates. Additional funding may not be available on acceptable terms, or at all. As a result of the war between Russia and Ukraine, conflict in the Middle East, bank failures, inflationary pressures on the economy and monetary policy responses taken by government agencies and other macroeconomic and political factors, the global credit and financial markets have experienced and may in the future experience extreme volatility and disruptions, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, and uncertainty about economic stability. If the equity and credit markets deteriorate, including as a result of recent or future bank failures, it may make any necessary debt or equity financing more difficult to obtain in a timely manner on favorable terms or at all.

The timing and amount of our operating expenditures will depend largely on factors outside of our control, some of which are discussed in this section, including the following:

●

the scope, number, timing and progress of preclinical and clinical development activities;

●

the price and pricing structure that we are able to obtain from our third-party contract manufacturers to manufacture our preclinical study and clinical trial materials and supplies and other vendors relevant to advancement of our programs;

● our ability to maintain our current licenses, achieve targets or milestones for existing or future collaborations, conduct our research and development programs and establish new strategic partnerships and collaborations;

●

the costs involved in obtaining, maintaining, enforcing and defending patents and other intellectual property rights and the resources needed to pursue regulatory approvals;

● the ~~Merger and the~~ costs related to the integration of ~~business~~assets, businesses, operations, networks, systems, technologies, policies and procedures; and

● our efforts to enhance operational systems, secure sufficient laboratory space and hire additional personnel, including personnel to support development of our programs and ~~development~~product candidates and satisfy our obligations as a public company.

4033

Table of Contents

To date, we have primarily financed our operations through the sale of equity securities ~~and convertible debt, and through our collaborations~~. We may seek to raise any necessary additional capital through a combination of public or private equity offerings, including pursuant to the 2024 ATM Agreement, debt financings, ~~additional~~ collaborations, strategic alliances, licensing arrangements, government contracts and other arrangements. We cannot assure you that we will be successful in acquiring additional funding at levels sufficient to fund our operations on terms favorable to us or at all. If we are unable to obtain adequate financing when needed, we may have to delay, reduce the scope of or suspend one or more of our preclinical studies, clinical trials, research and development programs or commercialization efforts. Because of the numerous risks and uncertainties associated with the development and commercialization of our ~~development~~product candidates and the extent to which we may enter into collaborations with third parties to participate in their development and commercialization, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated preclinical studies and clinical trials. To the extent that we raise additional capital through ~~additional~~further collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights, future revenue streams or research programs or to grant licenses on terms that may not be as favorable to us. If we do raise additional capital through public or private equity, including pursuant to the 2024 ATM Agreement, or convertible debt offerings, the ownership interest of our existing stockholders will be diluted, and the terms of certain securities may include liquidation or other preferences that adversely affect our stockholders’ rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.

We do not expect to realize revenue from product sales (either directly or through our collaborators) in the foreseeable future, if at all, unless and until our drug candidates complete clinical testing, are approved for commercialization and are successfully marketed.

Risks Related to Our Discovery, Development and Regulatory Approval of ~~Development~~Programs and Product Candidates

We may ~~not~~ be ~~successful~~unable into advance any of our ~~efforts~~product tocandidates ~~use~~into and ~~expand~~through ~~our~~clinical ~~discovery~~development, obtain regulatory approvals and ~~ADC~~ultimately ~~platforms~~commercialize tothem, ~~build~~or ~~and~~we ~~progress~~could aexperience ~~pipeline~~significant delays in doing so.*

ASome ~~key element~~ of our ~~strategy~~candidates isare toin ~~use~~the ~~and~~early ~~expand~~stages ~~our~~of ~~discovery~~development efforts, and ~~ADC~~we ~~platforms~~will need to ~~build~~continue ato ~~pipeline and~~ progress ~~the~~our ~~pipeline~~product candidates through preclinical studies and ~~clinical~~submit ~~development~~INDs ~~for~~to the ~~treatment~~FDA ofor ~~various~~appropriate ~~diseases.~~regulatory ~~Our~~documents ~~scientific~~to ~~research~~applicable ~~that~~foreign ~~forms~~authorities ~~the~~prior ~~basis~~to ofinitiating ~~our~~their ~~discovery~~clinical ~~and ADC platforms is ongoing~~development. ~~Further~~Additionally, ~~the~~we ~~scientific~~acquired ~~evidence~~varegacestat, toa ~~support~~Phase ~~the~~3 ~~feasibility~~clinical ofasset, ~~discovering~~which ~~and~~requires ~~developing~~additional ~~products~~clinical ~~based~~data onbefore ~~our~~we ~~technologies~~can ~~has~~submit ~~not~~an ~~been~~NDA ~~established.~~to Inthe ~~addition,~~FDA ~~our discovery~~ and ~~ADC~~other ~~platforms~~applicable ~~are~~foreign ~~not~~authorities. ~~proven~~We toalso beonly ~~superior~~recently toinitiated ~~competing~~our ~~technologies.~~Phase ~~Even~~1 ifclinical westudy ~~are~~for ~~successful~~IM-1021 inand ~~building~~have ~~our~~not ~~pipeline,~~yet ~~the~~initiated ~~development~~our ~~candidates~~Phase ~~that~~1 weclinical ~~identify~~study ~~may not be suitable~~ for ~~clinical~~IM-3050. ~~development~~We orhave ~~generate~~no ~~acceptable~~products ~~clinical~~on ~~data,~~the ~~including~~market asthat ahave ~~result~~gained ofregulatory ~~being~~approval. ~~shown~~Our ability to ~~have~~generate ~~unacceptable~~revenue ~~effects~~and orachieve ~~other~~and ~~characteristics~~sustain ~~that~~profitability ~~indicate~~depends ~~that~~on ~~they~~our ~~are~~ability ~~unlikely~~ to becontinue ~~products~~to ~~that~~identify ~~will~~programs ~~receive~~and ~~marketing~~nominate ~~approval~~product ~~from~~candidates, ~~regulatory~~advance ~~authorities~~them orinto ~~achieve~~preclinical ~~market~~and ~~acceptance.~~clinical Ifdevelopment weand orobtain ~~our~~regulatory ~~collaborators~~approvals dofor ~~not~~and successfully ~~develop~~commercializing ~~and commercialize development candidates~~them, weeither ~~will~~alone ~~not~~or bethrough ~~able~~a ~~to generate product revenue~~collaboration.

Before obtaining regulatory approval for the commercial distribution of any product candidates, we, either alone or with or through a collaborator, must conduct extensive preclinical studies, followed by clinical trials to demonstrate their safety and efficacy in humans. We ~~may~~cannot be ~~unable~~certain toof ~~advance~~the ~~any~~timely completion or outcome of our research and development ~~candidates~~activities ~~into~~or ~~and~~our ~~through~~planned clinical studies and cannot predict if the FDA or other regulatory authorities will ultimately support the further advancement of our product candidates. Most of our product candidates are in the early stages of development, ~~obtain~~other ~~regulatory~~than ~~approvals~~varegacestat, which is a Phase 3 clinical asset, and ~~ultimately~~IM-1021, ~~commercialize~~which ~~them~~is a Phase 1 clinical asset, orand we ~~could~~are ~~experience~~subject ~~significant~~to ~~delays~~the risks of failure inherent in ~~doing~~the sodevelopment of candidates based on novel approaches, targets and mechanisms of action.*

~~Some~~Reports of ~~our~~adverse ~~candidates~~events ~~are~~or insafety ~~the~~concerns ~~early~~involving ~~stages of development efforts and we will need to continue to progress~~ our ~~development~~product candidates ~~through~~could ~~preclinical~~result ~~studies~~in ~~and submit INDs to~~ the ~~FDA or appropriate regulatory documents to applicable foreign authorities prior to initiating their clinical development. Additionally~~limitation, wedenial ~~acquired~~or ~~AL102,~~withdrawal aof ~~Phase~~regulatory 3approval ~~clinical~~by ~~asset, which requires additional clinical data before we can submit an NDA to~~ the FDA ~~and~~or other ~~applicable~~regulatory ~~foreign~~ authorities ~~before~~for weany ~~can~~or ~~receive~~all ~~regulatory approval~~indications, ~~if at all. We have no products on~~ the ~~market~~need ~~that~~to ~~have~~conduct ~~gained~~additional ~~regulatory~~trials, ~~approval.~~implementation ~~Our~~of ~~ability~~a toREMS ~~generate~~or ~~revenue~~the ~~and~~inclusion ~~achieve~~of ~~and~~unfavorable ~~sustain~~information ~~profitability~~in ~~depends on~~ our ~~ability~~product tolabeling ~~continue to identify programs~~ and, ~~nominate~~in ~~development candidates~~turn, ~~advance~~could ~~them~~delay ~~into~~or ~~preclinical~~prevent ~~and~~us ~~clinical~~from ~~development and obtain regulatory approvals for and successfully~~ commercializing ~~them,~~the ~~either~~applicable ~~alone~~product or ~~through~~product ~~a collaboration~~candidate.

4134

Table of Contents

~~Before~~Any ~~obtaining~~failures ~~regulatory approval for the commercial distribution of any programs~~ or ~~development~~setbacks ~~candidates,~~in ~~we,~~our ~~either~~ADC ~~alone~~platform or with orrespect ~~through~~to aany ~~collaborator,~~of ~~must~~our ~~conduct~~additional ~~extensive~~proprietary ~~preclinical studies~~technologies, ~~followed~~including byadverse ~~clinical~~effects ~~trials~~resulting tofrom ~~demonstrate their safety and efficacy in humans. We cannot be certain of~~ the ~~timely~~use ~~completion or outcome~~ of ~~our~~this ~~research~~technology ~~and~~in ~~development~~human ~~activities or our planned~~ clinical ~~studies~~trials and/or ~~cannot predict if~~ the ~~FDA~~imposition orof ~~other~~clinical ~~regulatory~~holds ~~authorities~~on ~~will~~our ~~ultimately~~trials ~~support the further advancement~~ of our ~~development~~product candidates., ~~Most~~could ofhave ~~our~~a ~~development~~detrimental ~~candidates~~impact ~~are~~on inour ~~the~~current ~~early~~and ~~stages~~future ~~of development~~pipeline, ~~other~~as ~~than~~well ~~AL102,~~as ~~which~~our isability ato ~~Phase~~enter 3into ~~clinical asset,~~ and/or wemaintain ~~are~~collaborations ~~subject~~related to ~~the~~our ~~risks~~ADC oftechnology, ~~failure~~which ~~inherent~~could innegatively ~~the~~affect ~~development~~our ofbusiness ~~candidates based on novel approaches, targets~~ and ~~mechanisms~~financial ~~of action~~position.

WeAdditionally, ~~anticipate~~we ~~submitting~~may ~~INDs~~not ~~for~~have ~~IM-1021~~the ~~and~~financial ~~IM-3050~~resources into ~~the~~continue ~~first~~development ~~quarter~~ of ~~2025. However~~, ~~there~~or ~~can~~to beenter nointo ~~assurance~~new ~~that~~collaborations wefor, ~~will~~our beproduct ~~able~~candidates. toThis domay sobe asexacerbated ~~anticipated~~by orone ~~that we will not face regulatory~~ or ~~other~~more ~~hurdles,~~of ~~including~~ the ~~requirement to provide additional data.~~ following:

If● wenegative ~~do not advance IM-1021~~ or ~~IM-3050~~inconclusive toresults ~~IND~~from asour ~~anticipated,~~preclinical studies or ifclinical ~~the~~trials ~~FDA does not accept~~ or ~~delays~~the ~~our~~preclinical ~~IND~~studies ~~submission~~ or ~~puts~~clinical atrials ~~submission~~of onothers ~~hold,~~for weproduct ~~may~~candidates ~~incur~~similar ~~significant~~to ~~delays and expense identifying another development candidate~~ours, ifleading ~~any.~~to ~~Accordingly,~~a ~~you~~decision ~~should~~or ~~consider~~requirement ~~our~~to ~~prospects~~conduct inadditional ~~light~~preclinical ofstudies ~~the~~or ~~costs,~~clinical ~~uncertainties,~~trials ~~delays,~~or ~~and~~abandon ~~difficulties~~a ~~frequently encountered by biotechnology companies such as ours.~~program;

We● ~~may~~product-related ~~not~~side ~~have~~effects, including the ~~financial~~occurrence ~~resources~~of toadverse ~~continue development of~~events, orexperienced toby ~~enter~~participants ~~into~~in ~~new collaborations for,~~ our ~~development~~clinical ~~candidates.~~trials ~~This~~or ~~may~~by beindividuals ~~exacerbated~~using bydrugs ~~one~~ or ~~more~~therapeutic ofantibodies ~~the~~similar ~~following:~~to ours;

● negative or inconclusive results from our preclinical studies or clinical trials or the preclinical studies or clinical trials of others for development candidates similar to ours, leading to a decision or requirement to conduct additional preclinical studies or clinical trials or abandon a program;

● product-related side effects experienced by participants in our clinical trials or by individuals using drugs or therapeutic antibodies similar to ours;

●

delays in IND submissions or comparable foreign applications, or delays or failure in obtaining the necessary approvals from regulators to commence a clinical trial, or a suspension or termination of a clinical trial once commenced;

●

inadequate supply or quality of components or materials or other supplies necessary for the conduct of our preclinical studies or clinical trials;

● poor effectiveness of our ~~development~~product candidates during preclinical studies or clinical trials;

●

capital expenditures used to expand our current pipeline;

●

unfavorable FDA or other regulatory agency inspection and review of a clinical trial or manufacture site; failure of our third-party contractors or investigators to comply with regulatory requirements or otherwise meet their contractual obligations in a timely manner, or at all; or

●

the FDA or other regulatory agencies interpreting our data differently than we do.

Further, we and any existing or potential future partners may never receive necessary marketing and commercialization approvals from regulatory authorities. Even if we or a potential future partner obtains regulatory approval, the approval may be delayed, or may be for targets, disease indications or patient populations not as broad as we intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings. We or a potential future partner may be subject to post-marketing testing requirements to maintain regulatory approval.

42We may not be successful in our efforts to use and expand our ADC platform to build and progress a pipeline.

A key element of our strategy is to use and expand our ADC platform to build a pipeline and progress the pipeline through preclinical and clinical development for the treatment of various diseases. Our scientific research that forms the basis of our ADC platform is ongoing. Further, the scientific evidence to support the feasibility of discovering and developing products based on our technologies has not been established. In addition, our ADC platform are not proven to be superior to competing technologies. Even if we are successful in building our pipeline, the product candidates that we identify may not be suitable for clinical development or generate acceptable clinical data, including as a result of being shown to have unacceptable effects or other characteristics that indicate that they are unlikely to be products that will receive marketing approval from regulatory authorities or achieve market acceptance. If we or our collaborators do not successfully develop and commercialize product candidates, we will not be able to generate product revenue.

Table of Contents

We may pursue particular programs or ~~development~~product candidates over others; these decisions may prove to be wrong and may adversely impact our business.*

In the natural course of progressing our ~~development~~product candidates, we may make decisions about prioritization that may prove to be incorrect. In addition, because we have limited financial and other resources, we may be limited in our ability to pursue all potential ~~development~~product candidates of interest, including IM-1021, IM-3050 and ~~AL102~~varegacestat, even if we would otherwise choose to do so if these limitations did not exist. For these reasons, we may fail to capitalize on viable opportunities. If we do not accurately evaluate the commercial potential or target market for a program or ~~development~~product candidate, we may relinquish valuable rights to it through partnership, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights.

We may fail to realize the business benefits anticipated as a result of completed or ~~pending~~future strategic transactions.

The success of our business strategy to pursue acquisitions and in-licenses of assets will depend, in part, on our ability to successfully integrate, develop and advance the acquired assets. If we are unable to do so following the consummation of such transaction, the anticipated benefits of such transaction may not be realized fully or at all, or may take longer to realize than expected. Any failure to timely realize the anticipated benefits of our strategic transaction could have a material adverse effect on our business, operating results, financial condition and stock price. Furthermore, in connection with the consummation of such transactions, we may become responsible for unknown or contingent liabilities. These liabilities could include, among others, exposure to unexpected compliance and regulatory violations and issues, clinical trial design or contract manufacturing and supply issues or delays that may impact the timing to submit applications for regulatory approval, unanticipated obligations to vendors and other creditors and other problems that could result in significant costs and delays to us. All these factors could decrease or delay the expected accretive effect of the transactions, negatively impact our stock price, or have a material adverse effect on our business, financial condition and results of operations.

All these factors could decrease or delay the expected accretive effect of the transactions, negatively impact our stock price, or have a material adverse effect on our business, financial condition and results of operations.

As a targeted radioligand therapy, our IM-3050 program may face additional and potentially unpredictable challenges.*

Lutetium-177 (177Lu), or Lu-177, oncology therapy is relatively new; only two Lu-177 therapies have been approved in the United States or the European Union and only a limited number of clinical trials of products based on Lu-177 therapies have commenced. As such, it is difficult to accurately predict the developmental challenges we may incur in advancing IM-3050 through ~~candidate nomination, preclinical studies and~~ clinical trials, if at all. The IM-3050 program is subject to risks described above as well as others that may include:

● interruptions to our ability to obtain and deliver on a timely basis sufficient supply of raw materials, isotopes and clinical trial materials for our ~~preclinical~~nonclinical needs and potential future clinical and commercial needs;

●

we may not be able to find and retain suitable vendors, including contract research organizations, or CROs and clinical manufacturing organizations, for our development due to the limited number of suppliers qualified to work with radioactive material, or we may develop sole-source relationships with vendors, which may present additional risks inherent to a sole-source relationship;

●

if we initiate a clinical trial, our ability to recruit patients may be negatively impacted by the limited number of sites that can administer radioligand therapies;

●

if our product is successfully approved for commercial sale, our revenue may be negatively impacted by the limited number of sites that can administer radioligand therapies; and

●

due to the short half-life of Lu-177, we may incur significant expense developing the means required to effectively and timely distribute drug products to clinical sites and, if approved, to sites for administration to patients.

4336

Table of Contents

~~There~~Clinical istrials noare ~~guarantee that our collaboration with AbbVie Global Enterprises Ltd.~~expensive, ortime-consuming ~~AbbVie, will result in the successful discovery~~ and ~~validation~~difficult ofto ~~targets~~design ~~for further development~~ and ~~commercialization by AbbVie~~implement.*

Human clinical trials are expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. For example, we will incur additional expenses related to our varegacestat, IM-1021 and IM-3050 clinical trials. Additionally, because our other product candidates are based on new technologies and discovery approaches, we expect that they will require extensive research and development and have substantial manufacturing and processing costs. In addition, costs to treat study participants and to treat potential side effects that may result from our product candidates may be significant. Accordingly, our clinical trial costs are likely to be high and could have a material and adverse effect on our business, financial condition, results of operations and prospects.

~~Related~~Preliminary toresults ~~the~~from ~~AbbVie~~our ~~collaboration~~preclinical studies and ~~option~~clinical ~~agreement~~trials ~~entered~~that ~~into~~we onannounce ~~January 4, 2023,~~ or ~~the~~publish ~~Collaboration~~from ~~Agreement,~~time ~~there~~to istime nomay ~~guarantee~~change ~~that~~as ~~our~~more ~~discovery~~data ~~platform~~become ~~will~~available ~~successfully discover~~ and ~~validate~~as ~~targets, or that such targets may become~~ the ~~subject~~data ofundergo ~~further~~audit ~~successful development~~ and ~~commercialization~~verification ~~by AbbVie~~procedures. ~~Additionally~~Furthermore, ifclinical ~~there~~development ishas ~~any~~an ~~conflict,~~uncertain ~~dispute~~outcome, ~~disagreement,~~and orresults ~~issue~~ of ~~nonperformance~~earlier ~~between~~studies us and ~~AbbVie~~trials ~~regarding~~may ~~our~~not ~~rights~~be orpredictive ~~obligations~~of ~~under~~future ~~the~~trial ~~Collaboration~~results ~~Agreement,~~and ~~AbbVie~~generally ~~may~~could ~~have~~be aimpacted ~~right~~by toother ~~terminate~~factors ~~the~~beyond ~~agreement~~our ~~or reduce the payments due to us thereunder~~control.

WeFrom ~~have~~time ~~obtained rights~~ to ~~use~~time, ~~human~~we ~~samples~~may inpublish ~~furtherance~~preliminary ofresults from our ~~research~~preclinical studies and ~~development~~clinical trials. ~~However,~~Interim ifresults wefrom ~~failed~~clinical trials are subject to ~~obtain~~the ~~appropriate~~risk ~~permission~~that toone ~~use~~or ~~these~~more ~~samples~~of the clinical outcomes may materially change as enrollment continues and more data becomes available. Preliminary or ~~exceed~~top-line results also remain subject to audit and verification procedures that may result in the ~~scope~~final ofdata being materially different from the ~~permissions~~data ~~given~~we previously published or publish. As a result, ~~our~~preliminary ~~program~~and ~~could~~interim data should be ~~adversely~~viewed ~~affected~~with caution until the final data is available.

~~With~~Furthermore, ~~respect~~others, toincluding ~~certain~~regulatory ~~of our development candidates~~agencies, ~~our~~may ~~discovery~~not ~~process~~accept ~~involves~~or ~~gathering~~agree ~~tissue~~with ~~samples from humans. While we attempt to ensure that we and~~ our ~~vendors~~assumptions, ~~have~~estimates, ~~obtained these samples with all necessary permissions~~calculations, ~~there~~conclusions ~~is a risk that one~~ or ~~more~~analyses ~~individuals from whom samples were collected,~~ or ~~their representatives~~ may ~~assert~~interpret ~~that we have either failed to obtain appropriate permission~~ or ~~exceeded~~weigh the ~~scope~~importance of ~~permission~~data ~~granted. In such circumstances~~differently, wewhich could beimpact ~~required~~the tovalue ~~pay~~of ~~monetary~~the ~~damages,~~particular toprogram ~~pay~~and ~~a continuing royalty on any products created or invented by analyzing~~ the ~~person’s~~approvability ~~sample~~ or ~~even~~commercialization toof ~~cease using~~ the ~~sample~~particular ~~and~~product ~~any~~candidate. ~~and~~In ~~all~~addition, ~~materials derived from or created through analysis of~~ the ~~sample,~~information ~~any~~we ofchoose ~~which~~to ~~could~~publicly ~~result~~disclose inregarding a ~~change~~particular tostudy ~~our~~or ~~business~~clinical ~~plan~~trial ~~and~~is ~~materially~~typically ~~harm~~selected ~~our~~from ~~business,~~a ~~financial~~more ~~condition,~~extensive ~~results~~amount of ~~operations~~available ~~and prospects~~information. ~~Further,~~Others inmay ~~some~~not ~~cases,~~agree ~~these~~with ~~penalties~~what ~~could~~we ~~materially~~determine ~~impact~~to ~~the~~be ~~performance,~~material ~~availability,~~ or ~~validity~~otherwise ofappropriate ~~studies~~information ~~conducted~~to byinclude usin ~~or on~~ our ~~behalf. Even in the absence of violations resulting in penalties~~disclosure, ~~regulatory~~ and ~~other~~any ~~authorities~~information ~~may~~we ~~refuse~~determine tonot ~~authorize the conduct or~~ to ~~accept~~disclose ~~the~~may ~~results~~ultimately ofbe ~~studies~~deemed ~~for~~significant ~~regulatory~~with orrespect ~~ethical reasons, which could impact our ability~~ to ~~progress~~future ~~our~~decisions, ~~program into or through clinical trials~~conclusions, ~~and peer-reviewed journals may refuse to publish scientific findings~~views, ~~which~~activities ~~could~~or ~~limit~~otherwise ~~our~~regarding ~~ability~~a toparticular ~~disseminate~~product ~~information related to this program~~candidate.

~~Clinical~~Moreover, ~~trials~~if ~~are~~preliminary ~~expensive~~or topline results that we report differ from later, ~~time-consuming~~final ~~and~~or ~~difficult~~actual results, or if others, including regulatory authorities, disagree with the conclusions reached by us or other actions taken by us with respect to ~~design~~any clinical trial, our ability to obtain approval for, and ~~implement~~commercialize, the applicable product candidate or any of our other product candidates could be harmed, which could have an adverse impact on our business, financial condition, results of operations and prospects.

~~Human~~Additionally, ~~clinical~~we ~~trials~~have ~~are~~in ~~expensive~~the ~~and~~past ~~difficult to design~~ and ~~implement,~~may in ~~part~~the ~~because~~future ~~they~~create ~~are~~synthetic ~~subject~~molecules tofor ~~rigorous~~comparative ~~regulatory requirements~~purposes. For example, we ~~will~~have ~~incur~~created ~~additional~~a ~~expenses~~synthetic asversion aof ~~result~~zilovertamab ofvedotin ~~acquiring~~for ~~AL102~~use ~~and~~in ~~implementing~~preclinical ~~its~~efficacy ~~Phase~~studies. 3We ~~clinical~~believe ~~trial.~~the ~~Additionally,~~results ~~because~~of ~~our~~these ~~other~~tests ~~development~~help ~~candidates~~us ~~are~~understand ~~based~~how onthe ~~new~~therapeutic ~~technologies~~index of our programs and ~~discovery~~product ~~approaches~~candidates compared to competitors’ product candidates. However, we ~~expect~~cannot be certain that ~~they~~any ~~will~~synthetic ~~require~~molecule ~~extensive~~that ~~research~~we ~~and~~create ~~development~~is ~~and~~the ~~have~~same ~~substantial~~as ~~manufacturing~~the ~~and~~molecule ~~processing~~we ~~costs.~~are Inattempting ~~addition~~to recreate, ~~costs~~and tothe ~~treat~~results ~~study~~of ~~participants~~the ~~and~~tests tocomparing ~~treat~~any ~~potential~~such ~~side~~synthetic ~~effects~~molecule ~~that~~to ~~may~~any ~~result~~other ~~from~~program ~~our~~or ~~development~~product ~~candidates~~candidate may be ~~significant~~different than the actual results of a head-to-head test of any such other program or product candidate against a competitor molecule. ~~Accordingly,~~Additional ~~our~~preclinical and clinical ~~trial~~testing ~~costs~~will ~~are~~be ~~likely~~needed to beevaluate ~~high~~the therapeutic index of our programs or product candidates, and ~~could~~to ~~have~~understand atheir ~~material~~therapeutic potential relative to other programs and ~~adverse~~product ~~effect~~candidates onin ~~our~~development. ~~business~~Without head-to-head comparative data, ~~financial~~we ~~condition~~will not be able to make comparative claims to other products in our promotional materials, ~~results~~if ofour ~~operations~~programs and ~~prospects.~~product candidates are approved.

From time to time, we may publish preliminary results from our preclinical studies and clinical trials. Interim results from clinical trials are subject to the risk that one or more of the clinical outcomes may materially change as enrollment continues and more data becomes available. Preliminary or top-line results also remain subject to audit and verification procedures that may result in the final data being materially different from the data we previously published or publish. As a result, preliminary and interim data should be viewed with caution until the final data is available. Differences between preliminary or interim data and final data could significantly affect our business prospects.

Table of Contents

It is impossible to predict when or if any of our programs or ~~development~~product candidates will prove effective and safe in humans or will receive regulatory approval. Before obtaining marketing approval from regulatory authorities, we must, as applicable, complete preclinical studies and then conduct extensive clinical trials to demonstrate the safety and efficacy in humans. Clinical testing can take many years to complete, and its outcome is inherently uncertain. The results of preclinical studies and early clinical trials of any of our ~~development~~product candidates may not be predictive of the results of later-stage clinical trials. In addition, ~~development~~product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. A number of pharmaceutical companies have suffered significant setbacks in advanced clinical trials due to lack of efficacy or safety profiles, notwithstanding promising results in earlier trials. In addition, ~~AL102'~~varegacestat’s prior development was not conducted by us, and we did not conduct ~~any~~many of the preclinical studies for ~~the~~IM-1021, ~~ROR1~~which ~~ADC that~~ we initially in-licensed from Zentalis and subsequently acquired ~~from Zentalis~~ in October 2024. As a result, our assumptions about the potential of these programs are based in large part on the data generated in preclinical studies and clinical trials conducted by these third parties. Results from nonclinical studies and clinical trials can be interpreted in different ways. We may observe materially and adversely different results in any ongoing or future preclinical studies or clinical trials, or later discover errors or other issues with the data generated by these third parties.

We do not know whether planned preclinical studies and clinical trials will be completed on schedule or at all, or whether planned clinical trials will begin on time, need to be redesigned, enroll participants on time or be completed on schedule, if at all. Our development programs may be delayed ~~for~~or otherwise adversely affected due to a variety of reasons, including ~~delays related to~~:

●

inability to generate sufficient preclinical, toxicology, or other in vivo or in vitro data to support the initiation of clinical trials;

●

delays in sufficiently developing, characterizing or controlling a manufacturing process suitable for clinical trials;

● delays in developing suitable assays for screening participants for eligibility for trials with respect to certain ~~development~~product candidates;

●

delays in reaching agreement with the FDA, European Medicines Agency or other regulatory authorities as to the design or implementation of our clinical trials;

●

reaching agreement on acceptable terms with prospective CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites;

●

obtaining institutional review board, or IRB, approval at each clinical trial site;

●

recruiting suitable participants to participate in a clinical trial and having participants complete a clinical trial or return for post-treatment follow-up;

● clinical trial sites, CROs or other third parties deviating from trial protocol or dropping out of a trial or other vendors supporting a trial not performing as planned;

●

failure to perform in accordance with the FDA’s good clinical practice, or GCP, requirements, or applicable regulatory guidelines in other countries;

●

patients who enroll in clinical trials may later drop out due to adverse events, a perception they are not benefiting from participating in the study, fatigue with the clinical study process or personal issues;

●

any unresolved ethical issues associated with enrolling patients in clinical trials in lieu of prescribing existing treatments that have established safety and efficacy profiles;

Table of Contents

●

addressing participant safety concerns that arise during the course of a trial, including occurrence of adverse events that are viewed to outweigh potential benefits;

●

external factors such as an epidemic or pandemic which prevent execution of the study(ies) or recruitment of subjects to a trial or trials; or

45● having inadequate supply or quality of components, materials, diagnostics or other supplies necessary for the conduct of our preclinical studies or clinical trials.

~~Table~~Furthermore, we expect to rely on CROs, clinical trial sites and other vendors to ensure the proper and timely conduct of ~~Contents~~our clinical trials and, while we expect to enter into agreements governing their committed activities, we have limited influence over their actual performance or circumstances that could affect their performance.

●Clinical ~~having~~trials ~~inadequate~~may ~~supply~~be suspended or ~~quality~~terminated by us, our partners, the IRBs of ~~components~~the institutions in which such trials are being conducted, the Data Safety Monitoring Board for such trials or ~~materials~~by the FDA or other ~~supplies~~regulatory ~~necessary~~authorities ~~for~~due ~~the~~to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, inability to recruit appropriate subjects or an adequate number of subjects, failure to demonstrate a benefit from using a drug or therapeutic biologic, changes in governmental regulations or administrative actions, lack of adequate funding to continue the clinical trial and other factors beyond our ~~preclinical~~control. ~~studies~~If we experience delays in the completion of, or termination of, any clinical trial of any of our programs, the commercial prospects will be harmed, and our ability to generate product revenue, if any, will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow our product development and approval process and jeopardize our ability to commence product sales and generate revenue. Any of these occurrences may materially and adversely affect our business, financial condition, results of operations and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval.

~~Furthermore,~~If we ~~expect~~encounter todifficulties ~~rely~~enrolling onparticipants ~~CROs,~~in ~~clinical trial sites and other vendors to ensure the proper and timely conduct of~~ our clinical trials ~~and~~, ~~while~~our weclinical ~~expect~~development ~~to enter into agreements governing their committed~~ activities, wecould ~~have~~be ~~limited~~delayed ~~influence~~or ~~over~~otherwise ~~their~~adversely ~~actual performance~~affected.

~~Clinical~~We ~~trials~~ may not be ~~suspended~~able orto ~~terminated~~initiate byor ~~us,~~continue ~~our~~clinical ~~partners, the IRBs of the institutions in which such~~ trials ~~are being conducted, the Data Safety Monitoring Board~~ for ~~such~~our ~~trials~~programs or byproduct ~~the~~candidates ~~FDA~~if orwe ~~other~~are ~~regulatory~~unable ~~authorities~~to ~~due~~locate toand enroll a sufficient number of ~~factors,~~eligible ~~including~~participants ~~failure~~ to ~~conduct~~participate ~~the clinical trial~~ in ~~accordance~~these ~~with~~trials ~~regulatory~~as ~~requirements~~required ~~or our clinical protocols, inspection of the clinical trial operations or trial site~~ by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, inability to recruit appropriate subjects or an adequate number of subjects, failure to demonstrate a benefit from using a drug or therapeutic biologic, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. IfThe weenrollment ~~experience delays in the completion~~ of, orparticipants ~~termination~~depends ~~of,~~on any clinical trial of any of our programs, the commercial prospects will be harmed, and our ability to generate product revenue will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow our product development and approval process and jeopardize our ability to commence product sales and generate revenue. Any of these occurrences may materially and adversely affect our business, financial condition, results of operations and prospects. In addition, many ~~of the~~ factors ~~that cause~~, ~~or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval.~~including:

If we encounter difficulties enrolling participants in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.*

We may not be able to initiate or continue clinical trials for our programs or development candidates if we are unable to locate and enroll a sufficient number of eligible participants to participate in these trials as required by the FDA or other regulatory authorities. The enrollment of participants depends on many factors, including:

●

the severity of the disease under investigation;

●

the eligibility criteria defined in the clinical trial protocol and the size of the population required for analysis of the trial’s primary endpoints;

●

the existence of approved therapies, or ones available under Emergency Use Authorizations, for treating similar populations may limit recruitment into the clinical trial;

●

the willingness or availability of eligible individuals to participate in our clinical trials;

●

the proximity and availability of clinical trial sites;

●

the referral practices of physicians;

●

our ability to recruit clinical trial investigators with the appropriate competencies and experience;

●

perceptions as to the potential advantages of the candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating;

Table of Contents

●

our ability to obtain and maintain participant consents; and

●

the risk that those enrolled in clinical trials will drop out of the trials before completion.

46In addition, our future clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as those being pursued by us, and this competition will reduce the number and types of participants available to us, because some participants who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of participants who are available for our clinical trials at such clinical trial sites. Additionally, because we anticipate that some of our oncology clinical trials will be in patients with advanced solid tumors or lymphomas, the patients are typically in the late stages of the disease and may experience disease progression or adverse events independent from our product candidates, making them unevaluable for purposes of the trial and requiring additional enrollment. Delays in enrollment may result in increased costs or may affect the timing or outcome of the planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our pipeline.

~~Table~~We may experience delays in completion of ~~Contents~~our clinical trials based on study design.*

InThe ~~addition, our future~~ clinical ~~trials~~trial ~~will compete with other clinical trials~~ for ~~development~~varegacestat, ~~candidates~~RINGSIDE ~~that~~Part ~~are~~B inis ~~the~~an ~~same~~event-driven ~~therapeutic areas as those being pursued by us~~study, ~~and~~which ~~this~~means ~~competition~~that ~~will~~ending ~~reduce~~ the ~~number~~study ~~and~~is ~~types~~tied ~~of participants available~~ to ~~us,~~the ~~because~~occurrence ~~some~~of ~~participants who might have opted to enroll in our trials may instead opt to enroll in~~ a ~~trial~~certain ~~being~~number ~~conducted by one~~ of ~~our competitors~~events. ~~Since~~It ~~the number of qualified clinical investigators~~ is ~~limited,~~not wepossible ~~expect~~ to ~~conduct~~predict ~~some~~accurately ofwhen ~~our clinical trials at~~ the ~~same~~requisite ~~clinical~~events ~~trial~~will ~~sites that some of our competitors use~~occur, ~~which~~if ~~will reduce the number of participants who are available for our clinical trials~~ at ~~such~~all. ~~clinical~~Given ~~trial~~this ~~sites.~~inherent ~~Additionally~~uncertainty, ~~because~~there wecan ~~anticipate that some of our oncology clinical trials will~~ be inno ~~patients~~assurance ~~with~~that ~~advanced~~timing ~~solid~~for ~~tumors~~completion ~~or lymphomas, the patients are typically in the late stages~~ of the ~~disease~~study and ~~may~~reporting ~~experience~~of ~~disease~~data ~~progression~~will orbe ~~adverse~~achieved ~~events~~as ~~independent~~and ~~from~~when ~~our~~anticipated ~~development~~by ~~candidates, making them unevaluable for purposes of~~ the ~~trial and requiring additional enrollment~~Company. ~~Delays~~Any indelays ~~enrollment may result~~ in ~~increased~~our ~~costs or may affect the timing or outcome of the planned~~ clinical ~~trials,~~programs ~~which~~ could ~~prevent~~significantly ~~completion~~harm ~~of these trials and adversely affect~~ our ~~ability~~business, tofinancial ~~advance~~condition ~~the~~and ~~development of our pipeline~~prospects.

We ~~may~~face ~~experience~~substantial ~~delays~~competition, which may result in ~~completion~~others ofdiscovering, developing or commercializing products more quickly or marketing them more successfully than us. Additionally, if their product candidates are shown to be safer or more effective than ours, then our ~~clinical~~commercial ~~trials~~opportunity ~~based~~will onbe ~~study~~reduced ~~design~~or eliminated.*

The ~~clinical~~development ~~trial~~and ~~for~~commercialization ~~AL102,~~of ~~RINGSIDE~~new ~~Part~~product Bcandidates is anhighly ~~event-driven~~competitive. ~~study~~We compete in the segments of the pharmaceutical, ~~which~~biotechnology ~~means~~and other related markets that develop therapies for the ~~study~~treatment ~~can~~of ~~end~~cancer, ~~only~~which ~~when~~is ahighly ~~certain~~competitive ~~pre-specified~~with ~~number~~rapidly ofchanging ~~events~~standards ~~have~~of ~~occurred~~care. ItAs issuch, ~~not~~our ~~possible~~commercial toopportunity ~~predict~~could ~~accurately~~be ~~when~~reduced ~~the~~or ~~requisite~~eliminated ~~events~~if ~~will~~our ~~occur~~competitors ~~and~~develop or commercialize products that are safer, ~~given~~more ~~this~~effective, ~~inherent~~have ~~uncertainty~~fewer or less severe side effects, ~~there~~are ~~can~~more beconvenient, noor ~~assurance~~are ~~that~~less ~~timing~~expensive ~~for~~than ~~completion~~any ofproducts ~~the~~that ~~study~~we ~~and~~may ~~reporting~~develop ofor ~~data~~that ~~will~~would berender ~~achieved~~any asproducts ~~and~~that ~~when~~we ~~anticipated~~may bydevelop ~~the~~obsolete ~~Company~~or non-competitive. ~~Any~~Our ~~delays~~competitors inalso ~~our~~may ~~clinical~~obtain ~~programs~~marketing approval for their products more rapidly than we may obtain approval for ours, which could ~~significantly~~result ~~harm~~in our ~~business,~~competitors ~~financial~~establishing ~~condition~~a ~~and~~strong ~~prospects~~market position before we are able to enter the market.

We face substantial competition, which may result in others discovering, developing or commercializing products more quickly or marketing them more successfully than us. If their product candidates are shown to be safer or more effective than ours, then our commercial opportunity will be reduced or eliminated.*

The development and commercialization of new product candidates is highly competitive. We compete in the segments of the pharmaceutical, biotechnology and other related markets that develop therapies for the treatment of cancer, which is highly competitive with rapidly changing standards of care. As such, our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop or that would render any products that we may develop obsolete or non-competitive. Our competitors also may obtain marketing approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market.

We expect to compete with oncology companies advancing small molecules, ADCs, targeted radiotherapies, antibodies, and other therapeutic modalities. This may include large, multinational pharmaceutical companies such as Immunogen (acquired by AbbVie Inc.), AstraZeneca; Amgen; Bayer AG, BMS; Eli Lilly and Company; Genentech, Inc. (a member of Roche group); Merck & Co. Inc.; Novartis; Seagen (acquired by Pfizer) and Johnson & Johnson. If any of our current or future product candidates are eventually approved for sale, they will likely compete with a range of treatments that are either in development or currently marketed for use in those same disease indications.

With respect to ~~AL102~~varegacestat, we expect to compete with companies advancing treatments for desmoid tumors, including SpringWorks Therapeutics, Inc. In November 2023, ~~Springworks~~SpringWorks received FDA approval for its oral gamma secretase inhibitor, OGSIVEO® (nirogacestat), for the treatment of adult patients with progressing tumors who require systemic treatment. Desmoid ~~tumors~~tumor treatments also include surgery, hormonal therapy, cryotherapy, targeted therapy and chemotherapy. In April 2025, Merck KGaA announced a definitive agreement to acquire SpringWorks. We cannot predict the nature or extent of any impact that an acquisition of SpringWorks, if consummated, would have on the competitive landscape for varegacestat.

There are several other companies developing FAP-targeted radioligand therapies which may represent the most direct competition to our IM-3050 program. Novartis is advancing a FAP-targeted radioligand therapy (177Lu-FAP-2286) that was acquired from Clovis Oncology and is currently in Phase 1/2. In December 2023, Eli Lilly and Company acquired POINT Biopharma, which is developing a FAP-targeted radioligand therapy (PNT2004) that is currently in Phase 1. Yantai LNC Biotechnology has also initiated a Phase 1 trial for another FAP-targeted radioligand therapy (LNC1004.) Perspective Therapeutics lead pre-clinical candidate is a FAP- targeted radiopharmaceutical (RPT), PSV 359, with a Phase I expected in 2025. Additionally, our IM-3050 program faces competition from competitors who may have superior access to a consistent supply of radioactive isotopes. 40

Table of Contents

InRegarding ~~January 2023~~IM-3050, we ~~exclusively~~are ~~licensed~~aware aof ~~preclinical ROR1 ADC program from Zentalis with the potential to address hematologic and solid tumor indications, and acquired this program in October 2024. There are~~ several other companies developing ~~antibodies, ADCs, and CAR~~FAP-Ttargeted ~~therapies~~radioligand ~~targeting ROR1~~therapies, ~~and~~which ~~they~~ may represent ~~the most~~ direct competition to ~~our~~that ~~ROR1 ADC~~ program. ~~Merck~~For ~~has~~instance, anNovartis, ~~ADC~~Yantai ~~program~~LNC ~~(Zilovertamab~~Biotechnology, ~~vedotin)~~and inPerspective aTherapeutics ~~Phase~~have ~~2/3~~disclosed ~~clinical~~FAP-targeted ~~trial~~radioligand ~~for~~therapies ~~B-cell~~in ~~lymphoma~~clinical development. ~~CStone Pharmaceuticals~~Additionally, ~~Inc.~~our ~~has~~IM-3050 anprogram ~~ADC~~faces ~~program~~competition infrom acompetitors ~~Phase~~who Imay ~~trial.~~have ~~Lyell~~superior ~~Immunopharma~~access ~~has~~to a ~~pre-clinical~~consistent ~~CAR-T~~supply ~~program~~of ~~(LYL119)~~radioactive isotopes.

IM-1021 is a ROR1 ADC program with the potential to address hematologic and solid tumor indications. We are aware of several other companies developing therapeutics, including ADCs, targeting ROR1, and they may represent direct competition to our ROR1 ADC program. For example, Merck has a ROR1 ADC program (Zilovertamab vedotin) in a Phase 3 clinical trial for diffuse large B-cell lymphoma, and CStone Pharmaceuticals, Inc. has disclosed a ROR1 ADC program in clinical development.

Many of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, performing preclinical studies, conducting clinical studies, integrating assets into their portfolio, obtaining regulatory approvals and marketing approved products than we have. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical study sites and patient registration for clinical studies, as well as in acquiring technologies complementary to, or necessary for, our programs. In addition, these larger companies may be able to use their greater market power to obtain more favorable supply, manufacturing, distribution and sales-related agreements with third parties, which could give them a competitive advantage over us.

Further, as more product candidates within a particular class of drugs proceed through clinical development to regulatory review and approval, the amount and type of clinical data that may be required by regulatory authorities may increase or change. Consequently, the results of our clinical trials for product candidates in that class will likely need to show a risk benefit profile that is competitive with or more favorable than those products and product candidates in order to obtain marketing approval or, if approved, a product label that is favorable for commercialization. If the risk benefit profile is not competitive with those products or product candidates, or if the approval of other agents for an indication or patient population significantly alters the standard of care with which we tested our product candidates, we may have developed a product that is not commercially viable, that we are not able to sell profitably or that is unable to achieve favorable pricing or reimbursement. In such circumstances, our future product revenue and financial condition would be materially and adversely affected.

Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical study sites and subject enrollment for clinical studies, as well as in acquiring technologies complementary to, or necessary for, our current or future products or programs.

The market may not be receptive to our ~~development~~product candidates, and we may not generate any revenue from their sale, partnering or licensing.

Even if regulatory marketing approval is obtained, we may not generate or sustain revenue from sales of the corresponding product. Market acceptance will depend on, among other factors:

●

the timing of our receipt of any marketing and commercialization approvals and the terms of such approvals;

●

safety and efficacy;

●

limitations or warnings contained in any labeling approved by the FDA or other regulatory authority;

●

relative convenience and ease of administration;

●

the availability of coverage and adequate government and third-party payor reimbursement and the pricing of our products, particularly as compared to alternative treatments; and

● availability of alternative effective treatments for the disease indications that our programs or development candidates are intended to treat and the relative risks, benefits and costs of those treatments.41

Table of Contents

If● ~~any~~availability ~~program~~of oralternative ~~development~~effective ~~candidate~~treatments wefor ~~commercialize~~the ~~fails~~disease toindications ~~achieve~~that ~~market~~our ~~acceptance,~~programs itor ~~could~~product ~~have~~candidates aare ~~material~~intended ~~and~~to ~~adverse~~treat ~~effect~~and onthe ~~our~~relative ~~business~~risks, ~~financial~~benefits ~~condition,~~and ~~results~~costs of ~~operations~~those ~~and prospects~~treatments.

If ~~the~~any ~~market~~program ~~opportunities~~or ~~for~~product ~~our~~candidate ~~development~~we ~~candidates~~commercialize ~~are~~fails ~~smaller~~to ~~than~~achieve wemarket ~~believe they are~~acceptance, ~~our~~it ~~future~~could ~~product~~have ~~revenues~~a ~~may~~material beand ~~adversely~~adverse ~~affected,~~effect ~~and~~on our business, ~~may~~financial ~~suffer~~condition, results of operations and prospects.

~~Our~~If ~~understanding of~~ the ~~number~~market ofopportunities ~~people~~for ~~who suffer from certain types of medical conditions that may be able to be treated by~~ our ~~current~~product ~~and future potential development~~ candidates isare ~~based~~smaller onthan ~~estimates.~~we ~~These~~believe ~~estimates~~they ~~may prove to be incorrect~~are, ~~and~~our ~~new~~future ~~studies~~product ~~may~~revenues ~~reduce the estimated incidence or prevalence of these diseases. The number of patients in the United States or elsewhere~~ may ~~turn out to~~ be ~~lower~~adversely ~~than expected or may not be otherwise amenable to treatment. Additionally~~affected, ~~patients may become increasingly difficult to identify~~ and ~~access, all of which would adversely affect~~ our business ~~prospects and financial condition. In particular, the treatable population for various oncology indications~~ may ~~further be reduced if our estimates of addressable populations are erroneous or sub-populations of patients do not derive benefit from our development candidates~~suffer.

Our understanding of the number of people who suffer from certain types of medical conditions that may be able to be treated by our current and future potential product candidates is based on estimates. These estimates may prove to be incorrect, and new studies may reduce the estimated incidence or prevalence of these diseases. The number of patients in the United States or elsewhere may turn out to be lower than expected or may not be otherwise amenable to treatment. Additionally, patients may become increasingly difficult to identify and access, all of which would adversely affect our business prospects and financial condition. In particular, the treatable population for various oncology indications may further be reduced if our estimates of addressable populations are erroneous or sub-populations of patients do not derive benefit from our product candidates.

Further, there are several factors that could contribute to making the actual number of participants in clinical studies less than the potentially addressable market. These include the lack of widespread availability of, and limited reimbursement for, new therapies in many underdeveloped markets.

If we or others identify undesirable side effects caused by any of our current or future ~~development~~product candidates undergoing clinical trials, our ability to market and derive revenue from the ~~program~~product ~~or development~~ candidate could be compromised.

Undesirable side effects caused by any ~~development~~product candidates could cause regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other regulatory authorities. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of these side effects. In such an event, our trials could be suspended or terminated, and the FDA or other regulatory authorities could order us to cease further development of or deny approval of a ~~development~~product candidate for any or all targeted indications. Such side effects could also affect recruitment or the ability of enrolled participants to complete the trial or result in potential product liability claims. Any of these occurrences may materially and adversely affect our business and financial condition and impair our ability to generate revenues.

Further, clinical trials by their nature utilize a sample of the potential population. With a limited number of participants and limited duration of exposure, rare and severe side effects of a ~~program~~product ~~or development~~ candidate may only be uncovered when a significantly larger number of participants are exposed to the ~~development~~product candidate or when participants are exposed for a longer period of time.

InIf ~~the event that~~ any of our ~~development~~product candidates receive regulatory approval and we or others identify undesirable side effects caused by one of these products, any of the following adverse events could occur, which could result in the loss of significant revenue to us and materially and adversely affect our results of operations and business:

●

regulatory authorities may withdraw their approval of the product, seize the product or impose additional restrictions on the marketing of the particular product or the manufacturing processes for the product or any component thereof;

●

we may be required to recall the product, change the way the product is administered, conduct additional preclinical studies or clinical trials or change the labeling of the product;

●

we may be sued, subject to fines, injunctions or the imposition of civil or criminal penalties; and

● regulatory authorities may require the addition of labeling statements, such as a “black box” warning or a contraindication or a limitation on the indications for use or impose restrictions on the distribution in the form of a REMS in connection with approval.42

Table of Contents

If● ~~any~~regulatory ofauthorities ~~our~~may ~~development~~require ~~candidates is approved for marketing and commercialization in~~ the ~~future~~addition ~~and~~of welabeling ~~are~~statements, ~~unable~~such toas ~~develop~~a ~~sales,~~“black ~~marketing~~box” ~~and~~warning ~~distribution~~or ~~capabilities~~a oncontraindication ~~our own~~ or ~~enter~~a ~~into~~limitation ~~agreements~~on ~~with~~the ~~third~~indications ~~parties~~for touse ~~perform~~or ~~these~~impose ~~functions~~restrictions on ~~acceptable~~the ~~terms,~~distribution wein ~~will~~the beform ~~unable~~of toa ~~successfully~~REMS ~~commercialize~~in ~~any~~connection ~~such~~with ~~future products~~approval.

WeIf ~~currently~~any ~~have~~of noour ~~sales,~~product ~~marketing~~candidates oris ~~distribution~~approved ~~capabilities,~~for ~~which~~marketing ~~are~~and ~~necessary~~commercialization in ~~order~~the tofuture ~~commercialize each program~~ and development candidate that gains FDA approval. It would be expensive and time-consuming to build these capabilities or enter into strategic partnerships with third parties to perform these services. If we ~~decide~~are tounable ~~market any approved products directly, we will need~~ to ~~commit significant financial and managerial resources to~~ develop asales, marketing and ~~sales force with technical expertise and supporting~~ distribution, ~~administration and compliance~~ capabilities. ~~If we rely~~ on ~~third~~our ~~parties~~own ~~with such capabilities to market any approved products~~ or ~~decide~~enter tointo ~~co-promote~~agreements ~~products~~ with ~~partners, we will need to establish and maintain marketing and distribution arrangements with~~ third parties, ~~and there can be no assurance that we will be able~~ to ~~enter~~perform ~~into~~these ~~such~~functions ~~arrangements~~ on acceptable terms ~~or at all. In entering into third-party marketing or distribution arrangements~~, ~~any revenue~~ we ~~receive~~ will ~~depend upon the efforts of the third parties and we cannot assure you that such third parties will establish adequate sales and distribution capabilities or~~ be ~~successful~~unable into ~~gaining~~successfully ~~market~~commercialize ~~acceptance for~~ any ~~approved~~such ~~product. If we are not successful in commercializing any product approved in the~~ future, ~~either on our own or through third parties, our business and results of operations could be materially and adversely affected~~products.

We currently have no sales, marketing or distribution capabilities, which are necessary in order to commercialize each product candidate that gains FDA approval. It would be expensive and time-consuming to build these capabilities or enter into strategic partnerships with third parties to perform these services. If we decide to market any approved products directly, we will need to commit significant financial and managerial resources to develop a marketing and sales force with technical expertise and supporting distribution, administration and compliance capabilities. If we rely on third parties with such capabilities to market any approved products or decide to co-promote products with partners, we will need to establish and maintain marketing and distribution arrangements with third parties, and there can be no assurance that we will be able to enter into such arrangements on acceptable terms or at all. In entering into third-party marketing or distribution arrangements, any revenue we receive will depend upon the efforts of the third parties and we cannot assure you that such third parties will establish adequate sales and distribution capabilities or be successful in gaining market acceptance for any approved product. If we are not successful in commercializing any product approved in the future, either on our own or through third parties, our business and results of operations could be materially and adversely affected.

A Fast Track Designation from the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process, and does not increase the likelihood that our product candidates will receive regulatory approval.

The FDA has granted Fast Track designation for ~~AL102~~varegacestat for progressing desmoid tumors. We intend to seek such designation for some or all of our additional product candidates. The Fast Track program is intended to expedite or facilitate the process for reviewing new product candidates that meet certain criteria. Specifically, drugs and biologic are eligible for Fast Track designation if they are intended, alone or in combination with one or more drugs or biologics, to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast Track designation applies to the combination of the product candidate and the specific indication for which it is being studied. The sponsor of a Fast Track product candidate has opportunities for more frequent interactions with the applicable FDA review team during product development and, once a biologics license application, or biologics license applications, or BLA, or NDA is submitted, the application may be eligible for priority review. An NDA or BLA submitted for a Fast Track product candidate may also be eligible for rolling review, where the FDA may consider for review sections of the NDA or BLA on a rolling basis before the complete application is submitted. If the sponsor provides a schedule for the submission of the sections of the NDA or BLA, the FDA agrees to accept sections of the NDA or BLA, as applicable, and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the application.

The FDA has broad discretion whether or not to grant this designation. Even if we believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Even if we do receive Fast Track Designation for any of our product candidates, such product candidates may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may also withdraw Fast Track Designation if it believes that the designation is no longer supported by data from our clinical development program. Furthermore, such a designation does not increase the likelihood that ~~AL102~~varegacestat or any other product candidate that may be granted Fast Track designation will receive regulatory approval in the United States. Many product candidates that have received Fast Track Designation have ultimately failed to obtain regulatory approval.

5043

Table of Contents

We may attempt to secure approval from the FDA through the use of the accelerated approval pathway. If we are unable to obtain such approval, we may be required to conduct additional preclinical studies or clinical trials beyond those that we contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary regulatory approvals. Even if we receive accelerated approval from the FDA, if our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA may seek to withdraw any accelerated approval we have obtained.*

We may in the future seek accelerated approval for one or more of our product candidates. Under the accelerated approval program, the FDA may grant accelerated approval to a product candidate designed to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies upon a determination that the product candidate has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit.

The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is usually contingent on the sponsor’s agreement to conduct, in a diligent manner, additional confirmatory studies to verify and describe the drug’s clinical benefit. If such post-approval studies fail to confirm the drug’s clinical benefit or are not completed in a timely manner, the FDA may withdraw its approval of the drug on an expedited basis. In addition, the FDA may require a sponsor of a product seeking accelerated approval to have a confirmatory trial underway prior to such approval being granted.

Prior to seeking accelerated approval for any of our product candidates, we intend to seek feedback from the FDA and will otherwise evaluate our ability to seek and receive accelerated approval. There can be no assurance that after our evaluation of any feedback and other factors we will decide to pursue or submit an NDA for accelerated approval or any other form of expedited development, review or approval. Furthermore, if we decide to submit an application for accelerated approval for any of our product candidates, there can be no assurance that such application will be accepted or that any expedited development, review or approval will be granted on a timely basis, or at all. The FDA or other comparable foreign regulatory authorities could also require us to conduct further studies prior to considering our application or granting approval of any type. A failure to obtain accelerated approval or any other form of expedited development, review or approval for any of our product candidates would result in a longer time period to commercialization of such product candidate, if any, could increase the cost of development of such product candidate and could harm our competitive position in the marketplace.

Table of Contents

We may fail to obtain orphan drug designations from the FDA for our product candidates, and even if we obtain such designations, we may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity.

Regulatory authorities in some jurisdictions, including the United States, may designate biologics or drugs designed to address relatively small patient populations as “orphan drugs.” Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug or biologic intended to treat a rare disease or condition, which is defined as one occurring in a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States, where there is no reasonable expectation that the cost of developing the drug or biologic will be recovered from sales in the United States. In the United States, orphan designation entitles a party to financial incentives such as opportunities for grant funding for clinical trial costs, tax advantages and user-fee waivers. In addition, if a product candidate that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications, including an NDA, to market the same drug for the same disease or condition for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or where the manufacturer is unable to assure sufficient product quantity.

In November 2023, the FDA granted Orphan Drug Designation to AL102 for the treatment of desmoid tumors, and we may seek additional Orphan Drug Designations for our other product candidates. There can be no assurances that we will be able to obtain such designations. Even if we, or any future collaborators, obtain orphan drug designation for a product candidate, we, or they, may not be able to obtain or maintain orphan drug exclusivity for that product candidate. Further, even if we, or any future collaborators, obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs with different active ingredients may be approved for the same disease or condition. Even after an orphan drug is approved, the FDA can subsequently approve the same drug or biologic for the same disease or condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care, or the manufacturer of the product with orphan exclusivity is unable to maintain sufficient product quantity. Orphan drug designation neither shortens the development or regulatory review time of a drug nor gives the drug or biologic any advantage in the regulatory review or approval process. 44

Table of Contents

In November 2023, the FDA granted Orphan Drug Designation to varegacestat for the treatment of desmoid tumors, and we may seek additional Orphan Drug Designations for our other product candidates. There can be no assurances that we will be able to obtain such designations. Even if we, or any future collaborators, obtain orphan drug designation for a product candidate, we, or they, may not be able to obtain or maintain orphan drug exclusivity for that product candidate. Further, even if we, or any future collaborators, obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs with different active ingredients may be approved for the same disease or condition. Even after an orphan drug is approved, the FDA can subsequently approve the same drug or biologic for the same disease or condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care, or the manufacturer of the product with orphan exclusivity is unable to maintain sufficient product quantity. Orphan drug designation neither shortens the development or regulatory review time of a drug nor gives the drug or biologic any advantage in the regulatory review or approval process.

If we are required by the FDA to obtain approval of a companion diagnostic in connection with approval of any of our product candidates, and we do not obtain, or face delays in obtaining, FDA approval of such companion diagnostic, we will not be able to commercialize such product candidate and our ability to generate revenue will be materially impaired.

According to FDA guidance, if the FDA determines that a companion diagnostic device is essential to the safe and effective use of a novel therapeutic product or indication, the FDA generally will not approve the therapeutic product or new therapeutic product indication if the companion diagnostic is not also approved or cleared for that indication. Depending on the data from our clinical trials, we may decide to collaborate with diagnostic companies during our clinical trial enrollment process to help identify patients with characteristics that we believe will be most likely to respond to our product candidates. If a satisfactory companion diagnostic is not commercially available in this situation, we may be required to develop or obtain such diagnostic, which would be subject to regulatory approval requirements. The process of obtaining or creating a diagnostic is time consuming and costly.

Companion diagnostics are developed in conjunction with clinical programs for the associated product and are subject to regulation as medical devices by the FDA and comparable foreign regulatory authorities, and the FDA has generally required premarket approval of companion diagnostics for cancer therapies. The approval or clearance of a companion diagnostic as part of the therapeutic product’s further labeling limits the use of the therapeutic product to only those patients who express the specific characteristic that the companion diagnostic was developed to detect.

Table of Contents

If the FDA or a comparable foreign regulatory authority requires approval or clearance of a companion diagnostic for any of our product candidates, whether before or after the product candidate obtains regulatory approval, we and/or third-party collaborators may encounter difficulties in developing and obtaining approval or clearance for these companion diagnostics. Any delay or failure by us or third-party collaborators to develop or obtain regulatory approval or clearance of a companion diagnostic could delay or prevent approval or continued marketing of the relevant product. We or our collaborators may also experience delays in developing a sustainable, reproducible and scalable manufacturing process for the companion diagnostic or in transferring that process to commercial partners or negotiating insurance reimbursement plans, all of which may prevent us from completing our clinical trials or commercializing our product candidates, if approved, on a timely or profitable basis, if at all.

Table of Contents

Additional regulatory burdens and other risks and uncertainties in foreign markets may limit our growth.

Our future growth may depend, in part, on our ability to engage in development and commercialization efforts in foreign markets for which we may rely on strategic partnership with third parties. We will not be permitted to market or promote any program or ~~development~~product candidate before we receive regulatory approval from the applicable regulatory authority in a foreign market, and we may never receive such regulatory approval. To obtain separate regulatory approval in foreign markets, we generally must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing and distribution of a program or ~~development~~product candidate, and we cannot predict success in these jurisdictions. If we obtain approval of any of our programs or ~~development~~product candidates and ultimately commercialize any such program or ~~development~~product candidate in foreign markets, we would be subject to risks and uncertainties, including the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements and the reduced protection of intellectual property rights in some foreign countries. Pricing flexibility may be limited in foreign markets which may further limit revenue.

Our business entails a significant risk of product liability, which may not be sufficiently covered by our insurance.

As we continue to engage in preclinical studies and clinical trials, we will be exposed to significant product liability risks inherent in the development, testing, manufacturing and marketing of antibody treatments. Product liability claims could delay or prevent completion of our development programs. If we succeed in marketing products, such claims could result in an FDA investigation of the safety and effectiveness of our products, our manufacturing processes and facilities or our marketing programs and potentially a recall of our products or more serious enforcement action, limitations on the approved indications for which they may be used or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for our products, injury to our reputation, costs to defend the related litigation, a diversion of management’s time and our resources, substantial monetary awards to trial participants or patients and a decline in our stock price. Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, our partners or we may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused by product liability claims that could have a material and adverse effect on our business, financial condition, results of operations and prospects.

53We have obtained rights to use human samples in furtherance of our research and development. However, if we failed to obtain appropriate permission to use these samples or exceed the scope of the permissions given, our programs could be adversely affected.

With respect to certain of our product candidates, our discovery process involves gathering tissue samples from humans. While we attempt to ensure that we and our vendors have obtained these samples with all necessary permissions, there is a risk that one or more individuals from whom samples were collected, or their representatives may assert that we have either failed to obtain appropriate permission or exceeded the scope of permission granted. In such circumstances, we could be required to pay monetary damages, to pay a continuing royalty on any products created or invented by analyzing the person’s sample or even to cease using the sample and any and all materials derived from or created through analysis of the sample, any of which could result in a change to our business plan and materially harm our business, financial condition, results of operations and prospects. Further, in some cases, these penalties could materially impact the performance, availability, or validity of studies conducted by us or on our behalf. Even in the absence of violations resulting in penalties, regulatory and other authorities may refuse to authorize the conduct or to accept the results of studies for regulatory or ethical reasons, which could impact our ability to progress our program into or through clinical trials, and peer-reviewed journals may refuse to publish scientific findings, which could limit our ability to disseminate information related to this program.

Table of Contents

Risks Related to Government Regulation

We and the third parties with whom we work are subject to stringent and evolving U.S. and foreign laws, regulations, and rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security. Our (or the third parties with whom we work) actual or perceived failure to comply with such obligations could lead to regulatory investigations or government enforcement actions; private litigation (including class claims) and mass arbitration demands; fines and penalties; disruptions of our business operations; adverse publicity; and other consequences that could negatively affect our operating results and business.*

In the ordinary course of business, we collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively, process) personal information and other sensitive information, including proprietary and confidential business data, trade secrets, intellectual property, data we collect about trial participants in connection with clinical trials, and sensitive third-party data. Due to these data processing activities, we and the third parties with whom we work, including our current and potential collaborators are ~~or may become~~ subject to numerous data privacy and security obligations, such as federal, state, local and foreign laws and regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements, and other obligations related to data privacy and security.

In the United States, numerous federal, state and local laws and regulations, including federal health information privacy laws (e.g., the Health Insurance Portability and Accountability Act, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, state data breach notification laws, state health information privacy laws, federal and state consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act)), and other similar laws (e.g., wiretapping laws), that govern the collection, use, disclosure and protection of health-related and other personal information ~~could~~ apply to our operations or the operations of the third parties with whom we work. For example, HIPAA imposes specific requirements relating to the privacy, security, and transmission of individually identifiable protected health information. We ~~may~~ obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under HIPAA, or other data privacy and security laws. Depending on the facts and circumstances, we could be subject to criminal penalties if we knowingly obtain, use, or disclose protected health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA. However, determining whether protected health information has been handled in compliance with applicable privacy standards and our contractual obligations can be complex and ~~may be~~ subject to changing interpretation. Many state laws govern the data privacy and security of personal information and data in specified circumstances, are often not pre-empted by HIPAA, and may have a more prohibitive effect than HIPAA, thus complicating compliance efforts. In the past few years, numerous U.S. states—including California, Virginia, Colorado, Connecticut, and Utah—have enacted comprehensive privacy laws that impose certain obligations on covered businesses, including providing specific disclosures in privacy notices and affording residents with certain rights concerning their personal information. As applicable, such rights may include the right to access, correct, or delete certain personal information, and to opt-out of certain data processing activities, such as targeted advertising, profiling, and automated decision-making. The exercise of these rights may impact our business and ability to provide our products and services. Certain states also impose stricter requirements for processing certain personal information, including sensitive information, such as conducting data privacy impact assessments. These state laws allow for statutory fines for noncompliance. For example, the California Consumer Privacy Act of 2018, as amended by the California Privacy Rights Act of 2020, or CPRA (collectively, CCPA) applies to personal information of consumers, business representatives, and employees who are California residents. The CCPA provides for fines of up to $7,500 per intentional violation and allows private litigants affected by certain data breaches to recover significant statutory damages. While there is currently an exception for protected health information that is subject to HIPAA and clinical trial regulations in the CCPA and certain other U.S. state privacy laws, these laws increase compliance costs and potential liability with respect to other personal information we maintain. Similar laws are being considered in several other states, as well as at the federal and local levels, and we expect more states to pass similar laws in the future.

54Numerous U.S. states have enacted comprehensive privacy laws that impose certain obligations on covered businesses, including providing specific disclosures in privacy notices and affording residents with certain rights concerning their personal information. As applicable, such rights include the right to access, correct, or delete certain personal information, and to opt-out of certain data processing activities, such as targeted advertising, profiling, and automated decision-making. The exercise of these rights may impact our business and ability to provide our products and services. Certain states also impose stricter requirements for processing certain personal information, including sensitive information, such as conducting data privacy impact assessments. These state laws allow for statutory fines for noncompliance. While there is currently an exception for protected health information that is subject to HIPAA and clinical trial regulations in certain U.S. state privacy laws, these laws increase compliance costs and potential liability with respect to other personal information we maintain. Similar laws are being considered in several other states, as well as at the federal and local levels, and we expect more states to pass similar laws in the future.

Table of Contents

Outside the United States, an increasing number of laws, regulations, and industry standards govern data privacy and security. For example, the European Union’s General Data Protection Regulation, or EU GDPR, ~~and~~ the United Kingdom’s GDPR, or UK GDPR, (collectively, GDPR), Australia’s Privacy Act 1988, and Israel’s Protection of Privacy Law (“PPL”) impose strict requirements for processing personal information. For example, under the GDPR, companies subject to these laws and in the event of non-compliance may experience temporary or definitive bans on data processing and other corrective actions; fines of up to 20 million Euros under the EU GDPR, 17.5 million pounds sterling under the UK GDPR or, in each case, 4% of annual global revenue, whichever is greater; or private litigation related to processing of personal information brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests. In Canada, the Personal Information Protection and Electronic Documents Act, or PIPEDA, and various related provincial laws, as well as Canada’s Anti-Spam Legislation, or CASL, may apply to our operations. Compliance with foreign data privacy and security laws and regulations ~~could~~requires ~~require~~ us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, ~~impact~~impacts our ability to operate in certain jurisdictions.

In the ordinary course of business, we ~~may~~ transfer personal data from Europe and other jurisdictions to the United States or other countries. Europe and certain other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal data to other countries. In particular, the European Economic Area (EEA) and the United Kingdom (UK) have significantly restricted the transfer of personal data to the United States and other countries whose privacy laws it generally believes are inadequate. Other jurisdictions may adopt ~~similarly~~or ~~stringent~~have ~~interpretations~~already ofadopted ~~their~~similarly stringent data localization and cross-border data transfer laws.

Although there are currently various mechanisms that ~~may~~can be used to transfer personal data from the EEA and UK to the United States in compliance with law, such as the EEA standard contractual clauses, these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these mechanisms to lawfully transfer personal data to the United States.

If there were no lawful manner for us to transfer personal data from the EEA, the UK or other jurisdictions to the United States, or if the requirements for a legally-compliant transfer are too onerous, we could face significant adverse consequences, including the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions (such as Europe) at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third parties, and injunctions against our processing or transferring of personal data necessary to operate our business. Additionally, companies that transfer personal data out of the EEA and UK to other jurisdictions, particularly to the United States, are subject to increased scrutiny from regulators, individual litigants, and activist groups. Some European regulators have ordered certain companies to suspend or permanently cease certain transfers out of Europe for allegedly violating the GDPR’s cross-border data transfer limitations. Regulators in the United States are also increasingly scrutinizing certain personal data transfers and have and may further impose personal data localization requirements or restrictions on cross-border personal data transfers.

~~Our~~Additionally, ~~employees~~the ~~and~~U.S. ~~personnel~~Department ~~have~~of ~~used,~~Justice ~~and~~issued ~~may~~a inrule entitled the ~~future~~Preventing ~~use,~~Access ~~generative~~to ~~artificial~~U.S. ~~intelligence,~~Sensitive Personal Data and Government-Related Data by Countries of Concern or AICovered Persons, ~~technologies~~which toplaces ~~perform~~additional ~~their~~restriction ~~work~~on certain data transactions involving countries of concern (e.g., ~~and~~China, ~~the~~Russia, ~~disclosure~~Iran) and ~~use~~covered ofindividuals ~~personal~~(i.e., ~~information~~individuals inand ~~generative~~entities AIlocated ~~technologies~~in isor ~~subject~~controlled toby ~~various~~individuals ~~privacy~~or ~~laws~~entities ~~and~~located ~~other~~in ~~privacy~~those ~~obligations.~~jurisdictions) ~~Governments~~that ~~have~~may ~~passed~~impact ~~and~~certain ~~are~~business ~~likely~~activities tosuch ~~pass~~as ~~additional~~vendor ~~laws~~engagements, ~~regulating~~sale ~~generative~~or ~~AI.~~sharing ~~Our~~of ~~use~~data, employment of ~~this~~certain ~~technology~~individuals, ~~could~~and ~~result~~investor inagreements. ~~additional~~Violations ~~compliance~~of ~~costs,~~the ~~regulatory~~rule ~~investigations~~could lead to significant civil and ~~actions,~~criminal fines and ~~lawsuits~~penalties. IfThe werule ~~are~~applies ~~unable~~regardless toof ~~use~~whether ~~generative~~data AIis anonymized, itkey-coded, ~~could~~pseudonymized, ~~make~~de-identified ~~our~~or ~~business~~encrypted, ~~less~~which ~~efficient~~presents particular challenges for companies like ours and ~~result~~may impact our ability to transfer data in ~~competitive~~connection ~~disadvantages~~with certain transactions or agreements.

We may also ~~have~~become ~~used,~~subject ~~and~~to ~~may~~new inlaws ~~the~~that ~~future~~regulate ~~use,~~non-personal AIdata. ~~and~~For ~~machine learning~~example, orthe ~~ML,~~European ~~technologies~~Union’s toData ~~assist~~Act usimposes incertain ~~making~~data ~~certain~~and ~~decisions,~~cloud ~~which~~service isinteroperability ~~regulated~~and byswitching ~~certain~~obligations ~~data~~to ~~privacy~~enable ~~and~~users ~~security~~to ~~laws.~~switch ~~Due~~between tocloud ~~inaccuracies~~service orproviders ~~flaws~~without inundue ~~the~~delay ~~inputs,~~or ~~outputs~~cost, oras ~~logic~~well ofas ~~the~~certain ~~AI/ML,~~requirements ~~the~~concerning ~~model~~cross-border ~~could~~international betransfers ~~biased~~of, and ~~could~~governmental ~~lead~~access us to, ~~make~~non-personal ~~decisions~~data ~~that~~outside ~~could~~the ~~bias~~EEA. ~~certain~~Depending ~~individuals~~on ~~(or~~how ~~classes~~this ofAct ~~individuals),~~ and ~~adversely~~any ~~impact~~similar ~~their~~laws ~~rights,~~are ~~employment,~~implemented and ~~ability~~interpreted, we may have to ~~obtain~~adapt ~~certain~~our ~~pricing,~~business ~~products,~~practices ~~services,~~and orcontractual ~~benefits~~arrangements to comply with such obligations.

5548

Table of Contents

InOur ~~addition~~employees toand ~~data~~personnel ~~privacy~~use ~~and~~generative ~~security~~artificial ~~laws~~intelligence, weor ~~are~~AI, ~~contractually~~technologies ~~subject~~ to ~~industry~~perform ~~standards~~their ~~adopted~~work, byand ~~industry~~the ~~groups,~~disclosure and weuse ~~may~~of ~~become~~personal information in AI technologies is subject to ~~such~~various ~~obligations~~privacy inlaws ~~the~~and ~~future.~~other Weprivacy ~~are~~obligations. ~~also~~Governments ~~bound~~have bypassed ~~contractual~~and ~~obligations~~are ~~related~~likely to ~~data~~pass ~~privacy~~additional ~~and~~laws ~~security,~~regulating ~~and~~AI. ~~our~~Our ~~efforts~~use toof ~~comply~~this ~~with~~technology ~~such~~could ~~obligations~~result ~~may~~in ~~not~~additional becompliance ~~successful.~~costs, ~~For~~regulatory ~~example,~~investigations ~~clinical~~and ~~trial~~actions, ~~sites~~and ~~who~~lawsuits. ~~share~~If ~~data~~we ~~about~~are ~~clinical~~unable ~~trial~~to ~~participants~~use ~~may~~AI, ~~contractually~~it ~~limit~~could make our ~~ability~~business toless ~~use~~efficient and ~~disclose~~result ~~personal~~in ~~information~~competitive disadvantages.

WeIn ~~publish~~addition to data privacy ~~policies~~and security laws, ~~marketing~~we ~~materials~~are ~~and~~contractually ~~other~~subject ~~statements~~to industry standards adopted by industry groups, and we may become subject to such asadditional ~~compliance~~obligations ~~with~~in ~~certain~~the ~~certifications~~future. orWe ~~self-regulatory~~are ~~principles,~~also ~~regarding~~bound by contractual obligations related to data privacy and security., Ifand ~~these~~our ~~policies,~~efforts ~~materials~~to orcomply ~~statements~~with ~~are~~such ~~found~~obligations tomay not be ~~deficient,~~successful. ~~lacking~~For ~~in transparency~~example, ~~deceptive,~~some ~~unfair,~~clinical ortrial ~~misrepresentative~~sites ofwho ~~our~~share ~~practices,~~data weabout ~~may~~clinical betrial ~~subject~~participants tocontractually ~~investigation,~~limit ~~enforcement~~our ~~actions~~ability byto ~~regulators~~use orand ~~other~~disclose ~~adverse~~personal ~~consequences~~information.

~~Obligations~~We ~~related~~publish toprivacy ~~data~~policies, ~~privacy~~marketing ~~and~~materials, ~~security~~whitepapers, (and ~~consumers’~~other ~~data~~statements, ~~privacy~~such ~~expectations)~~as ~~are~~statements ~~quickly~~related ~~changing,~~to ~~becoming~~compliance ~~increasingly~~with ~~stringent,~~certain ~~and~~certifications ~~creating~~or ~~uncertainty.~~self-regulatory ~~Additionally~~principles, ~~these~~regarding ~~obligations~~data ~~may~~privacy beand ~~subject~~security. toRegulators ~~differing~~in ~~applications~~the ~~and~~United ~~interpretations,~~States ~~which~~are ~~may~~increasingly bescrutinizing ~~inconsistent~~these orstatements, ~~conflict~~and ~~among~~if ~~jurisdictions.~~these ~~Preparing~~policies, ~~for~~materials ~~and~~or ~~complying~~statements ~~with~~are ~~these~~found ~~obligations~~to ~~requires~~be usdeficient, tolacking ~~devote~~in ~~significant~~transparency, ~~resources~~deceptive, ~~which~~unfair, ~~may~~misleading, ~~necessitate~~or ~~changes~~misrepresentative toof our ~~services~~practices, ~~information~~we ~~technologies,~~may ~~systems,~~be ~~and~~subject ~~practices and~~ to ~~those~~investigation, ofenforcement ~~any~~actions ~~third~~by ~~parties~~regulators ~~with~~or ~~whom~~other weadverse ~~work~~consequences.

WeObligations ~~may~~related ~~at times fail (or be perceived~~ to ~~have~~data ~~failed)~~privacy inand ~~our~~security ~~efforts~~(and toconsumers’ ~~comply with our~~ data privacy ~~and~~expectations) ~~security~~are ~~obligations.~~quickly ~~Moreover~~changing, ~~despite~~becoming ~~our~~increasingly ~~efforts~~stringent, ~~our~~and ~~personnel~~creating oruncertainty. ~~third~~Additionally, ~~parties~~these ~~with~~obligations ~~whom~~are wesubject ~~work may fail~~ to ~~comply~~differing ~~with~~applications ~~such~~and ~~obligations~~interpretations, which ~~could~~may ~~negatively~~be ~~impact~~inconsistent ~~our~~or ~~business~~conflict ~~operations~~among jurisdictions. IfPreparing wefor orand ~~the~~complying ~~third parties~~ with ~~whom~~these weobligations ~~work~~requires ~~fail,~~us ~~or are perceived~~ to ~~have~~devote ~~failed~~significant resources, ~~to address or comply with applicable U.S.~~ and ~~foreign~~has ~~data~~in ~~privacy~~the ~~and~~past ~~security laws~~ and ~~regulations,~~may wein ~~could~~the ~~face~~future ~~government~~necessitate ~~enforcement~~changes ~~actions~~to ~~(e.g.,~~our ~~investigations~~services, ~~fines,~~information ~~penalties~~technologies, ~~audits~~systems, ~~inspections,~~ and ~~similar);~~practices ~~litigation (including class claims) or mass arbitration demands; additional reporting requirements~~ and~~/or~~ ~~oversight; bans on processing personal information; orders~~ to ~~destroy~~those ~~or not use personal information; and imprisonment~~ of ~~company~~any ~~officials. Claims that we or the~~ third parties with whom we work have violated individuals’ privacy rights, failed to comply with data privacy and security laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time consuming to defend and could result in adverse publicity that could harm our business. Plaintiffs have become increasingly more active in bringing privacy-related claims against companies, including class claims and mass arbitration demands. Some of these claims allow for the recovery of statutory damages on a per violation basis, and, if viable, carry the potential for monumental statutory damages, depending on the volume of data and the number of violations.

Failure or the perceived failure to address or comply with applicable data privacy and security obligations, could result in government enforcement actions (e.g., investigations, fines, penalties, audits, inspections, and similar); litigation (including class claims) or mass arbitration demands; additional reporting requirements and/or oversight; bans on processing personal information; orders to destroy or not use personal information; and imprisonment of company officials. Claims that we or the third parties with whom we work have violated individuals’ privacy rights, failed to comply with data privacy and security laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time consuming to defend and could result in adverse publicity that could harm our business. Plaintiffs have become increasingly more active in bringing privacy-related claims against companies, including class claims and mass arbitration demands. Some of these claims allow for the recovery of statutory damages on a per violation basis, and, if viable, carry the potential for monumental statutory damages, depending on the volume of data and the number of violations.

Any of the aforementioned events could have a material adverse effect on our reputation, business, or financial condition, including: interruptions or stoppages in our business operations (including, as relevant, clinical trials); inability to process personal information or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or substantial changes to our business model or operations.

5649

Table of Contents

Health care legislative reform measures may have a material adverse effect on our business and results of operations.*

In the United States, there have been and continue to be a number of legislative initiatives to contain health care costs. For example, in March 2010, the Patient Protection and Affordable Care Act, or ACA, was signed into law. This legislation changed the system of health care insurance and benefits and was intended to broaden access to health care coverage, enhance remedies against fraud and abuse, add transparency requirements for the health care and health insurance industries, impose taxes and fees on the health care industry, impose health policy reforms, and control costs. This law also contains provisions that would affect companies in the pharmaceutical industry and other health care related industries by imposing additional costs and changes to business practices. Since its enactment, there have been judicial and congressional challenges and amendments to certain aspects of the ACA. For example, on June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the individual mandate was repealed by the U.S. Congress. In addition, on August 16, 2022, ~~President Biden signed~~ the Inflation Reduction Act of 2022, or the IRA, was signed into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the “donut hole” under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program. The uncertainty around the future of the ACA and other health reform measures, and in particular the impact to reimbursement levels, may lead to uncertainty or delay in the purchasing decisions of our customers, which may in turn negatively impact our product sales. ~~We continue to evaluate the effect that the ACA and any other health reform measures could have on our business.~~ Additional federal and state legislative and regulatory developments are likely, particularly in light of the change in Presidential administrations, and we expect ongoing initiatives in the United States to increase pressure on drug and biologic pricing and reimbursement. Such reforms could have an adverse effect on anticipated revenues from ~~development~~product candidates that we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop ~~development~~product candidates.

Further, among other things, the IRA has multiple provisions that may impact the prices of ~~drug~~ products that are both sold into the Medicare program and throughout the United States. Starting in 2023, the Centers for Medicare & Medicaid Services, or CMS, began to implement the program in which a manufacturer of a drug or biological product covered by Medicare Parts B or D must pay a rebate to the federal government if the ~~drug~~ product’s price increases faster than the rate of inflation. This calculation is made on a ~~drug~~ product by ~~drug~~ product basis and the amount of the rebate owed to the federal government is directly dependent on the volume of a ~~drug~~ product that is paid for by Medicare Parts B or D. Additionally, starting in payment year 2026, CMS will begin to reimburse negotiated drug prices annually for a select number of single source Part D drugs that have been on the market for at least 7 years without generic or biosimilar competition, or the Medicare Drug Price Negotiation Program. On August 15, 2024, CMS announced the agreed-upon ~~reimbursement~~ prices of the first ten drugs that were subject to price negotiations, although the Medicare ~~drug~~Drug ~~price~~Price ~~negotiation~~Negotiation ~~program~~Program is currently subject to legal challenges. ~~CMS~~On ~~will~~January ~~select~~17, up2025, toCMS selected fifteen additional ~~drugs~~products covered under Part D for price negotiation in 2025. ~~CMS~~Each ~~will~~year ~~also~~thereafter ~~negotiate~~more ~~drug~~Part ~~prices~~B ~~for~~and aPart ~~select~~D ~~number~~products ofwill ~~Part B~~become ~~drugs~~subject ~~starting~~to ~~for~~the ~~payment~~Medicare ~~year~~Drug ~~2028.~~Price Negotiation Program If a ~~drug~~ product is selected by CMS for negotiation, it is expected that the revenue generated from such drug will decrease. ~~CMS has and will continue to issue and update guidance as these programs are implemented.~~ The IRA permits the U.S. Department of Health and Human Services, or HHS, to implement many of these provisions through guidance, as opposed to regulation, for the initial years. HHS has and will continue to issue and update guidance as these programs are implemented. It is unclear how the IRA will be implemented but is likely to have a significant impact on the pharmaceutical industry.

Further, on February 14, 2023, HHS released a report outlining three new models for testing by the Centers for Medicare & Medicaid Services Innovation Center which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. Additionally, on December ~~7, 2023, the Biden administration announced an initiative to control the price of prescription drugs through the use of march-in rights under the Bayh-Dole Act. On December~~ 8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not previously been exercised, it is uncertain if that will continue under the new framework.

Table of Contents

Individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. For example, on January 5, 2024, the FDA approved Florida’s Section 804 Importation Program, or SIP, proposal to import certain drugs from Canada for specific state healthcare programs. It is unclear how this program will be implemented, including which drugs will be chosen, and whether it will be subject to legal challenges in the United States or Canada. Other states have also submitted SIP proposals that are pending review by the FDA. Any such approved importation plans, when implemented, may result in lower drug prices for products covered by those programs.

Table of Contents

Those new laws and initiatives may result in additional reductions in Medicare and other health care funding, which could have a material adverse effect on our future customers and accordingly, our financial operations. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we otherwise may have obtained and we may not achieve or sustain profitability, which would adversely affect our business, prospects, financial condition and results of operations.

We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad, particularly given the recent change in administration. The current Trump administration is pursuing policies to reduce regulations and expenditures across government including at HHS, the FDA, CMS and related agencies. These actions, presently directed by executive orders or memoranda from the Office of Management and Budget, may propose policy changes that create additional uncertainty for our business. These actions include, for example, directives to reduce agency workforce, program cuts, rescinding a Biden administration executive order tasking the Center for Medicare and Medicaid Innovation to consider new payment and healthcare models to limit drug spending and eliminating the Biden administration’s executive order that directed HHS to establishing an AI task force and developing a strategic plan, directing HHS to lower prescription drug costs for Medicare through a variety of initiatives, including by improving upon the Medicare Drug Negotiation Program, and directing certain federal agencies to enforce existing law regarding hospital and plan price transparency and by standardizing prices across hospitals and health plans. Additionally, in its June 2024 decision in Loper Bright Enterprises v. Raimondo, the U.S. Supreme Court overturned the longstanding Chevron doctrine, under which courts were required to give deference to regulatory agencies’ reasonable interpretations of ambiguous federal statutes. The Loper Bright decision could result in additional legal challenges to current regulations and guidance issued by federal agencies applicable to our operations, including those issued by the FDA. Congress may introduce and ultimately pass health care related legislation that could impact the drug approval process and make changes to the Medicare Drug Price Negotiation Program created under the IRA. We expect that additional state and federal health care reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for health care products and services, which could result in reduced demand for our ~~development~~product candidates or additional pricing pressures, or otherwise adversely impact our operations.

If we or our existing or potential future partners, manufacturers or other service providers fail to comply with health care laws and regulations, we or they could be subject to enforcement actions, which could affect our ability to develop, market and sell our products and may harm our reputation.

Health care providers and third-party payors, among others, will play a primary role in the prescription and recommendation of any programs or ~~development~~product candidates for which we obtain marketing approval. Our current and future arrangements with third-party payors, providers and customers, among others, may expose us to broadly applicable fraud and abuse and other health care laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our ~~development~~product candidates for which we obtain marketing approval. These laws and regulations, include:

●

the federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce, or in return for, purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item or service reimbursable under Medicare, Medicaid or other federally financed healthcare programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other. Although there are several statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution, the exceptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Further, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;

5851

Table of Contents

●

federal civil and criminal false claims laws, including the federal False Claims Act, which prohibit any person from knowingly presenting, or causing to be presented, a false claim for payment to the federal government or knowingly making, or causing to be made, a false statement to get a false claim paid. Over the past few years, several pharmaceutical and other healthcare companies have been prosecuted under these laws for a variety of alleged promotional and marketing activities, including: allegedly providing free items and services, sham consulting fees and grants and other monetary benefits to prescribers; reporting to pricing services inflated average wholesale prices that were then used by federal programs to set reimbursement rates; engaging in off-label promotion that caused claims to be submitted to government healthcare programs for non-covered, off-label uses; and submitting inflated best price information to the Medicaid Drug Rebate Program to reduce liability for Medicaid rebates. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act;

●

HIPAA, which prohibits, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, of any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless or the payor (e.g., public or private), willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services; like the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;

●

HIPAA, as amended by HITECH, and their respective implementing regulations, including the Final Omnibus Rule which impose requirements relating to the privacy, security and transmission of individually identifiable health information on certain health care providers, health care clearinghouses, and health plans, known as covered entities, as well as independent contractors, or agents of covered entities that create, receive or obtain individually identifiable health information in connection with providing a service on behalf of a covered entity, known as a business associates, and their covered subcontractors;

●

the federal transparency requirements known as the federal Physician Payments Sunshine Act, created as part of the ACA, which requires manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program (with certain exceptions) to report annually to the government information related to payments or other “transfers of value” made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physician assistants and nurse practitioners) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; and

● analogous local, state and foreign laws and regulations such as state anti-kickback and false claims laws, that may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; some state laws that require biotechnology companies to comply with the industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; some state laws that require biotechnology companies to report information on the pricing of certain ~~drug~~ products; and some state and local laws require the registration or pharmaceutical sales representatives.

5952

Table of Contents

Ensuring that our future business arrangements with third parties comply with applicable health care laws and regulations could involve substantial costs. The shifting compliance environment and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance or reporting requirements increases the possibility that a health care company may run afoul of one or more of the requirements. It is possible that governmental authorities will conclude that our business practices, including certain advisory agreements we have entered into with physicians who are paid, in part, in the form of stock or stock options, do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any such requirements, we may be subject to significant penalties, including criminal and civil monetary penalties, damages, fines, individual imprisonment, disgorgement, contractual damages, reputational harm, exclusion from participation in government health care programs, integrity obligations, injunctions, recall or seizure of products, total or partial suspension of production, denial or withdrawal of pre-marketing product approvals, private qui tam actions brought by individual whistleblowers in the name of the government, refusal to allow us to enter into supply contracts, including government contracts, additional reporting requirements and oversight if subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.

We intend to develop and implement a comprehensive corporate compliance program prior to the commercialization of our ~~development~~product candidates and have already undertaken efforts in this regard. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management’s attention from the operation of our business, even if our defense is successful. In addition, achieving and sustaining compliance with applicable laws and regulations may be costly to us in terms of money, time and resources. Moreover, federal, state or foreign laws or regulations are subject to change, and while we, our collaborators, manufacturers and/or service providers currently may be compliant, that could change due to changes in interpretation, prevailing industry standards or for other reasons.

Any programs or ~~development~~product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated.*

Even if we are successful in achieving regulatory approval to commercialize a program or ~~development~~product candidate ahead of our competitors, our ~~development~~programs or product candidates may face competition from biosimilar or generic products. In the United States, our antibody-based programs and ~~development~~product candidates are expected to be regulated by the FDA as biological products, and we intend to seek approval for these ~~development~~programs and product candidates pursuant to the BLA pathway. The Biologics Price Competition and Innovation Act of 2009, or BPCIA, created an abbreviated pathway for FDA approval of biosimilar and interchangeable biological products based on a previously licensed reference product. Under the BPCIA, an application for a biosimilar biological product cannot be approved by the FDA until 12 years after the original reference biological product was approved under a BLA.

6053

Table of Contents

We believe that any of our ~~development~~product candidates approved as a biological product under a BLA should qualify for the 12-year period of exclusivity available to reference biological products. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our ~~development~~product candidates to be reference biological products pursuant to its interpretation of the exclusivity provisions of the BPCIA for competing products, potentially creating the opportunity for generic follow-on biosimilar competition sooner than anticipated. Moreover, the extent to which a biosimilar product, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing including whether a future competitor seeks an interchangeability designation for a biosimilar of one of our products. Under the BPCIA as well as state pharmacy laws, only interchangeable biosimilar products are considered substitutable for the reference biological product without the intervention of the health care provider who prescribed the original biological product. However, as with all prescribing decisions made in the context of a patient-provider relationship and a patient’s specific medical needs, health care providers are not restricted from prescribing biosimilar products in an off-label manner. In addition, a competitor could decide to forego the abbreviated approval pathway available for biosimilar products and to submit a full BLA for product licensure after completing its own preclinical studies and clinical trials. In such a situation, any exclusivity for which our ~~development~~product candidates may be eligible under the BPCIA would not prevent the competitor from marketing its biological product as soon as it is approved.

In Europe, the European Commission has granted marketing authorizations for several biosimilar products pursuant to a set of general and product class-specific guidelines for biosimilar approvals issued over the past few years. In addition, companies may be developing biosimilar products in other countries that could compete with our products, if approved. If competitors are able to obtain marketing approval for biosimilars referencing our ~~development~~product candidates, if approved, our future products may become subject to competition from such biosimilars, whether or not they are designated as interchangeable, with the attendant competitive pressure and potential adverse consequences. Such competitive products may be able to immediately compete with us in each indication for which our ~~development~~product candidates may have received approval.

If the FDA, the European Medicines Agency, or EMA, the European Commission, or other comparable foreign regulatory authorities approve generic versions of any of our small molecule drug candidates that receive marketing approval, or such authorities do not grant our products appropriate periods of exclusivity before approving generic versions of those products, the sales of our products, if approved, could be adversely affected.

Once an NDA is approved, the product covered thereby becomes a “reference listed drug” in the FDA’s publication, “Approved Drug Products with Therapeutic Equivalence Evaluations,” commonly known as the Orange Book. Manufacturers may seek approval of generic versions of reference listed drugs through submission of abbreviated new drug applications, or ANDAs, in the United States. In support of an ANDA, a generic manufacturer need not conduct clinical trials to assess safety and efficacy. Rather, the sponsor generally must show that its product has the same active ingredient(s), dosage form, strength, route of administration and conditions of use or labelling as the reference listed drug and that the generic version is bioequivalent to the reference listed drug, meaning it is absorbed in the body at the same rate and to the same extent. Generic products may be significantly less costly to bring to market than the reference listed drug and companies that produce generic products are generally able to offer them at lower prices. Thus, following the introduction of a generic drug, a significant percentage of the sales of any branded product or reference listed drug is typically lost to the generic product.

The FDA may not approve an ANDA for a generic product until any applicable period of non-patent exclusivity for the reference listed drug has expired. The Federal Food, Drug and Cosmetic Act provides a period of five years of non-patent exclusivity for a new drug containing a new chemical entity. Specifically, in cases where such exclusivity has been granted, an ANDA may not be submitted to the FDA until the expiration of five years unless the submission is accompanied by a Paragraph IV certification that a patent covering the reference listed drug is either invalid or will not be infringed by the generic product, in which case the sponsor may submit its application four years following approval of the reference listed drug.

6154

Table of Contents

Generic drug manufacturers may seek to launch generic products following the expiration of any applicable exclusivity period we obtain if our small molecule product candidates are approved, even if we still have patent protection for such products. Competition that our products could face from generic versions of our products could materially and adversely affect our future revenue, profitability, and cash flows and substantially limit our ability to obtain a return on the investments we have made in those product candidates.

Disruptions at the FDA, the SEC and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.

The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes, and other events that may otherwise affect the FDA’s ability to perform routine functions. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.

Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, in recent years, including beginning on December 22, 2018, the U.S. government shut down several times and certain regulatory agencies, such as the FDA and the SEC, had to furlough critical employees and stop critical activities.

If a prolonged government shutdown occurs, or if global health concerns prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, in our operations as a public company, future government shutdowns or delays could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.

Even if we receive regulatory approval of our ~~development~~product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements.

If our ~~development~~product candidates are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post- marketing studies, and submission of safety, efficacy, and other post-market information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities.

Manufacturers and manufacturers’ facilities must comply with extensive FDA, and comparable foreign regulatory authority, requirements, including ensuring that quality control and manufacturing procedures conform to cGMP regulations. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any BLA, other marketing applications, and previous responses to inspection observations. Accordingly, we and others with whom we work must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production, and quality control.

6255

Table of Contents

Any regulatory approvals that we receive for our ~~development~~product candidates may be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials, and surveillance to monitor the safety and efficacy of the program and ~~development~~product candidate. The FDA may also require a REMS program as a condition of approval of our ~~development~~product candidates, which could entail requirements for long-term patient follow-up, a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves our ~~development~~product candidates, we will have to comply with requirements, including submissions of safety and other post-marketing information and reports, and registration, as well as continued compliance with cGMP and GCP for any clinical trials that we conduct post-approval.

The FDA strictly regulates marketing, labeling, advertising, and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.

Failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:

●

restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;

●

fines, warning letters or other enforcement-related letters or clinical holds on post-approval clinical trials;

●

refusal of the FDA to approve pending BLAs or supplements to approved BLAs, or suspension or revocation of product approvals;

●

product seizure or detention, or refusal to permit the import or export of products;

●

injunctions or the imposition of civil or criminal penalties; and

●

consent decrees, corporate integrity agreements, debarment, or exclusion from federal health care programs; or mandated modification of promotional materials and labeling and the issuance of corrective information.

The policies of the FDA and of other regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our ~~development~~product candidates. For example, the U.S. Supreme Court’s June 2024 decision in Loper Bright Enterprises v. Raimondo overturned the longstanding Chevron doctrine, under which courts were required to give deference to regulatory agencies’ reasonable interpretations of ambiguous federal statutes. The Loper decision could result in additional legal challenges to regulations and decisions issued by federal agencies, including the FDA, on which we rely. Any such legal challenges, if successful, could have a material impact on our business. Additionally, the Loper decision may result in increased regulatory uncertainty, inconsistent judicial interpretations, and other impacts to the agency rulemaking process, any of which could adversely impact our business and operations. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.

6356

Table of Contents

Even if we are able to commercialize any program or ~~development~~product candidate, the program and ~~development~~product candidate may become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies, which would harm our business.

We cannot be sure that coverage and reimbursement will be available for, or accurately estimate the potential revenue from, our ~~development~~product candidates or assure that coverage and reimbursement will be available for any product that we may develop. The regulations that govern marketing approvals, pricing and reimbursement for new drug and biological products vary widely from country to country. Some countries require approval of the sale price of a drug or biologic before it can be marketed. In many countries, the pricing review period begins after marketing or product approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. We are monitoring these regulations as several of our programs move into later stages of development, including ~~AL102~~varegacestat which is in Phase 3 clinical development; however, a majority of our programs are currently in the earlier stages of development and we will not be able to assess the impact of price regulations for a number of years. As a result, we might obtain regulatory approval for a product in a particular country, but then be subject to price regulations that could delay our commercial launch of the product and negatively impact any potential revenues we may be able to generate from the sale of the product in that country and potentially in other countries due to reference pricing.

Our ability to commercialize any products successfully will also depend in part on the extent to which coverage and adequate reimbursement/payment for these products and related treatments will be available from government health administration authorities, private payors and other organizations. Even if we succeed in bringing one or more products to the market, these products may not be considered medically necessary and/or cost-effective, and the amount reimbursed for any products may be insufficient to allow us to sell our products on a competitive basis. At this time, we are unable to determine their cost effectiveness or the likely level or method of reimbursement for our ~~development~~product candidates. Increasingly, third-party payors, such as government and private insurance plans, are requiring that biotechnology companies provide them with predetermined discounts from list prices and are seeking to reduce the prices charged or the amounts paid for biotechnology products. If the price we are able to charge for any products we develop, or the payments provided for such products, is inadequate in light of our development and other costs, our return on investment could be adversely affected.

We currently expect that any drugs we develop may need to be administered under the supervision of a physician on an outpatient basis. Under currently applicable U.S. law, certain therapeutic products that are not usually self-administered (such as most injectable drugs and biologics) may be eligible for coverage under the Medicare Part B program if:

●

they are incident to a physician’s services;

●

they are reasonable and necessary for the diagnosis or treatment of the illness or injury for which they are administered according to accepted standards of medical practice; and

●

they have been approved by the FDA and meet other requirements of the statute.

6457

Table of Contents

There may be significant delays in obtaining coverage for newly approved biologics, and coverage may be more limited than the indications for which the biologic is approved by the FDA or comparable foreign regulatory authorities. Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians, generally rely on third-party payors to pay all or part of the costs associated with their prescription medications. Patients are unlikely to use our products unless coverage is provided, and payment is adequate to cover all or a significant portion of the cost of our products. Therefore, coverage and adequate payment is critical to new product acceptance. Coverage decisions may depend upon clinical and economic standards that disfavor new products when more established or lower cost therapeutic alternatives are already available or subsequently become available. Moreover, eligibility for coverage does not imply that any of our products, if approved, will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim payments for new drugs or biologics, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement may be based on payments allowed for lower-cost products that are already reimbursed, may be incorporated into existing payments for other services and may reflect budgetary constraints or imperfections in Medicare data. Net prices for drugs or biologics may be reduced by mandatory discounts or rebates required by government health care programs or private payors and by any future relaxation of laws that presently restrict imports of medicines from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates. However, no uniform policy requirement for coverage and reimbursement for drug or biologic products exists among third-party payors in the United States. Therefore, coverage and reimbursement for drug and biologic products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Additionally, we or our collaborators may develop companion diagnostic tests for use with our current and future potential ~~development~~product candidates. We or our collaborators will be required to obtain coverage and reimbursement for these tests separately and apart from the coverage and reimbursement we may seek for our current and future potential ~~development~~product candidates. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for new products we develop and for which we obtain regulatory approval could adversely affect our operating results, our ability to raise capital needed to commercialize products, and our overall financial condition.

A number of legislative and regulatory changes in the health care system in the United States and other major health care markets have been proposed and/or adopted in recent years, and such efforts have expanded substantially in recent years. We believe that the efforts of governments and third-party payors to contain or reduce the cost of health care and legislative and regulatory proposals to broaden the availability of health care will continue to affect the business and financial condition of pharmaceutical and biotechnology companies.

We are subject to U.S. and foreign anti-corruption and anti-money laundering laws with respect to our operations and non-compliance with such laws can subject us to criminal or civil liability and harm our business.

We are subject to the Foreign Corrupt Practices Act, or the FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. § 201, the U.S. Travel Act, the USA PATRIOT Act, and possibly other state and national anti-bribery and anti-money laundering laws in countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, third-party intermediaries, joint venture partners and collaborators from authorizing, promising, offering or providing, directly or indirectly, improper payments or benefits to recipients in the public or private sector. We interact with officials and employees of government agencies and government-affiliated hospitals, universities and other organizations. In addition, we may engage third-party intermediaries to promote our clinical research activities abroad or to obtain necessary permits, licenses and other regulatory approvals. We can be held liable for the corrupt or other illegal activities of these third-party intermediaries, our employees, representatives, contractors, partners and agents, even if we do not explicitly authorize or have actual knowledge of such activities.

6558

Table of Contents

We adopted a Code of Business Conduct and Ethics and implemented training programs, policies and procedures to ensure compliance with such code. The Code of Business Conduct and Ethics mandates compliance with the FCPA and other anti-corruption laws applicable to our business throughout the world. However, we cannot assure you that our employees and third-party intermediaries will comply with this code or such anti-corruption laws. Noncompliance with anti-corruption and anti-money laundering laws could subject us to whistleblower complaints, investigations, sanctions, settlements, prosecution, other enforcement actions, disgorgement of profits, significant fines, damages, other civil and criminal penalties or injunctions, suspension or debarment from contracting with certain persons, the loss of export privileges, reputational harm, adverse media coverage and other collateral consequences. If any subpoenas, investigations or other enforcement actions are launched, or governmental or other sanctions are imposed, or if we do not prevail in any possible civil or criminal litigation, our business, results of operations and financial condition could be materially harmed. In addition, responding to any action will likely result in a materially significant diversion of management’s attention and resources and significant defense and compliance costs and other professional fees. In certain cases, enforcement authorities may even cause us to appoint an independent compliance monitor which can result in added costs and administrative burdens.

Risks Related to Strategic Transactions, Manufacturing, Commercialization and Reliance on Third Parties

IfWe wehave, and may in the future choose, to ~~continue~~engage toin and pursue collaborations and other strategic transactions,. weWe may not be able to enter into such transactions on acceptable terms, if at all, which could adversely affect our development and commercialization activities, impact our cash position, increase our expenses, and present significant distractions to our management.*

We have engaged in, and may continue to consider and engage in, strategic transactions, asset purchases, collaborations, joint ventures and out- or in-licensing. The competition for partners is intense, and the negotiation process is time-consuming and complex. If we desire to enter into strategic transactions but are not able to do so, we may not have access to the required liquidity or expertise to further develop our ~~development~~product candidates and our ~~discovery and~~ ADC ~~platforms~~platform. ~~Any~~Such ~~such collaboration~~collaborations, or other strategic ~~transaction~~transactions, have required, and may in the future require, us to incur non-recurring or other charges, increase our near- and long-term expenditures and pose significant integration or implementation challenges and/or disrupt our management or business. We may acquire additional technologies and assets, form strategic alliances or create joint ventures with third parties that we believe will complement or augment our existing business, but we may not be able to realize the benefit of acquiring such assets. Conversely, any new collaboration that we do enter into may be on terms that are not optimal for us. These transactions ~~would~~have and may in the future entail numerous operational and financial risks, including:

●

exposure to unknown liabilities and higher-than-expected collaboration, acquisition or integration costs, write-downs of assets or goodwill or impairment charges, increased amortization expenses; and

●

disruption of our business and diversion of our management’s time and attention in order to manage a collaboration or develop acquired products, programs or technologies, including impairment of relationships with key suppliers, manufacturers or customers of any acquired business due to changes in management and ownership.

Accordingly, although there can be no assurance that we will undertake or successfully complete any existing or future transactions of the nature described above, any transactions that we dohave or may in the future complete may be subject to the foregoing or other risks and our business could be materially harmed by such transactions. Conversely, any failure to enter into any collaboration or other strategic transaction that would be beneficial to us could delay the development and potential commercialization of our ~~development~~product candidates and have a negative impact on the competitiveness of any program or ~~development~~product candidate that reaches market.

In addition, to the extent that any of our current or potential future partners were to terminate a collaboration agreement, we may be forced to independently develop our ~~development~~product candidates, including funding preclinical studies or clinical trials, assuming marketing and distribution costs and maintaining, enforcing and defending intellectual property rights, or, in certain instances, abandoning any program or ~~development~~product candidate altogether, any of which could result in a change to our business plan and materially harm our business, financial condition, results of operations and prospects.

6659

Table of Contents

If third parties on which we ~~intend to~~ rely to conduct our current and future preclinical studies and clinical trials do not perform as contractually required, fail to satisfy regulatory or legal requirements or miss expected deadlines, our programs could be delayed with material and adverse impacts on our business and financial condition. *

We currently rely, and intend to continue to rely, on third-party clinical investigators, CROs, clinical data management organizations and consultants to design, conduct, supervise and monitor certain preclinical studies and any clinical trials, including for the Phase 3 clinical trial of ~~AL102.~~varegacestat ~~Because~~and wethe ~~intend~~Phase to1 clinical trials of IM-1021 and IM-3050. Since we rely on these third parties and will not have the ability to conduct certain preclinical studies or clinical trials independently, we will have less control over the timing, quality and other aspects of such preclinical studies and clinical trials than we would have had we conducted them on our own. These investigators, CROs and consultants ~~will~~are not be our employees and we will have limited control over the amount of time and resources that they dedicate to our programs. These third parties may have contractual relationships with other entities, some of which may be our competitors, which may draw time and resources from our programs. The third parties with which we may contract might not be diligent, careful or timely in conducting our preclinical studies or clinical trials, resulting in the preclinical studies or clinical trials being delayed or unsuccessful.

The FDA requires certain preclinical studies to be conducted in accordance with good laboratory practices and clinical trials must be conducted in accordance with GCPs, including for designing, conducting, recording and reporting the results of preclinical studies and clinical trials to ensure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of clinical trial participants are protected. Our reliance on third parties that we do not control will not relieve us of these responsibilities and requirements. Any adverse development or delay in our clinical trials could have a material and adverse impact on our commercial prospects and may impair our ability to generate revenue.

Because we ~~may~~ rely on third parties for manufacturing, supply and testing, some of which may be sole source vendors, for preclinical and clinical development materials and commercial supplies, our supply may become limited or interrupted or may not be of satisfactory quantity or quality.*

We ~~may~~currently rely, and intend to continue to rely, on third-party contract manufacturers for our preclinical and ~~future~~ clinical trial product materials and commercial supplies, including for our Phase 3 clinical trial of ~~AL102~~varegacestat and our Phase 1 clinical trials of IM-1021 and IM-3050. We do not intend to produce any meaningful quantity of materials needed for preclinical and clinical development through our internal resources, and we do not currently own manufacturing facilities for producing such supplies. While we intend to try to avoid sole-source arrangements with any of our manufacturing, supply and testing vendors, it may not always be possible to do so. We cannot assure you that our preclinical or future clinical development product supplies and commercial supplies will not be limited or interrupted, especially with respect to any sole source third-party manufacturing and supply partners or will be of satisfactory quality or continue to be available at acceptable prices. In particular, any replacement of our manufacturers could require significant effort and expertise because there may be a limited number of qualified replacements.

The manufacturing process for a program or ~~development~~product candidate is subject to FDA and other regulatory authority review. Suppliers and manufacturers must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities in order to comply with regulatory standards, such as cGMP. In the event that any of our future manufacturers fails to comply with such requirements or to perform its obligations to us in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, we may be forced to manufacture the materials ourselves, for which we currently do not have the capabilities or resources, or enter into an agreement with another third party, which we may not be able to do on reasonable terms, or at all. In some cases, the technical skills or technology required for manufacture may be unique or proprietary to the original manufacturer and we may have difficulty transferring such skills or technology to another third party and a feasible alternative may not exist. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to have another third party manufacture our materials. If we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop in a timely manner or within budget.

6760

Table of Contents

Certain Chinese biotechnology companies, CROs and contract development and manufacturing organizations may become subject to trade restrictions, tariffs, sanctions, other regulatory requirements, or proposed legislation by the U.S. government, which could potentially impact services available for our research and development or our ability to secure the materials we need for our ~~development~~product candidates. For example, the ~~BIOSECURE Act recently passed in the U.S.~~ House of Representatives, asof ~~well~~the asprior aCongress ~~substantially~~(the ~~similar~~118th ~~bill~~Congress) inpassed the ~~U.S.~~BIOSECURE ~~Senate~~Act, ~~target~~which proposed targeting U.S. government contracts, grants, and loans for entities that use biotechnology equipment ~~and~~or services from certain named Chinese ~~biotech~~biotechnology companies, and ~~would~~potentially ~~authorize the U.S. government to name~~ additional Chinese biotechnology companies ofdesignated ~~concern~~in the future. The ~~current~~language ~~version~~ of the proposed BIOSECURE Act ~~includes~~would, aamong ~~grandfathering~~other ~~provision~~things, ~~allowing~~prohibit ~~biotechnology~~U.S. ~~equipment~~federal ~~and~~agencies ~~services~~from ~~provided~~entering into or ~~produced~~renewing byany ~~named~~contract ~~biotechnology~~with ~~companies~~any ofentity ~~concern~~that ~~under~~uses abiotechnology ~~contract~~equipment or ~~agreement~~services ~~entered~~produced ~~into~~or ~~before~~provided ~~the~~by ~~effective~~a ~~date~~“biotechnology ~~until~~company ~~January~~of ~~1, 2032~~concern.” ~~Depending~~The onversion ~~whether~~of the ~~BIOSECURE~~bill ~~Act~~passed ~~becomes~~by ~~law, what~~ the ~~final~~prior ~~language~~House of ~~the~~Representatives ~~BIOSECURE~~included ~~Act~~a ~~includes,~~grandfathering ~~and~~provision ~~how~~allowing ~~the~~biotechnology ~~law~~equipment isand ~~interpreted~~services byprovided ~~U.S. federal agencies, we could be potentially restricted from pursuing U.S. federal government business~~ or ~~funding~~produced ifby wenamed ~~use suppliers or partners identified as “~~biotechnology companies of concern” ~~beyond~~under ~~the~~a ~~grandfathering~~contract ~~period.~~or ~~Such~~agreement ~~disruption~~entered ~~could~~into ~~have~~before ~~adverse~~the ~~effects~~effective ondate ~~our~~until ~~research~~January ~~and~~1, ~~development activities~~2032. InThe ~~addition to the~~ BIOSECURE Act, ~~any~~did ~~additional~~not ~~U.S.~~become ~~executive~~law ~~action,~~in ~~legislative~~the ~~action,~~118th orCongress. ~~potential~~It ~~sanctions~~is ~~with~~unclear ~~China~~whether ~~could~~the ~~materially~~current ~~impact~~Congress ~~our~~(the ~~business~~119th ~~and~~Congress) ~~activities.~~will ~~U.S.~~introduce ~~executive agencies have~~ the ~~ability~~BIOSECURE toAct ~~designate~~or ~~entities~~similar ~~and~~legislation ~~individuals~~in onthis ~~various~~congressional ~~governmental~~session ~~prohibited~~ and, ~~restricted~~if ~~parties~~so, ~~lists.~~how ~~Depending on~~ the ~~designation~~scope, ~~potential~~prohibitions, ~~consequences can range from a comprehensive prohibition on all transactions~~ or ~~dealings with~~ designated ~~parties,~~biotechnology orcompanies aof ~~limited~~concern ~~prohibition~~may ondiffer ~~certain~~from ~~types~~the version of ~~activities,~~the ~~such~~BIOSECURE asAct ~~exports~~passed ~~and~~by ~~financing~~the ~~activities,~~House ~~with~~in ~~designated~~the ~~parties~~prior 118th Congress.

IfSince we engage third party vendors located outside the United States, we are ~~unable~~exposed to ~~obtain~~the orpossibility ~~maintain~~of ~~third-party~~product ~~manufacturing~~supply ~~for~~disruption ~~any~~and ~~program~~increased costs in the event of changes in the policies of the United States or ~~development~~applicable ~~candidate~~foreign government, political unrest or tounstable doeconomic soconditions. onAny ~~commercially~~additional ~~reasonable~~U.S. ~~terms~~executive action, welegislative ~~may~~action, ~~not~~or bepotential ~~able~~sanctions towith ~~complete~~China or any other country could materially impact our ~~development~~business and ~~commercialization~~activities. ~~efforts~~Furthermore, ~~successfully~~U.S. ~~Our~~executive oragencies have the ability to designate entities and individuals on various governmental prohibited and restricted parties lists. Depending on the designation, potential consequences can range from a ~~third~~comprehensive ~~party’s~~prohibition ~~failure~~on toall ~~execute~~transactions or dealings with designated parties, or a limited prohibition on ~~our~~certain ~~manufacturing~~types ~~requirements~~of activities, such as exports and ~~comply~~financing activities, with ~~cGMP~~designated parties. Additionally, a trade war could lead to tariffs on supplies and materials we use that are manufactured internationally, including in China. Any of these matters could materially and adversely affect our business inand aresults ~~number~~ of ~~ways, including:~~operations.

If we are unable to obtain or maintain third-party manufacturing for any program or product candidate, or to do so on commercially reasonable terms, or if our relationship with third-party vendors on whom we rely is otherwise adversely impacted by changing United States or applicable foreign government policies, we may not be able to complete our development and commercialization efforts successfully. Our or a third party’s failure to execute on our manufacturing requirements and comply with cGMP could adversely affect our business in a number of ways, including:

●

an inability to initiate or continue clinical trials;

●

delay in submitting regulatory applications, or receiving regulatory approvals;

●

loss of the cooperation of a potential future partner;

●

subjecting third-party manufacturing facilities or our potential future manufacturing facilities to additional inspections by regulatory authorities;

●

requirements to cease distribution or to recall batches; and

●

in the event of approval to market and commercialize a product, an inability to meet commercial demands.

~~We may be unable to successfully scale manufacturing in sufficient quality and quantity, which would delay or prevent us from completing our development and commercialization efforts, if any.~~ 61

In order to conduct our research and development efforts, including clinical trials, for our development candidates, we will need to manufacture large quantities. If any programs or development candidates are commercialized, we will need to scale up manufacturing efforts even further. We currently expect to continue to use third parties for our manufacturing needs, as we do not currently have, nor do we currently intend to establish, our own manufacturing capacity. Our manufacturing partners may be unable to successfully increase the manufacturing capacity for any program or development candidate in a timely or cost-effective manner, or at all. In addition, quality issues may arise during scale-up activities and our manufacturers may fail to perform under their contracts with us, which could result in an unexpected need to change manufacturers. If we or our manufacturing partners are unable to successfully scale the manufacture at any stage, in sufficient quality and quantity, the development, testing and clinical trials of that program or development candidate may be delayed or infeasible, and regulatory approval or commercial launch of any potential resulting product may be delayed or not obtained, which could significantly harm our business.

Table of Contents

We may be unable to successfully scale manufacturing in sufficient quality and quantity, which would delay or prevent us from completing our development and commercialization efforts, if any.

In order to conduct our research and development efforts, including clinical trials, for our product candidates, we will need to manufacture large quantities. If any programs or product candidates are commercialized, we will need to scale up manufacturing efforts even further. We currently expect to continue to use third parties for our manufacturing needs, as we do not currently have, nor do we currently intend to establish, our own manufacturing capacity. Our manufacturing partners may be unable to successfully increase the manufacturing capacity for any program or product candidate in a timely or cost-effective manner, or at all. In addition, quality issues may arise during scale-up activities and our manufacturers may fail to perform under their contracts with us, which could result in an unexpected need to change manufacturers. If we or our manufacturing partners are unable to successfully scale the manufacture at any stage, in sufficient quality and quantity, the development, testing and clinical trials of that program or product candidate may be delayed or infeasible, and regulatory approval or commercial launch of any potential resulting product may be delayed or not obtained, which could significantly harm our business.

Our significant reliance on third-party vendors could impair our ability to implement our business plan.

We rely on, and expect to continue to rely on, third-party vendors for many aspects of our business. We depend on these third parties, and likely will continue to depend on them, to perform their obligations in a timely manner consistent with contractual and regulatory requirements. We also at times need to rely, and may continue to need to rely, on certain vendors as our sole source for research, development, manufacturing or other services. Establishing additional or replacement sole source vendors, if required, may not be accomplished quickly. In addition, these vendors may now or in the future partner with and conduct services for third parties developing in enabling technologies that are competitive with our ~~discovery and~~ ADC ~~platforms~~platform and/or current or future ~~development~~product candidates. If we are unable to make arrangements with a vendor for a particular need, or maintain our relationship with that vendor, on commercially reasonable terms, we may not be able to develop and commercialize our programs or ~~development~~product candidates successfully or operate our business as we intend, which could harm our business, result of operations, financial condition and prospects.

A cyber- attack or breach of our information technology systems or data, or those of the third parties with whom we work, could cause adverse consequences, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; and other adverse consequences.*

In the ordinary course of business, we, our collaborators, ~~and~~ our vendors ~~may collect~~, ~~receive,~~and ~~store,~~other ~~process,~~third ~~generate,~~parties ~~use,~~with ~~transfer,~~whom ~~disclose,~~we ~~make~~work ~~accessible,~~may ~~protect, secure, dispose of, transmit, and share, or collectively,~~ process, proprietary, confidential, and sensitive data, including our clinical trial data, health-related data or personal information, or collectively, sensitive data.

Cyber-attacks, malicious internet-based activity, online and offline fraud, and other similar activities threaten the confidentiality, integrity, and availability of our sensitive data and information technology systems, and those of the third parties with whom we work. Such threats are prevalent and continue to rise, are increasingly difficult to detect, and come from a variety of sources, including traditional computer “hackers,” threat actors, “hacktivists,” organized criminal threat actors, personnel (such as through theft or misuse), sophisticated nation states, and nation-state-supported actors.

Some actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, we and the third parties with whom we work ~~may~~are be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks, that could materially disrupt our systems and operations, supply chain, and ability to conduct our business as presently conducted. For example, we have clinical trial activities in regions experiencing geopolitical or other conflicts, including in Israel, where businesses have experienced an increase in cyberattacks in relation to the Israel/Hamas conflict.

We and the third parties with whom we work are subject to a variety of evolving threats, including social-engineering attacks (including through deep fakes, which may be increasingly more difficult to identify as fake, and phishing attacks), malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat intrusions), denial-of-service attacks, credential stuffing, credential harvesting, personnel misconduct or error, ransomware attacks, supply-chain attacks, software bugs, server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, telecommunications failures, earthquakes, fires, floods, attacks enhanced or facilitated by AI, and other similar threats. 62

In particular, severe ransomware attacks are becoming increasingly prevalent and can lead to significant interruptions in our operations, ability to provide our products or services, loss of sensitive data and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments.

Remote work has become more common and has increased risks to our information technology systems and data, as more of our employees utilize network connections, computers and devices outside our premises or network, including working at home, while in transit and in public locations.

Table of Contents

We and the third parties with whom we work are subject to a variety of evolving threats, including social-engineering attacks (including through deep fakes, which are increasingly more difficult to identify as fake, and phishing attacks), malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat intrusions), denial-of-service attacks, credential stuffing attacks, credential harvesting, personnel misconduct or error, ransomware attacks, supply-chain attacks, software bugs, server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, telecommunications failures, earthquakes, fires, floods, attacks enhanced or facilitated by AI, and other similar threats.

It may be difficult and costly to detect, investigate, mitigate, contain, and remediate a security incident. Our efforts to do so may not be successful. Actions taken by us or the third parties with whom we work to detect, investigate, mitigate, contain, and remediate a security incident could result in outages, data losses, and disruptions of our business. Threat actors may also gain access to other networks and systems after a compromise of our networks and systems.

Remote work has increased risks to our information technology systems and data, as more of our employees utilize network connections, computers and devices outside our premises or network, including working at home, while in transit and in public locations.

Future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities’ systems and technologies. Furthermore, we may discover security issues that were not found during due diligence of such acquired or integrated entities, and it may be difficult to integrate companies into our information technology environment and security program.

We rely on third parties and technologies to operate critical business systems to process sensitive data in a variety of contexts, including cloud-based infrastructure, data center facilities, encryption and authentication technology, employee email, and other functions. Our ability to monitor these third parties’ information security practices is limited, and these third parties may not have adequate information security measures in place. If the third parties with whom we work experience a material security incident or other interruption, we could experience adverse consequences. While we may be entitled to damages if the third parties with whom we work fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such award. In addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties’ infrastructure in our supply chain or third-parties’ with whom we work supply chains have not been compromised.

While we have implemented security measures designed to protect against and recover from security incidents, there can be no assurance that these measures will be effective. We take steps designed to detect, mitigate and remediate vulnerabilities in our information security systems (such as our hardware and/or software, including that of third parties with whom we work), but we may not be able to detect, mitigate, and remediate all such vulnerabilities including on a timely basis. Further, we may experience delays in developing and deploying remedial measures and patches designed to address identified vulnerabilities. Vulnerabilities could be exploited and result in a security incident.

~~Any~~Certain of the previously identified or similar threats ~~could~~have in the past and may in the future cause a security incident or other interruption that could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to our sensitive data or our information technology systems, or those of the third parties upon whom we rely. A security incident or other interruption could disrupt or otherwise impact our ability (and that of third parties upon whom we rely) to conduct our business. asWe ~~presently~~have ~~conducted.~~in Wethe past and may in the future expend significant resources or modify our business activities (including our clinical trial activities) to try to protect against security incidents. Certain data privacy and security obligations ~~may~~ require us to implement and maintain specific security measures or industry-standard or reasonable security measures in an effort to protect our information technology systems and sensitive data.

Applicable data privacy and security obligations may require us, or we may voluntarily choose, to notify relevant stakeholders, including affected individuals, customers, regulators, and investors, of security incidents, or to take other actions, such as providing credit monitoring and identity theft protection services. Such disclosures and related actions can be costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences. If we (or a third party with whom we work) experience a security incident or are perceived to have experienced a security incident, we may experience adverse consequences, such as government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive data (including personal information); litigation (including class claims) and mass arbitration demands; indemnification obligations; negative publicity; reputational harm; monetary fund diversions; diversion of management attention; interruptions in our operations (including availability of data); disputes with physicians and other healthcare providers, clinical trial participants and our partners; increases in operating expenses; expenses or lost revenues or other adverse consequences, any of which could have a material adverse effect on our business, results of operations, financial condition, prospects and cash flows.63

Further, our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations.

Although we have insurance coverage, including cybersecurity insurance, in place, we cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims by third parties or losses that we directly incur.

Table of Contents

Applicable data privacy and security obligations require us, or we may voluntarily choose, to notify relevant stakeholders, including affected individuals, customers, regulators, and investors, of security incidents, or to take other actions, such as providing credit monitoring and identity theft protection services. Such disclosures and related actions can be costly, and the disclosure or the failure to comply with such requirements could lead to material adverse consequences. Security incidents or perceived security incidents may result in material adverse consequences, such as government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive data (including personal information); litigation (including class claims) and mass arbitration demands; indemnification obligations; negative publicity; reputational harm; monetary fund diversions; diversion of management attention; interruptions in our operations (including availability of data); disputes with physicians and other healthcare providers, clinical trial participants and our partners; increases in operating expenses; expenses or lost revenues; or other adverse consequences, any of which could have a material adverse effect on our business, results of operations, financial condition, prospects and cash flows.

Further, some of our contracts do not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations.

In addition to experiencing a security incident, third parties may gather, collect, or infer sensitive data about us from public sources, data brokers, or other means that reveal competitively sensitive details about our organization and could be used to undermine our competitive advantage or market position. Additionally, sensitive data of the Company could be leaked, disclosed, or revealed as a result of or in connection with the use of generative AI technologies by our employees, our personnel, or third parties with whom we work.

Our current laboratory operations are concentrated in one location, and we orand the third parties upon whom we depend may be adversely affected by natural or other disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.*

Our current business operations are concentrated in the greater Seattle area. Any unplanned event, such as flood, fire, explosion, extreme weather condition, medical epidemics, including any potential effects from a pandemic, such as power shortage, telecommunication failure or other natural or manmade accidents or incidents that result in us being unable to fully utilize our facilities or the manufacturing facilities of our third-party contract manufacturers, or lose our repository of blood-based and other valuable laboratory samples, may have a material and adverse effect on our ability to operate our business, particularly on a daily basis, and have significant negative consequences on our financial and operating conditions. Loss of access to these facilities may result in increased costs, delays in the development efforts or interruption of our business operations. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our locations, that damaged critical infrastructure, such as our research facilities or the manufacturing facilities of our third-party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time. In addition, terrorist acts or acts of war targeted at the United States, and specifically the greater Seattle area, could cause damage or disruption to us, our employees, facilities, partners and suppliers. The disaster recovery and business continuity plan we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse effect on our business. As part of our risk management policy, we maintain insurance coverage at levels that we believe are appropriate for our business. However, in the event of an accident or incident at these facilities, we cannot assure you that the amounts of insurance will be sufficient to satisfy any damages and losses. If our facilities, or the manufacturing facilities of our third-party contract manufacturers, are unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our research and development programs may be harmed. Any business interruption may have a material and adverse effect on our business and financial condition.

Table of Contents

Risks Related to Our Intellectual Property

It is difficult and costly to protect our intellectual property and our proprietary technologies, and we may not be able to ensure their protection.*

Our success will depend in part on obtaining and maintaining patent protection and trade secret protection for our ~~discovery and~~ ADC ~~platforms~~platform and/or targeted therapeutics, as well as on successfully defending these patents against potential third-party challenges. Our ability to protect our technologies from unauthorized making, using, selling, offering to sell or importing by third parties is dependent on the extent to which we have rights under valid and enforceable patents that cover these activities.

The patent positions of pharmaceutical, biotechnology and other life sciences companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved and have in recent years been the subject of much litigation. Changes in either the patent laws or in interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property. Over the past decade, U.S. federal courts have increasingly invalidated pharmaceutical and biotechnology patents during litigation often based on changing interpretations of patent law. Further, the determination that a patent application or patent claim meets all the requirements for patentability is a subjective determination based on the application of law and jurisprudence. The ultimate determination by the U.S. Patent and Trademark office, or USPTO, or by a court or other trier of fact in the United States, or corresponding foreign national patent offices or courts, on whether a claim meets all requirements of patentability cannot be assured. We cannot be certain that all relevant information has been identified. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our own patent portfolio.

Table of Contents

We cannot provide assurances that any of our patent applications will be found to be patentable, including over our own prior art publications or patent literature, or will issue as patents. Neither can we make assurances as to the scope of any claims that may issue from our pending and future patent applications nor to the outcome of any proceedings by any potential third parties that could challenge the patentability, validity or enforceability of our patent portfolio in the United States or foreign jurisdictions. Any such challenge, if successful, could limit patent protection for our targeted therapeutics and/or materially harm our business.

In addition to challenges during litigation, third parties can challenge the validity of our patents in the United States using post-grant review and inter partes review proceedings, which some third parties have been using to cause the cancellation of selected or all claims of issued patents of competitors. For a patent filed March 16, 2013 or later, a petition for post-grant review can be filed by a third party in a nine-month window from issuance of the patent. For a patent filed before March 16, 2013, a petition for inter partes review can be filed immediately following the issuance of the patent. A petition for inter partes review can be filed after the nine-month period for filing a post-grant review petition has expired for a patent with an effective filing date of March 16, 2013 or later. Post-grant review proceedings can be brought on any ground of invalidity, whereas inter partes review proceedings can only raise an invalidity challenge based on published prior art and patents. These adversarial actions at the USPTO review patent claims without the presumption of validity afforded to U.S. patents in lawsuits in U.S. federal courts and use a lower burden of proof than used in litigation in U.S. federal courts. Therefore, it is generally considered easier for a competitor or third party to have a U.S. patent invalidated in a USPTO post-grant review or inter partes review proceeding than invalidated in a litigation in a U.S. federal court. If any of our patents are challenged by a third party in such a USPTO proceeding, there is no guarantee that we will be successful in defending the patent, which may result in a loss of the challenged patent right to us.

The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example:

●

we may not be able to generate sufficient data to support full patent applications that protect the entire breadth of developments in one or more of our targeted therapeutics programs;

●

it is possible that one or more of our pending patent applications will not become an issued patent or, if issued, that the patent(s) claims will have sufficient scope to protect any one of our targeted therapeutics, provide us with commercially viable patent protection or provide us with any competitive advantages;

Table of Contents

●

if our pending applications issue as patents, they may be challenged by third parties as invalid or unenforceable under United States or foreign laws;

●

we may not successfully commercialize our targeted therapeutics, if approved, before our relevant patents expire;

●

we may not be the first to make the inventions covered by our patent portfolio; or

●

we may not develop additional proprietary technologies or targeted therapeutics that are separately patentable.

In addition, to the extent that we are unable to obtain and maintain patent protection for our targeted therapeutics, or in the event that such patent protection expires, it may no longer be cost-effective to extend our portfolio by pursuing additional development of any of our targeted therapeutics for follow-on indications.

Table of Contents

Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.

In order to obtain and maintain our patents, we are required to pay application fees, periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents or applications to the USPTO and various government patent agencies outside of the United States over the lifetime of our owned and in-licensed patents or applications and any patent rights we may own or in-license in the future. The USPTO and various non-U.S. government patent agencies require compliance with several procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply with these requirements, and we are also dependent on our licensors to take the necessary action to comply with these requirements with respect to our in-licensed intellectual property. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market with similar or identical products or platforms, which could have a material adverse effect on our business prospects and financial condition.

Patent terms may not be able to protect our competitive position for an adequate period of time with respect to our current or future targeted therapeutics.

Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional or international Patent Corporation Treaty filing date. The patent term of a U.S. patent may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the USPTO in granting a patent, or may be shortened if a patent is terminally disclaimed over an earlier-filed patent.

Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Given the amount of time required for the development, testing and regulatory review of new commercial products arising from our discovery ~~and ADC platforms~~efforts, patents protecting such products might expire before or shortly after such products are commercialized.

In the United States, the Drug Price Competition and Patent Term Restoration Act of 1984 permits a Patent Term Extension, or PTE, of up to five years beyond the normal expiration of the patent to compensate patent owners for loss of an enforceable patent term due to the lengthy regulatory approval process. A PTE grant cannot extend the remaining term of a patent beyond a total of 14 years from the date of the product approval. Further, PTE may only be applied once per product, and only with respect to an approved indication - in other words, only one patent (for example, covering the product itself, an approved use of said product, or a method of manufacturing said product) can be extended by PTE. We anticipate applying for PTE in the United States. Similar extensions may be available in other countries where we are prosecuting patents, and we likewise anticipate applying for such extensions.

The granting of a PTE is not guaranteed and is subject to numerous requirements. We might not be granted an extension because of, for example, failure to apply within applicable periods, failure to apply prior to the expiration of relevant patents or otherwise failure to satisfy any of the numerous applicable requirements. In addition, to the extent we wish to pursue a PTE based on a patent that we in-license from a third party, we would need the cooperation of that third party. Moreover, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. If this occurs, our competitors may be able to obtain approval of competing products following our patent expiration by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case. If this were to occur, it could have a material adverse effect on our ability to generate revenue.66

Table of Contents

Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our current or any future targeted therapeutics.

The U.S. Congress is responsible for passing laws establishing patentability standards. As with any laws, implementation is left to federal agencies and the federal courts based on their interpretations of the laws. Interpretation of patent standards can vary significantly within the USPTO and across the various federal courts, including the U.S. Supreme Court. Recently, the U.S. Supreme Court has ruled on several patent cases, generally limiting the types of inventions that can be patented. Further, there are open questions regarding interpretation of patentability standards that the U.S. Supreme Court has yet to decisively address. Absent clear guidance from the U.S. Supreme Court, the USPTO has become increasingly conservative in its interpretation of patent laws and standards.

In addition to increasing uncertainty with regard to our ability to obtain patents in the future, the legal landscape in the United States has created uncertainty with respect to the value of patents. Depending on any actions by the U.S. Congress, and future decisions by the lower federal courts and the U.S. Supreme Court, along with interpretations by the USPTO, the laws and regulations governing patents could change in unpredictable ways and could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.

The U.S. Supreme Court has ruled on several patent cases in recent years; these cases often narrow the scope of patent protection available to inventions in the biotechnology and pharmaceutical spaces. For example, in Association for Molecular Pathology v. Myriad Genetics, Inc., or Myriad, the Supreme Court ruled that a “naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated,” and invalidated Myriad Genetics’ claims on the isolated BRCA1 and BRCA2 genes. To the extent that any of our patent application claims are deemed to be directed to natural products, or to lack an inventive concept above and beyond an isolated natural product, a court may decide the claims are directed to patent-ineligible subject matter and are invalid. The application of Myriad to biotechnology inventions has continued to develop and may continue to change over time. Subsequent rulings in cases or guidance or procedures issued by the USPTO relating to patent eligibility may have a negative impact on our business.

In Amgen Inc. v. Sanofi, or Amgen, the U.S. Supreme Court held that certain of Amgen’s patent claims defined a class of antibodies by their function of binding to a particular antigen. The Court further wrote that because the patent claims defined the claimed class of antibodies only by their function of binding to a particular antigen, a skilled artisan would have to use significant trial and error to identify and make all of the molecules in that class. The Court ultimately held that Amgen failed to properly enable its patent claims. Certain claims of our patent portfolio relate to broad classes of therapeutic agents, antibodies or antigen binding fragments. To the extent that a court finds that the skilled artisan would need significant trial and error to identify all the species in that class, the court may find the claims invalid under Amgen. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.

7467

Table of Contents

Further, a new court system recently became operational in the European Union. The Unified Patent Court, or UPC, began accepting patent cases on June 1, 2023. The UPC is a common patent court with jurisdiction over patent infringement and revocation proceedings effective for multiple member states of the European Union. The broad geographic reach of the UPC could enable third parties to seek revocation of any of our European patents in a single proceeding at the UPC rather than through multiple proceedings in each of the individual European Union member states in which the European patent is validated. Under the UPC, a successful revocation proceeding for a European Patent under the UPC would result in loss of patent protection in those European Union countries. Accordingly, a single proceeding under the UPC could result in the partial or complete loss of patent protection in numerous European Union countries. Such a loss of patent protection could have a material adverse impact on our business and our ability to commercialize our technology and product candidates and, resultantly, on our business, financial condition, prospects and results of operations. Moreover, the controlling laws and regulations of the UPC will develop over time and we cannot predict what the outcomes of cases tried before the UPC will be. The case law of the UPC may adversely affect our ability to enforce or defend the validity of our European patents. Patent owners have the option to opt-out their European patents from the jurisdiction of the UPC, defaulting to pre-UPC enforcement mechanisms. We have decided to opt out certain European patents and patent applications from the UPC. However, if certain formalities and requirements are not met, our European patents and patent applications could be subject to the jurisdiction of the UPC. We cannot be certain that our European patents and patent applications will avoid falling under the jurisdiction of the UPC, if we decide to opt out of the UPC.

We may not be able to protect our intellectual property rights throughout the world, which could negatively impact our business.

Filing, prosecuting, enforcing and defending patents protecting our current or future targeted therapeutics in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. The requirements for patentability may differ in certain countries, particularly in developing countries; thus, even in countries where we do pursue patent protection, there can be no assurance that any patents will issue with claims that cover our targeted therapeutics.

Moreover, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in foreign intellectual property laws. Additionally, the laws of some foreign jurisdictions do not protect intellectual property rights to the same extent as the laws in the United States and Europe. Many companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. The legal systems of certain countries, including certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biotechnology, which could make it difficult for us to stop the infringement of our owned and in-licensed patents or the marketing of competing products in violation of our intellectual property and proprietary rights generally. Proceedings to enforce our owned or in-licensed intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and could divert our efforts and attention from other aspects of our business. Such proceedings could also put our owned or in-licensed patents at risk of being invalidated or interpreted narrowly, could put our owned or in-licensed patent applications at risk of not issuing, and could provoke third parties to assert claims against us or our licensors. We or our licensors may not prevail in any lawsuits or other adversarial proceedings that we or our licensors initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our and our licensors’ efforts to enforce such intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or in-license.

Further, many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of its patents. If we or any of our licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position in the relevant jurisdiction may be impaired and our business prospects may be materially adversely affected.

7568

Table of Contents

Proceedings to enforce our patent rights, whether successful or not, could result in substantial costs and divert our efforts and resources from other aspects of our business. Further, such proceedings could put our patents at risk of being invalidated, held unenforceable or interpreted narrowly; put our pending patent applications at risk of not issuing; and provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Furthermore, while we intend to protect our intellectual property rights in major markets for our targeted therapeutics, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our products, if approved. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate.

In order to protect our competitive position around our future products, we may become involved in lawsuits to enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful and which may result in our patents being found invalid or unenforceable.

Competitors may seek to commercialize competitive products to our current or future targeted therapeutics. In order to protect our competitive position, we may become involved in lawsuits asserting infringement of our patents, or misappropriation or other violations of our intellectual property rights. Litigation is expensive and time-consuming and would likely divert the time and attention of our management and scientific personnel. There can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings.

If we or our licensors file a patent infringement lawsuit against a perceived infringer, such a lawsuit could provoke the defendant to counterclaim that we infringe their patents and/or that our patents are invalid and/or unenforceable. In patent litigation in the United States, it is commonplace for a defendant to counterclaim alleging invalidity and/or unenforceability. In any patent litigation there is a risk that a court will decide that the asserted patents are invalid or unenforceable, in whole or in part, and that we do not have the right to stop the defendant from using the invention at issue. With respect to a counterclaim of invalidity, we cannot be certain that there is no invalidating prior art of which we and the patent examiner were unaware during prosecution. There is also a risk that, even if the validity of such patent is upheld, the court will construe the patent claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the grounds that our patent claims do not cover the invention. If any of our patents are found invalid or unenforceable, or construed narrowly, our ability to stop the other party from launching a competitive product would be materially impaired. Further, such adverse outcomes could limit our ability to assert those patents against future competitors. Loss of patent protection would have a material adverse impact on our business.

Even if we establish infringement of any of our patents by a competitive product, a court may decide not to grant an injunction against further infringing activity, thus allowing the competitive product to continue to be marketed by the competitor. It is difficult to obtain an injunction in U.S. litigation and a court could decide that the competitor should instead pay us a “reasonable royalty” as determined by the court, and/or other monetary damages. A reasonable royalty or other monetary damages may or may not be an adequate remedy. Loss of exclusivity and/or competition from a related product would have a material adverse impact on our business.

Litigation often involves significant amounts of public disclosures. Such disclosures could have a materially adverse impact on our competitive position or our stock prices. During any litigation we would be required to produce voluminous records related to our patents and our research and development activities in a process called discovery. The discovery process may result in the disclosure of some of our confidential information. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could adversely affect the price of our common stock.

7669

Table of Contents

Litigation is inherently expensive, and the outcome is often uncertain. Any litigation likely would substantially increase our operating losses and reduce our resources available for development activities. Further, we may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. As a result, we may conclude that even if a competitor is infringing any of our patents, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best interest of our company or our stockholders. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other non-litigious action or solution.

If in the future, we in-license any patent rights, we may not have the right to file a lawsuit for infringement and may have to rely on a licensor to enforce these rights for us. If we are not able to directly assert our licensed patent rights against infringers or if a licensor does not vigorously prosecute any infringement claims on our behalf, we may have difficulty competing in certain markets where such potential infringers conduct their business, and our commercialization efforts may suffer as a result.

Concurrently with an infringement litigation, third parties may also be able to challenge the validity of our patents before administrative bodies in the United States or abroad. Such mechanisms include re-examination, post grant review and equivalent proceedings in foreign jurisdictions, e.g., opposition proceedings. Such proceedings could result in revocation or amendment of our patents in such a way that they no longer cover our products, potentially negatively impacting any concurrent litigation.

We may need to acquire or license additional intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.

A third party may hold intellectual property, including patent rights, that are important or necessary to the development of our targeted therapeutics. It may be necessary for us to use the patented or proprietary technology of one or more third parties to commercialize our current and future targeted therapeutics.

The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development. If we are unable to acquire such intellectual property outright, or obtain licenses to such intellectual property from such third parties when needed or on commercially reasonable terms, our ability to commercialize any of our targeted therapeutics, if approved, would likely be delayed or we may have to abandon development of that targeted therapeutic and our business and financial condition could suffer. Further, we may be required to expend significant time and resources to redesign our targeted therapeutics or the methods for manufacturing them, or to develop or license replacement technology, all of which may not be commercially or technically feasible. In such events, there could be a material adverse effect on our ability to commercialize and on our business, financial condition, results of operations and prospects.

If we in-license additional targeted therapeutics or other technologies in the future, we might become dependent on proprietary rights from third parties with respect to those ~~targeted~~licensed ~~therapeutics~~assets. Any termination of such licenses could result in the loss of significant rights and would cause material adverse harm to our ability to develop and commercialize any targeted therapeutics subject to or dependent upon such licenses. Even if we are able to in-license any such necessary intellectual property, it could be on nonexclusive terms, including with respect to the use, field or territory of the licensed intellectual property, thereby giving our competitors and other third parties access to the same intellectual property licensed to us. In-licensing intellectual property rights could require us to make substantial licensing and royalty payments. Patents licensed to us could be put at risk of being invalidated or interpreted narrowly in litigation filed by or against our licensors or another licensee or in administrative proceedings. If any in-licensed patents are invalidated or held unenforceable, we may not be able to prevent competitors or other third parties from developing and commercializing competitive products.

7770

Table of Contents

We may not have the right to control the prosecution, maintenance, enforcement or defense of patents and patent applications that we license from third parties. In such cases, we would be reliant on the licensor to take any necessary actions. We cannot be certain that such licensor would act with our best interests in mind, or in compliance with applicable laws and regulations, or that their actions would result in valid and enforceable patents. For example, it is possible that a licensor’s actions in enforcing and/or defending a patent licensed by us may be less vigorous than had we conducted them ourselves. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.

Disputes may also arise between us and our licensors regarding intellectual property subject to a license agreement, including:

●

the scope of rights granted under the license agreement and other interpretation-related issues;

●

our financial or other obligations under the license agreement;

●

whether and the extent to which our technology and processes infringe intellectual property of the licensor that is not subject to the licensing agreement;

●

our right to sublicense patent and other rights to third parties under collaborative development relationships;

●

our diligence obligations with respect to the use of licensed technology in relation to our development and commercialization of our targeted therapeutics and what activities satisfy those diligence obligations;

●

the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and

●

the priority of invention of patented technology.

If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected targeted therapeutics.

The risks described elsewhere pertaining to our intellectual property rights also apply to the intellectual property rights that we may own or in-license now or in the future, and any failure by us or our licensors to obtain, maintain, defend and enforce these rights could have an adverse effect on our business. In some cases we may not have control over the prosecution, maintenance, defense or enforcement of the patents that we license, and may not have sufficient ability to provide input into the patent prosecution, maintenance and defense process with respect to such patents, and potential future licensors may fail to take the steps that we believe are necessary or desirable in order to obtain, maintain, defend and enforce the licensed patents.

If we fail to comply with our obligations under any license, collaboration or other intellectual property-related agreements, we may be required to pay damages and could lose intellectual property rights that may be necessary for developing, commercializing and protecting our current or future targeted therapeutics, or we could lose certain rights to grant sublicenses.*

We are reliant upon in-licenses to certain patent rights and proprietary technologies from third parties that are or may become important or necessary to our ~~discovery and~~ ADC ~~platforms~~platform and/or targeted therapeutics pipeline.

7871

Table of Contents

Our current license agreements impose, and any future license agreements we enter into are likely to impose, various development, commercialization, funding, milestone, royalty, diligence, sublicensing, insurance, patent prosecution, and enforcement or other obligations on us. In addition, certain of our license agreements require us to bear the costs of filing and maintaining patent applications. If we are in breach of our license agreements, we may be required to pay damages and the licensor may have the right to terminate the license. Termination of any of our license agreements could result in a material adverse effect on our ability to use our ~~discovery and~~ ADC ~~platforms~~platform and/or targeted therapeutics and our ability to develop, manufacture, and sell products that are discovered using or are otherwise covered by technology licensed under those agreements, or could enable a competitor to gain access to the licensed technology.

Under our current and future license agreements, we may not have all intellectual property rights necessary for developing, commercializing, and protecting our current or future targeted therapeutics.*

We may not have the right to control the preparation, filing, prosecution, maintenance, enforcement and defense of patents and patent applications that we license from third parties. For example, pursuant to certain of our license agreements, while we may comment on patent applications and may lead enforcement of the patents and patent applications, the licensing institution is responsible for the preparation, filing, prosecution and maintenance and defense of the patents and patent applications. While we may provide input on patent strategy, including strategy relating to patent drafting and prosecution, we cannot be certain that the in-licensed patents and patent applications will be prepared, filed, prosecuted, maintained, and defended in a manner consistent with the best interests of our business. If our licensors and future licensors lose rights to licensed patents or patent applications, our right to develop and commercialize any of our targeted therapeutics that is the subject of such licensed rights could be materially adversely affected.

Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing, misappropriating or otherwise violating the licensor’s intellectual property rights. In addition, while we cannot currently determine the amount of the royalty obligations we would be required to pay on sales of future products if infringement or misappropriation were found, those amounts could be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we use in products that we successfully develop and commercialize, if any. Therefore, even if we successfully develop and commercialize products, we may be unable to achieve or maintain profitability.

In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to disagreement regarding interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse impact on our business and ability to achieve profitability. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize any affected targeted therapeutics, which could have a material adverse effect on our business and financial conditions.

7972

Table of Contents

Intellectual property rights of third parties could adversely affect our ability to commercialize our targeted therapeutics, and we might be required to obtain licenses from third parties to engage in development or marketing efforts, which may not be available on commercially reasonable terms or at all.

Our commercial success depends, in part, on our ability to develop, manufacture, market and sell our targeted therapeutics without infringing, misappropriating or otherwise violating the intellectual property and other proprietary rights of third parties. However, our research, development and commercialization activities may be subject to claims that we infringe, misappropriate or otherwise violate patents or other intellectual property rights owned or controlled by third parties. Third parties may have U.S. and non-U.S. issued patents and pending patent applications relating to targeted therapeutics or components thereof, methods of manufacturing our targeted therapeutics or components thereof, and/or methods of use for the treatment of the disease indications for which we are developing our targeted therapeutics. If any third-party patents or patent applications are found to cover any of our targeted therapeutics, or their methods of use or manufacture, we may not be free to manufacture or market such targeted therapeutics as planned without obtaining a license, which may not be available on commercially reasonable terms, or at all. We or our licensors, or any future strategic partners, may be party to, or be threatened with, adversarial proceedings or litigation regarding intellectual property rights. In some instances, we may be required to indemnify our licensors for the costs associated with any such adversarial proceedings or litigation.

There is a substantial amount of intellectual property litigation in the biotechnology and pharmaceutical industries, and we may become party to, or threatened with, litigation or other adversarial proceedings regarding intellectual property rights with respect to our targeted therapeutics, including patent infringement lawsuits in the U.S. or abroad. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the composition, use or manufacture of our targeted therapeutics. Our competitive position may materially suffer if patents issued to third parties or other third-party intellectual property rights cover our targeted therapeutics or elements thereof or our manufacture or uses relevant to our development plans. In such cases, we may not be in a position to develop or commercialize current or future targeted therapeutics unless we successfully pursue litigation to nullify or invalidate the third-party intellectual property right concerned or enter into a license agreement with the intellectual property right holder, if available on commercially reasonable terms. There may be issued patents of which we are not aware, held by third parties that, if found to be valid and enforceable, could be alleged to be infringed by our current or future targeted therapeutics. There also may be pending patent applications of which we are not aware that may result in issued patents, which could be alleged to be infringed by our current or future targeted therapeutics. Additionally, claims in pending patent applications, subject to certain limitations, can be amended in a manner that could cover our targeted therapeutics. If a third-party infringement claim should successfully be brought, we may be required to pay substantial damages or be forced to abandon our current or future targeted therapeutics or to seek a license from any patent holders. No assurances can be given that a license will be available on commercially reasonable terms, if at all.

Third parties may assert infringement claims against us based on patents that exist now or may arise in the future, regardless of the merit of such patents or infringement claims. The outcome of intellectual property litigation is subject to uncertainties that cannot be adequately quantified in advance. The pharmaceutical and biotechnology industries have produced a significant number of patents, and it may not always be clear to industry participants, including us, which patents cover various types of products or methods of use or manufacture. The scope of protection afforded by a patent is subject to interpretation by the courts, and the interpretation is not always uniform. If we were sued for patent infringement, we would need to demonstrate that the relevant product or methods of using the product either do not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not be able to do this. Proving invalidity is difficult. For example, in the United States, proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted in pursuing these proceedings, which could significantly harm our business and operating results. In addition, parties making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources, and we may not have sufficient resources to bring these actions to a successful conclusion.

8073

Table of Contents

While we perform periodic searches for relevant patents and patent applications with respect to our programs and ~~development~~product candidates, and uses thereof, we cannot guarantee the completeness or thoroughness of any of our patent searches or analyses including, but not limited to, the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, nor can we be certain that we have identified each and every patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of any of our targeted therapeutics in any jurisdiction. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that any of our targeted therapeutics may be accused of infringing. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Accordingly, third parties may assert infringement claims against us based on intellectual property rights that exist now or arise in the future.

Numerous third-party U.S. and foreign issued patents and pending patent applications exist which are related to our targeted therapeutics or components of our targeted therapeutics. For example, we are aware of patent portfolios related to compounds containing FAP targeting ligands that are owned by 3B Pharmaceuticals, Cornell University, Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, and Johns Hopkins University. There may also be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our targeted therapeutics.

If our defenses to such assertions of infringement were unsuccessful, we could be liable for a court-determined reasonable royalty on our existing sales and further damages to the patent owner (or licensee), such as lost profits. Such royalties and damages could be significant. If we are found to have willfully infringed the claims of a third party's patent, the third party could be awarded treble damages and attorney's fees. Further, if we are found to infringe, misappropriate or otherwise violate a third party’s intellectual property rights, we could be forced, including by court order, to cease developing, manufacturing or commercializing the infringing product. We might, if possible, also be forced to redesign current or future targeted therapeutics so that we no longer infringe, misappropriate or violate the third-party intellectual property rights. Alternatively, we may be required to obtain a license from such third party in order to use the infringing technology and continue developing, manufacturing or marketing the infringing product. If we were required to obtain a license to continue to manufacture or market the affected product, we may be required to pay substantial royalties or grant cross-licenses to our patents. Even if we were able to obtain a license, it could be nonexclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us. We cannot assure you that any such license will be available on acceptable terms, if at all. Ultimately, we could be prevented from commercializing a product, or be forced to cease some aspect of our business operations as a result of claims of patent infringement or violation of other intellectual property rights, Further, the outcome of intellectual property litigation is subject to uncertainties that cannot be adequately quantified in advance, including the demeanor and credibility of witnesses and the identity of any adverse party. This is especially true in intellectual property cases that may turn on the testimony of experts as to technical facts upon which experts may reasonably disagree. Furthermore, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us; alternatively or additionally, it could include terms that impede or destroy our ability to compete successfully in the commercial marketplace. In addition, we could be found liable for significant monetary damages, including treble damages and attorneys’ fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing a product or force us to cease some of our business operations, which could harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have material adverse effects on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operations, financial condition and prospects.

Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business, which could have a material adverse effect on our financial condition and results of operations.

8174

Table of Contents

Others may challenge inventorship or claim an ownership interest in our intellectual property which could expose us to litigation and have a significant adverse effect on our prospects.*

Determinations of inventorship can be subjective. While we undertake to accurately identify correct inventorship of inventions made on our behalf by our employees, consultants and contractors, an employee, consultant or contractor may disagree with our determination of inventorship and assert a claim of inventorship. Any disagreement over inventorship could result in our being forced to defend our determination of inventorship in a legal action which could result in substantial costs and be a distraction to our senior management and scientific personnel.

While we typically require employees, consultants and contractors who may develop intellectual property on our behalf to execute agreements assigning such intellectual property to us, we may be unsuccessful in obtaining execution of assignment agreements with each party who in fact develops intellectual property that we regard as our own. Moreover, even when we obtain agreements assigning intellectual property to us, the assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached. In either case, we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Furthermore, individuals executing agreements with us may have preexisting or competing obligations to a third party, such as an academic institution, and thus an agreement with us may be ineffective in perfecting ownership of inventions developed by that individual. If we are unsuccessful in obtaining assignment agreements from an employee, consultant or contractor who develops intellectual property on our behalf, the employee, consultant or contractor may later claim ownership of the invention. Any disagreement over ownership of intellectual property could result in our losing ownership, or exclusive ownership, of the contested intellectual property, paying monetary damages and/or being enjoined from clinical testing, manufacturing and marketing of the affected product candidate(s). Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to our senior management and scientific personnel.

If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.

We consider trade secrets, including confidential and unpatented know-how, important to the maintenance of our competitive position. We may rely on trade secrets or confidential know-how to protect certain aspects of our technology, especially where patent protection is believed by us to be of limited value. We expect to rely on third parties for future manufacturing of our targeted therapeutics, and any future targeted therapeutics. We also expect to collaborate with third parties on the development of our targeted therapeutics and any future targeted therapeutics. As a result of the aforementioned collaborations, we must, at times, share trade secrets with our collaborators. We also conduct joint research and development programs that may require us to share trade secrets under the terms of our research and development partnerships or similar agreements.

Trade secrets or confidential know-how can be difficult to maintain as confidential. We protect and plan to protect trade secrets and confidential and unpatented know-how, in part, by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements prior to beginning research or disclosing proprietary information with parties, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants under which they are obligated to maintain confidentiality and to assign their inventions to us. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. However, current or former employees, consultants, contractors and advisors may unintentionally or willfully disclose our confidential information to competitors, and confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. The need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor’s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on our business and results of operations. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret or securing title to an employee- or consultant-developed invention if a dispute arises, is difficult, expensive and time-consuming, and the outcome is unpredictable.

8275

Table of Contents

The enforceability of confidentiality agreements may vary from jurisdiction to jurisdiction. In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. A competitor’s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business.

We may be subject to claims by third parties that we or our employees or consultants have wrongfully used or disclosed their alleged trade secrets or other proprietary information.*

Many of our current or former employees or consultants and our licensors’ current or former employees or consultants, including our senior management, were previously employed at universities or biotechnology or biopharmaceutical companies, including some which may be competitors or potential competitors. Although we take commercially reasonable steps to ensure that our employees and consultants do not use the proprietary information, know-how or trade secrets of others in their work for us, including incorporating such intellectual property into our ~~platforms~~platform and programs, we may be subject to claims that we or these employees or consultants have misappropriated the intellectual property of a third party or breached other obligations to. Litigation or arbitration may be necessary to defend against these claims.

If we fail in defending against such claims, in addition to paying monetary damages, we may sustain reputational damage, lose valuable intellectual property rights or key personnel or may be enjoined from using such intellectual property. Further, it may become necessary for us to obtain a license from such third party to commercialize any of our products. Such license(s) may not be available on commercially reasonable terms or at all. Any such proceedings and possible aftermath would likely divert significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities. A loss of key personnel or their work product could limit our ability to commercialize, or prevent us from commercializing, our current or future targeted therapeutics, which could materially harm our business. Even if we are successful in defending against any such claims, litigation or arbitration could result in substantial costs and could be a distraction to our management.

8376

Table of Contents

If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.

Our trademarks or trade names may be challenged, infringed, circumvented, declared generic or determined to be infringing on other marks. We rely on both registration and common law protection for our trademarks. As a means to enforce our trademark rights and prevent infringement, we may be required to file trademark claims against third parties or initiate trademark opposition proceedings. This can be expensive and time-consuming, particularly for a company of our size. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. During trademark registration proceedings, we may receive rejections. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. Moreover, any name we propose to use for our products in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA objects to any of our proposed product names, we may be required to expend significant additional resources in an effort to identify a usable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected.

Intellectual property rights do not necessarily address all potential threats to our business.

The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. The following examples are illustrative:

●

others may be able to make products or formulations that are similar or competitive to our targeted therapeutics, but that are not covered by the claims of any patents that we own, license or control;

●

we or any of our licensors or strategic partners might not have been the first to make the inventions covered by the issued patents or pending patent applications that we own, license or control;

●

we or our licensors or strategic partners might not have been the first to file patent applications covering certain of our owned and in-licensed inventions;

●

others may independently develop the same, similar, or alternative technologies without infringing, misappropriating or violating our owned or in-licensed intellectual property rights;

●

it is possible that our owned or in-licensed pending patent applications will not lead to issued patents;

●

others may have access to the same intellectual property rights licensed to us on a non-exclusive basis in the future;

●

issued patents that we own, in-license, or control may not provide us with any competitive advantages, or may be narrowed or held invalid or unenforceable, including as a result of legal challenges;

8477

Table of Contents

●

our competitors might conduct research and development activities in the United States and other countries that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights, and may then use the information learned from such activities to develop competitive products for sale in our major commercial markets;

●

we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such trade secrets or know-how;

●

ownership of our patent portfolio may be challenged by third parties;

●

patent enforcement is expensive and time-consuming and difficult to predict; thus, we may not be able to enforce any of our patents against a competitor; and

●

the patents of third parties or pending or future patent applications of third parties, if issued, may have an adverse effect on our business.

Should any of these events occur, they could have a material adverse impact on our business and financial condition.

Risks Related to Our Business Operations and Industry

Our success largely depends on the continued service of key management, advisors, consultants and other specialized personnel. While we have written employment agreements with our management team and each of our key employees, those employment arrangements are at-will and could be terminated at any time. The loss of one or more members of our management team or other key employees, advisors or consultants could delay our research and development programs and have a material and adverse effect on our business, financial condition, results of operations and prospects. We do not currently maintain “key man” insurance on any of our executive officers.

~~The~~In ~~relationships~~addition, ~~that~~although our ~~key~~leadership ~~management~~ team ~~members~~and ~~have~~other ~~cultivated~~key ~~within~~personnel ~~our~~previously ~~industry~~played ~~make~~key usroles ~~particularly~~in ~~dependent upon their continued employment with us. We are dependent on~~ the ~~continued service of our technical personnel because of the highly technical nature of our programs~~design, development, ~~candidates~~ and ~~technologies~~commercialization ~~and the specialized nature~~ of ~~the~~cutting-edge ~~regulatory~~targeted ~~approval~~cancer ~~process. Our future success will depend in large part on our continued ability to attract and retain other highly qualified scientific~~therapies, ~~technical~~no ~~and~~assurance ~~management~~can ~~personnel,~~be asgiven ~~well~~that astheir ~~personnel~~prior ~~with~~successes ~~expertise~~will inbe ~~clinical~~indicative ~~testing,~~of ~~manufacturing,~~our ~~governmental regulation and commercialization. Our~~ future success ~~is also dependent on our ability to retain qualified advisors and consultants~~. ~~We face competition for personnel from other companies, universities, public and private research institutions, government entities and other organizations.~~

AsThe ofrelationships ~~September 30, 2024,~~that weour ~~had~~key ~~105~~management ~~full-time~~team ~~employees~~members have cultivated within our industry make us particularly dependent upon their continued employment with us. ~~The~~We are dependent on the continued ~~operation~~service of our ~~business~~technical ~~and~~personnel ~~execution~~because of the highly technical nature of our ~~plans~~programs, ~~will~~product ~~require~~candidates ~~material~~and ~~additional~~technologies ~~staffing~~and ~~within~~the specialized nature of the ~~next~~regulatory ~~twelve~~approval ~~months~~process. WeOur ~~cannot~~future ~~provide~~success ~~assurance~~will ~~that~~depend wein ~~will~~large bepart ~~able~~on our continued ability to ~~hire~~attract orand retain ~~adequate~~other ~~staffing~~highly ~~levels~~qualified toscientific, ~~advance~~technical ~~our~~and ~~discovery~~management ~~and~~personnel, ~~ADC~~as ~~platforms~~well as personnel with expertise in clinical testing, ~~develop~~manufacturing, ~~our~~governmental ~~programs~~regulation orand ~~development~~commercialization. ~~candidates~~Our orfuture ~~run~~success ~~our~~is ~~operations~~also ordependent on our ability to ~~accomplish~~retain ~~our~~qualified ~~objectives~~advisors and consultants. We face competition for personnel from other companies, universities, public and private research institutions, government entities and other organizations.

85As of March 31, 2025, we had 131 full-time employees. The continued operation of our business and execution of our plans will require material additional staffing within the next twelve months. We cannot provide assurance that we will be able to hire or retain adequate staffing levels to advance our ADC platform, develop our programs or product candidates or run our operations or to accomplish our objectives.

Table of Contents

We may experience difficulties in managing our growth and expanding our operations.

As our ~~development~~product candidates enter and advance through preclinical studies and any clinical trials, including our Phase 1 clinical trial of IM-1021 and our Phase 3 clinical trial of ~~AL102~~varegacestat, we will need to expand our development, regulatory and manufacturing capabilities or contract with other organizations to provide these capabilities for us. We may also experience difficulties in the discovery and development of new ~~development~~product candidates using our ~~discovery and~~ ADC ~~platforms~~platform if we are unable to meet demand as we grow our operations. In the future, we also expect to have to manage additional relationships with collaborators, suppliers and other organizations. Our ability to manage our operations and future growth will require us to continue to improve our operational, financial and management controls, reporting systems and procedures and secure adequate facilities for our operational needs. We may not be able to implement improvements to our management information and control systems in an efficient or timely manner and may discover deficiencies in existing systems and controls.

Our employees, principal investigators, vendors and commercial partners may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.

We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, vendors and commercial partners. Misconduct by employees could include intentional failures to comply with FDA regulations, provide accurate information to the FDA, comply with manufacturing standards we may establish, comply with federal and state health care fraud and abuse laws and regulations, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. For example, individuals conducting the non-interventional clinical studies that we sponsor through which we obtain antibodies for development into potential antibody-based therapeutics may violate applicable laws and regulations regarding personal information. It is not always possible to identify and deter misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a material and adverse effect on our business and financial condition, including the imposition of significant criminal, civil, and administrative fines or other sanctions, such as monetary penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government-funded health care programs, such as Medicare and Medicaid, integrity obligations, reputational harm and the curtailment or restructuring of our operations.

Risks Related to our Common Stock

An active trading market for our common stock may not be sustained, which may make it difficult for you to sell your shares.

The trading market for our common stock on The Nasdaq Capital Market has been limited and an active trading market for our shares may not be sustained. If an active market for our common stock is not sustained, it may be difficult for you to sell your shares at a price that is attractive to you, or at all.

The market price of our common stock is expected to be volatile, and purchasers of our common stock could incur substantial losses.*

The market price of our common stock could be subject to significant fluctuations. Market prices for securities of biotechnology, early-stage pharmaceutical and other life sciences companies have historically been particularly volatile. Some of the factors that may cause the market price of our common stock to fluctuate include:79

● our ability to successfully develop and obtain regulatory approvals for our development candidates, and delays or failures to obtain such approvals;

Table of Contents

●The ~~failure~~market ofprice ~~any~~ of our ~~development~~common ~~candidates,~~stock ifis ~~approved,~~expected to ~~achieve~~be ~~commercial~~volatile, ~~success;~~and purchasers of our common stock could incur substantial losses.

●

our ability to successfully develop and obtain regulatory approvals for our product candidates, and delays or failures to obtain such approvals;

●

failure of any of our product candidates, if approved, to achieve commercial success;

●

failure by us to maintain our existing third-party license and supply agreements;

●

failure by us or our licensors to prosecute, maintain, or enforce our intellectual property rights;

● changes in laws or regulations applicable to our ~~development~~product candidates;

● any inability to obtain adequate supply of our ~~development~~product candidates or the inability to do so at acceptable prices;

●

adverse regulatory authority decisions;

●

introduction of new products, services or technologies by our competitors;

●

failure to meet or exceed any projections we may provide to the public;

●

failure to meet or exceed the financial and development projections of the investment community;

●

the perception of the pharmaceutical industry by the public, legislatures, regulators and the investment community;

● the effects of ~~the Merger and~~ our financing transactions, which materially increase our public float;

●

announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by us or our competitors;

●

disputes or other developments relating to proprietary rights, including patents, litigation matters, and our ability to obtain patent protection for our technologies;

●

additions or departures of key personnel;

●

significant lawsuits, including patent or stockholder litigation;

●

if securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our business and stock;

●

changes in the market valuations of similar companies;

●

general market or macroeconomic conditions;

●

sales of our common stock by us, including pursuant to the 2024 ATM Agreement, or our stockholders in the future;

Table of Contents

●

trading volume of our common stock;

●

failure to maintain compliance with the listing requirements of The Nasdaq Capital Market;

●

announcements by commercial partners or competitors of new commercial products, clinical progress or the lack thereof, significant contracts, commercial relationships or capital commitments;

●

adverse publicity generally, including with respect to other products and potential products in such markets;

Table of Contents

●

the introduction of technological innovations or new therapies that compete with our potential products;

●

changes in the structure of healthcare payment systems; and

●

period-to-period fluctuations in our financial results.

Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of our common stock.

In the past, following periods of volatility in the market price of a company’s securities, stockholders have often instituted class action securities litigation against those companies. Such litigation, if instituted, could result in substantial costs and diversion of management attention and resources, which could significantly harm our profitability and reputation.

Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.

Certain of our executive officers, directors and large stockholders own a significant percentage of our outstanding capital stock. As a result of their share ownership, these stockholders will have the ability to influence us through their ownership positions. These stockholders may be able to determine all matters requiring stockholder approval. For example, these stockholders, acting together, may be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. These stockholders’ interests may not always coincide with our corporate interests or the interests of other stockholders, and these stockholders may exercise their voting and other rights in a manner with which you may not agree or that may not be in the best interests of our other stockholders. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may believe are in your best interest as one of our stockholders.

Table of Contents

Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.*

We expect that significant additional capital may be needed in the future to continue our planned operations, including further development of our programs and ~~development~~product candidates, preparing IND filings, conducting clinical trials, commercialization efforts, expanded research and development activities and costs associated with operating a public company. To raise capital, we may sell common stock, preferred stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. In this regard, we filed a shelf registration statement on Form S-3, which was declared effective by the SEC on October 14, 2021, pursuant to which we may issue from time to time securities with an aggregate value of up to $200.0 million in ~~one or more offerings at prices and terms to be determined at the time of sale. In~~ October 2023, we completed our Merger and concurrent PIPE transaction for gross proceeds of approximately $125.0 million before deducting fees and offering expenses. An aggregate of 21,690,871 shares of our common stock at $5.75 per share were issued pursuant to the subscription agreements and have been registered for resale pursuant to a registration statement on Form S-3 filed with the SEC and made effective on November 27, 2023. InAdditionally, in February 2024, we filed an automatic shelf registration statement on Form S-3, pursuant to which we have, and may in the future issue from time-to-time securities in one or more offerings at prices and terms to be determined at the time of sale. For example, in February 2024 and January 2025, we raised $230.0 million and $172.5 million, respectively, before deducting underwriting discounts and commissions and estimated offering expenses payable by us, through athe public offering of our common stock. In connection with the closing of the public ~~offering~~offerings, we issued and sold 11,500,000 shares of our common stock in February 2024 and 22,258,064 shares of our common stock in January 2025. In May 2024, we also entered into the 2024 ATM Agreement with TD Cowen, pursuant to which we may offer and sell, from time to time through TD Cowen, at our option, shares of our common stock. As of the filing of this Annual Report, we have sold 2,030,431 shares of our common stock for gross proceeds of approximately $20.0 million pursuant to the 2024 ATM Agreement and approximately $180.0 million remains available for future sales. If we sell shares of common stock, preferred stock, convertible securities or other equity securities, including pursuant to sales under the 2024 ATM Agreement, investors may be materially diluted. Such sales may also result in material dilution to our existing stockholders, and new investors could gain rights, preferences and privileges senior to the holders of our common stock.

We issued 2,298,586 shares to Zentalis in connection with the Zentalis License Agreement, 2,175,489 shares to Ayala in connection with the Ayala Asset Purchase Agreement, ~~and~~ 230,415 shares to BMS in connection with the BMS License Agreement Amendment and 1,805,502 shares to Zentalis in connection with the Zentalis Asset Purchase, all of which are registered for resale on Forms S-3 filed with the SEC in April 2024, ~~and~~ October 2024. Inand ~~October~~November 2024, werespectively. ~~also~~The ~~issued 1,805,502~~ shares issued to Zentalis asin ~~consideration~~October ~~for~~2024 ~~the~~are ~~Zentalis~~subject ~~Asset~~a ~~Purchase, and we agreed~~ to ~~use~~a ~~commercially~~six-month ~~reasonable~~lock-up ~~efforts~~with respect to ~~register~~half ~~the shares for resale within 30 days~~ of the ~~closing~~shares. ofThe ~~the~~shares ~~Zentalis~~issued ~~Asset~~to ~~Purchase,~~Ayala ~~The~~in ~~shares~~April ~~issued~~2024 toand Zentalis ~~and~~in ~~Ayala~~October 2024 are subject a to ~~(i)~~ aan ~~six-month~~orderly ~~lock-up~~market ~~with~~disposition ~~respect~~for toone ~~half~~year offrom the ~~shares~~date ~~and~~of ~~(ii) an orderly market disposition~~issuance. Notwithstanding these contractual protections, any sales of these shares may cause our stock price to fall.

88Pursuant to our 2020 Equity Incentive Plan, or 2020 Plan, our board of directors or committee thereof or, in accordance with applicable law, designated members of management are authorized to grant stock options to our employees, directors and consultants. In addition, pursuant to our 2024 Inducement Plan, as amended, our board of directors, or a committee thereof, is authorized to grant inducement awards to new hires as a material inducement to their employment with us. The aggregate number of shares of our common stock that may be issued pursuant to stock awards under our 2020 Plan as of March 31, 2025 shall not exceed 10,774,732 shares, and the aggregate number of shares of our common stock that may be issued pursuant to stock awards under our 2024 Inducement Plan shall not exceed 3,500,000 shares.

Table of Contents

Additionally, the number of shares of our common stock reserved for issuance under our 2020 Plan will automatically increase on ~~February~~January ~~13,~~1 ~~2024~~of each year, webeginning ~~filed~~on anJanuary 1, ~~automatic~~2021 ~~shelf~~and ~~registration~~continuing ~~statement~~through onand ~~Form~~including January ~~S-3~~1, ~~pursuant~~2030, toby ~~which~~4% weof ~~may~~the ~~issue~~total ~~from~~number ~~time-to-time~~of ~~securities~~shares inof ~~one~~our orcapital ~~more~~stock ~~offerings~~outstanding aton ~~prices~~December 31 ~~and~~of ~~terms~~the topreceding becalendar year, or a lesser number of shares determined atby ~~the~~our ~~time~~board of ~~sale~~directors. ~~For~~Unless ~~example,~~our inboard ~~May~~of ~~2024,~~directors weelects ~~entered~~not ~~into~~to increase the ~~2024~~number ~~ATM~~of ~~Agreement~~shares ~~with~~available TDfor ~~Cowen,~~future ~~pursuant~~grant toeach ~~which~~year, weour stockholders may ~~offer~~experience ~~and~~additional ~~sell~~dilution, ~~from~~which ~~time~~could cause our stock price to ~~time~~fall. ~~through~~Additionally, TDpursuant ~~Cowen~~to Morphimmune Inc.’s 2020 Equity Incentive Plan, ator ~~our~~the ~~option~~Morphimmune Plan, ~~shares~~the aggregate number of ~~our~~shares ~~common~~that may be issued pursuant to stock ~~having~~awards anunder ~~aggregate~~the ~~offering~~Morphimmune ~~price~~Plan as of upMarch to31, ~~$200.0~~2025 ~~million~~may not exceed 2,822,308 shares. IfAlthough we ~~sell~~did ~~shares~~not ofinitially ~~common~~anticipate ~~stock,~~issuing ~~preferred~~awards ~~stock,~~under ~~convertible~~the ~~securities~~Morphimmune orPlan, ~~other~~depending ~~equity~~on ~~securities~~our needs, ~~including~~we ~~pursuant~~may toin ~~sales~~the future issue awards under the ~~2024~~Morphimmune ~~ATM~~Plan. ~~Agreement~~Additionally, ~~investors~~on ~~may~~June be28, ~~materially~~2023, ~~diluted.~~Clay ~~Such~~Siegall ~~sales~~was ~~may~~granted ~~also~~options ~~result~~to inpurchase ~~material~~shares ~~dilution~~of the Company’s common stock pursuant to ~~our~~an ~~existing~~Inducement ~~stockholders,~~Grant. ~~and~~The ~~new~~aggregate ~~investors~~number ~~could~~of ~~gain~~stock ~~rights,~~awards ~~preferences~~that ~~and~~may ~~privileges~~be ~~senior~~issued tounder the ~~holders~~Inducement ofGrant ~~our~~may ~~common~~not ~~stock~~exceed 2,137,080 shares.

Pursuant to our 2020 Equity Incentive Plan, or 2020 Plan, our board of directors or committee thereof or, in accordance with applicable law, designated members of management are authorized to grant stock options to our employees, directors and consultants. In addition, pursuant to our 2024 Inducement Plan, our board of directors, or a committee thereof, is authorized to grant inducement awards to new hires as a material inducement to their employment with us. The aggregate number of shares of our common stock that may be issued pursuant to stock awards under our 2020 Plan shall not exceed 8,080,286 shares, and the aggregate number of shares of our common stock that may be issued pursuant to stock awards under our 2024 Inducement Plan shall not exceed 2,000,000 shares.

Additionally, the number of shares of our common stock reserved for issuance under our 2020 Plan will automatically increase on January 1 of each year, beginning on January 1, 2021 and continuing through and including January 1, 2030, by 4% of the total number of shares of our capital stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares determined by our board of directors. Unless our board of directors elects not to increase the number of shares available for future grant each year, our stockholders may experience additional dilution, which could cause our stock price to fall. Additionally, pursuant to Morphimmune Inc.’s 2020 Equity Incentive Plan, or the Morphimmune Plan, the aggregate number of shares that may be issued pursuant to stock awards under the Morphimmune Plan is 2,429,630 shares. Although we did not initially anticipate issuing awards under the Morphimmune Plan, depending on our needs, we may in the future issue awards under the Morphimmune Plan.

We are an “emerging growth company” and our election of reduced reporting requirements applicable to emerging growth companies may make our common stock less attractive to investors.

We are an “emerging growth company” as defined in the Jumpstart Our Business Startups Act, or JOBS Act. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, or Section 404, reduced disclosure obligations regarding executive compensation in this ~~Quarterly~~Annual Report and our periodic reports and proxy statements and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. In addition, as an emerging growth company, we are only required to provide two years of audited financial statements and two years of selected financial data in this ~~Quarterly~~Annual Report. We could be an emerging growth company for up to five years following the completion of our initial public offering, although circumstances could cause us to lose that status earlier, including if we are deemed to be a “large accelerated filer,” which occurs when the market value of our common stock that is held by non-affiliates exceeds $700 million as of the prior June 30, or if we have total annual gross revenue of $1.235 billion or more during any fiscal year before that time, in which cases we would no longer be an emerging growth company as of the following December 31, or if we issue more than $1.0 billion in non-convertible debt during any three-year period before that time, in which case we would no longer be an emerging growth company immediately. Even after we no longer qualify as an emerging growth company, we could still qualify as a “smaller reporting company,” which would allow us to take advantage of many of the same exemptions from disclosure requirements including not being required to comply with the auditor attestation requirements of Section 404 and reduced disclosure obligations regarding executive compensation in this ~~Quarterly~~Annual Report and our other periodic reports and proxy statements. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our share price may be more volatile.

89Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have elected to avail ourselves of an exemption that allows us to delay adopting new or revised accounting standards until such time as those standards apply to private companies. As a result, we will not be subject to the same new or revised accounting standards as other public companies that comply with the public company effective dates, including but not limited to the new lease accounting standard. We have also elected to take advantage of certain of the reduced disclosure obligations in this Annual Report and may elect to take advantage of other reduced reporting requirements in future filings. As a result of these elections, the information that we provide to our stockholders may be different than you might receive from other public reporting companies. However, if we later decide to opt out of the extended period for adopting new accounting standards, we would need to disclose such decision and it would be irrevocable.

Table of Contents

~~Under~~Our ~~the~~ability ~~JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply~~ to ~~private~~use ~~companies.~~net Weoperating ~~have~~loss ~~elected~~carryforwards to avail ourselves of an exemption that allows us to delay adopting new or revised accounting standards until such time as those standards apply to private companies. As a result, we will not be subject to the same new or revised accounting standards as other public companies that comply with the public company effective dates, including but not limited to the new lease accounting standard. We have also elected to take advantage of certain of the reduced disclosure obligations in this Quarterly Report and ~~may elect to take advantage of~~ other ~~reduced~~tax ~~reporting~~attributes ~~requirements in future filings. As a result of these elections, the information that we provide to our stockholders~~ may be ~~different than you might receive from other public reporting companies~~limited. ~~However, if we later decide to opt out of the extended period for adopting new accounting standards, we would need to disclose such decision and it would be irrevocable.~~

~~Our~~We ~~ability~~have incurred losses during our history, and we do not expect to ~~use~~become profitable in the near future and may never achieve profitability. To the extent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income, if any, until such unused losses expire, if at all. Under current law, U.S. federal net operating loss, or NOL, carryforwards generated in taxable periods beginning after December 31, 2017, may be carried forward indefinitely, but the deductibility of such NOL carryforwards in a taxable year is limited to 80% of taxable income in such year. In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, federal NOL carryforwards and other tax attributes may become subject to an annual limitation in the event of certain cumulative changes in ownership. An “ownership change” pursuant to Section 382 of the Code generally occurs if one or more stockholders or groups of stockholders who own at least 5% of a company’s stock increase their ownership by more than 50 percentage points over their lowest ownership percentage within a rolling three-year period. Our ability to utilize our NOL carryforwards and other tax attributes to offset future taxable income or tax liabilities may be limited as a result of ownership changes, including changes in connection with the Merger and potential changes due to other transactions.* Similar rules may apply under state tax laws. In addition, there may be other limitations under state law on our ability to utilize NOLs, including temporary suspensions or other limitations on the use of NOLs to offset taxable income. If we earn taxable income, such limitations could result in increased future income tax liability to us, and our future cash flows could be adversely affected.

We have incurred losses during our history, and we do not expect to become profitable in the near future and may never achieve profitability. To the extent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income, if any, until such unused losses expire, if at all. Under current law, U.S. federal net operating loss, or NOL, carryforwards generated in taxable periods beginning after December 31, 2017, may be carried forward indefinitely, but the deductibility of such NOL carryforwards is limited to 80% of taxable income. In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, federal NOL carryforwards and other tax attributes may become subject to an annual limitation in the event of certain cumulative changes in ownership. An “ownership change” pursuant to Section 382 of the Code generally occurs if one or more stockholders or groups of stockholders who own at least 5% of a company’s stock increase their ownership by more than 50 percentage points over their lowest ownership percentage within a rolling three-year period. Our ability to utilize our NOL carryforwards and other tax attributes to offset future taxable income or tax liabilities may be limited as a result of ownership changes, including changes in connection with the Merger and potential changes due to other transactions. Similar rules may apply under state tax laws. In addition, there may be other limitations under state law on our ability to utilize NOLs, including temporary suspensions or other limitations on the use of NOLs to offset taxable income. If we earn taxable income, such limitations could result in increased future income tax liability to us, and our future cash flows could be adversely affected.

Capital appreciation, if any, will be a stockholder’s sole source of gain.

We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. As a result, capital appreciation, if any, of our common stock will be our stockholder’s sole source of gain for the foreseeable future.

Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.

Provisions in our amended and restated certificate of incorporation and our amended and restated bylaws may delay or prevent an acquisition of our company or a change in our management. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Because our board of directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team. These provisions include:

●

a prohibition on actions by our stockholders by written consent;

●

a requirement that special meetings of stockholders, which our company is not obligated to call more than once per calendar year, be called only by the chairman of our board of directors, our chief executive officer, or our board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors;

●

advance notice requirements for election to our board of directors and for proposing matters that can be acted upon at stockholder meetings;

Table of Contents

●

division of our board of directors into three classes, serving staggered terms of three years each; and

●

the authority of the board of directors to issue preferred stock with such terms as the board of directors may determine.

Table of Contents

Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, as amended, or the DGCL, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. These provisions would apply even if the proposed merger or acquisition could be considered beneficial by some stockholders.

Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware and the federal district courts of the United States will be the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.

Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: (i) any derivative action or proceeding brought on our behalf; (ii) any action asserting a claim of breach of a fiduciary duty; (iii) any action or proceeding asserting a claim against us or any of our current or former directors, officers or other employees, arising out of or pursuant to any provision of the DGCL, our amended and restated certificate of incorporation or our amended and restated bylaws; and (iv) any action asserting a claim against us or any of our directors, officers or other employees, governed by the internal affairs doctrine; provided, that, this provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act, or any other claim for which the federal courts have exclusive jurisdiction.

Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated certificate of incorporation further provides that the federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act.

These exclusive-forum provisions may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees and may discourage these types of lawsuits against us and our directors, officers, and other employees. While the Delaware courts have determined that such choice of forum provisions are facially valid, and several state trial courts have enforced such provisions and required that suits asserting Securities Act claims be filed in federal court, there is no guarantee that courts of appeal will affirm the enforceability of such provisions and a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instances, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions. If a court were to find either exclusive forum provision in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with litigating Securities Act claims in state court, both state and federal court, or other jurisdictions which could seriously harm our business, financial condition, results of operations, and prospects.

Table of Contents

We could be subject to securities class action litigation or stockholder derivative litigation.

Securities litigation or stockholder derivative litigation frequently follows the announcement of certain significant business transactions, such as the sale of a business division or announcement of a business combination transaction. Additionally, in the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because pharmaceutical companies have experienced significant stock price volatility in recent years. If we face any litigation, it could result in substantial costs and a diversion of management’s attention and resources, which could harm our business.

Table of Contents

General Risk Factors

Unfavorable global economic and political conditions, including tariffs and trade barriers, could adversely affect our business, financial condition or results of operations.*

The results of our operations could be adversely affected by general conditions in the global economy, the global financial markets and the global political conditions. The United States and global economies are facing ~~growing~~ inflation, higher interest rates and potential recession. Furthermore, uncertainties associated with a severe or prolonged economic downturn, recessions or depressions, or political disruption such as potential trade wars, tariffs or the war between Ukraine and Russia and the conflicts in the Middle East, and other macroeconomic developments could result in a variety of risks to our business, including weakened demand for our ~~development~~product candidates, if approved, relationships with any vendors or business partners located in affected geographies and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy or political disruption, including any international trade disputes, could also strain our manufacturers or suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our potential products, if approved. Any of the foregoing could seriously harm our business, and we cannot anticipate all of the ways in which the political or economic climate and financial market conditions could seriously harm our business.

In particular, we utilize third-party suppliers and vendors in several countries outside of the United States for various aspects of our business, including research and manufacturing activities, and those third parties may do the same in their performance of their work for us. Accordingly, there is inherent risk, based on the complex relationships among the U.S. and certain of these countries, that political, diplomatic, and national security factors can lead to global trade restrictions and changes in trade policies and export regulations. Additionally, the current international trade and regulatory environment is subject to significant ongoing uncertainty. For example, the U.S. government has recently announced substantial new tariffs affecting a wide range of products and jurisdictions and has indicated an intention to continue developing new trade policies, including with respect to the pharmaceutical industry. In response, certain foreign governments have announced or implemented retaliatory tariffs and other protectionist measures. Current or future tariffs could complicate or disrupt our existing and future supply chain and may result in increased research and development expenses. Trade restrictions affecting the import of necessary materials could result increased costs to us or cause delays in our research and development timelines, thereby placing us at a competitive disadvantage as compared to companies operating in regions with more favorable trade relationships or with more resources than ours or those of our vendors. In addition, as we advance toward future commercialization, tariffs and trade restrictions could hinder our ability to establish cost-effective production capabilities and vendor relationships. All of these developments have created a dynamic and unpredictable landscape, which may adversely impact our business, results of operations, financial condition and prospects.

In addition, actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. Furthermore, concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult to acquire financing on acceptable terms or at all. Any decline in available funding or access to cash and liquidity resources could, among other risks, adversely impact our and our vendors’, collaborators’ and other business relations’ ability to meet operating expenses, financial obligations or fulfill other obligations, potentially resulting in breaches of financial and/or contractual obligations and/or result in violations of federal or state wage and hour laws. Any of these impacts could have material adverse impacts on our business operations, financial condition and results of operations.

~~Future changes in financial accounting standards or practices may cause adverse and unexpected revenue fluctuations and adversely affect our reported results of operations.~~ 86

Future changes in financial accounting standards may cause adverse, unexpected revenue fluctuations and affect our reported financial position or results of operations. Financial accounting standards in the United States are constantly under review and new pronouncements and varying interpretations of pronouncements have occurred with frequency in the past and are expected to occur again in the future. As a result, we may be required to make changes in our accounting policies. Those changes could affect our financial condition and results of operations or the way in which such financial condition and results of operations are reported. We intend to invest resources to comply with evolving standards, and this investment may result in increased general and administrative expenses and a diversion of management time and attention from business activities to compliance activities. See the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Part II of this Quarterly Report.

Table of Contents

~~Changes~~Future changes in ~~tax~~financial ~~laws~~accounting orstandards ~~regulations that are applied adversely to us~~ or ~~our~~practices ~~customers~~ may ~~have~~cause ~~a material~~ adverse ~~effect~~and onunexpected ~~our~~revenue ~~business,~~fluctuations ~~cash~~and ~~flow,~~adversely ~~financial~~affect ~~condition~~our orreported results of operations. *

~~New~~Future ~~income,~~changes ~~sales,~~in ~~use~~financial oraccounting ~~other~~standards ~~tax~~may ~~laws,~~cause ~~statutes~~adverse, ~~rules,~~unexpected ~~regulations~~revenue orfluctuations ~~ordinances~~and ~~could be enacted at any time, which could adversely~~ affect our ~~business~~reported ~~operations and~~ financial ~~performance.~~position ~~Further, existing tax laws, statutes, rules, regulations~~ or ~~ordinances~~results ~~could~~of ~~be interpreted, changed, modified or applied adversely to us~~operations. ~~For~~Financial ~~example,~~accounting ~~legislation~~standards ~~informally~~in ~~titled~~ the ~~Tax~~United ~~Cuts~~States ~~and~~are ~~Jobs~~constantly ~~Act;~~under ~~the~~review ~~Coronavirus Aid, Relief,~~ and ~~Economic~~new ~~Security~~pronouncements ~~Act;~~ and ~~the~~varying ~~Inflation~~interpretations ~~Reduction~~of ~~Act~~pronouncements ~~enacted~~have ~~many~~occurred ~~significant~~with ~~changes~~frequency toin the ~~U.S.~~past ~~tax laws. Future guidance from the Internal Revenue Service~~ and ~~other~~are ~~tax~~expected ~~authorities~~to ~~with~~occur ~~respect~~again toin ~~such~~the ~~legislation~~future. ~~may~~As ~~affect~~a usresult, ~~and~~we ~~certain~~may ~~aspects of such legislation could~~ be ~~repealed~~required orto ~~modified~~make changes in ~~future~~our ~~legislation.~~accounting ~~The Biden administration and the U~~policies.S. ~~Congress~~Those ~~could also enact other tax law~~ changes ~~that~~ could ~~have~~affect ~~an adverse effect on~~ our ~~operations,~~financial ~~cash~~condition ~~flows~~ and results ~~from~~of operations ~~and~~or ~~contribute~~the toway ~~overall~~in ~~market~~which ~~volatility.~~such Infinancial ~~addition,~~condition ~~it is uncertain if~~ and toresults ~~what~~of ~~extent~~operations ~~various~~are ~~states~~reported. ~~will~~We ~~conform~~intend to ~~federal~~invest ~~tax~~resources ~~legislation.~~to ~~Changes~~comply inwith ~~corporate~~evolving ~~tax rates~~standards, ~~the~~and ~~realization~~this ofinvestment ~~net~~may ~~deferred~~result ~~tax~~in ~~assets~~increased ~~relating~~general toand ~~our~~administrative ~~operations,~~expenses ~~the~~and ~~taxation~~a diversion of ~~foreign~~management ~~earnings,~~time and ~~the~~attention ~~deductibility~~from ofbusiness ~~expenses~~activities ~~could~~to ~~have~~compliance aactivities. ~~material~~See ~~impact on~~ the ~~value~~section oftitled ~~our~~“Management’s ~~deferred~~Discussion ~~tax~~and ~~assets,~~Analysis ~~could~~of ~~result~~Financial inCondition ~~significant~~and ~~one-time~~Results ~~charges,~~of ~~and~~Operations” ~~could~~in ~~increase~~Part ~~our~~I ~~future~~of ~~U.S.~~this ~~tax~~Quarterly ~~expense~~Report.

IfChanges wein ~~unable~~tax tolaws ~~maintain~~or anregulations ~~effective~~that ~~system~~are ofapplied ~~disclosure~~adversely ~~controls~~to ~~and~~us ~~internal~~or ~~control~~our ~~over~~vendors ~~financial~~or ~~reporting,~~collaborators ~~our~~may ~~ability~~have toa ~~produce~~material ~~timely~~adverse ~~and~~effect ~~accurate~~on ~~financial~~our ~~statements~~business, orcash ~~comply~~flow, ~~with~~financial ~~applicable~~condition ~~regulations~~or ~~could~~results beof ~~impaired~~operations.

New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect our business operations and financial performance. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. For example, legislation informally titled the Tax Cuts and Jobs Act; the Coronavirus Aid, Relief, and Economic Security Act; and the Inflation Reduction Act enacted many significant changes to the U.S. tax laws. Future guidance from the Internal Revenue Service and other tax authorities with respect to such legislation may affect us, and certain aspects of such legislation could be repealed or modified in future legislation. The Trump administration and the U.S. Congress could also enact other tax law changes that could have an adverse effect on our operations, cash flows and results from operations and contribute to overall market volatility. In addition, it is uncertain if and to what extent various states will conform to federal tax legislation. Changes in corporate tax rates, the realization of net deferred tax assets relating to our operations, the taxation of foreign earnings, and the deductibility of expenses could have a material impact on the value of our deferred tax assets, could result in significant one-time charges, and could increase our future U.S. tax expense.

If we are unable to maintain an effective system of disclosure controls and internal control over financial reporting, our ability to produce timely and accurate financial statements or comply with applicable regulations could be impaired.

As a public company, we are subject to requirements of the Sarbanes-Oxley Act, the regulations of The Nasdaq Capital Market, the rules and regulations of the SEC, expanded disclosure requirements, accelerated reporting requirements and more complex accounting rules. Company responsibilities required by the Sarbanes-Oxley Act include, among other things, that we maintain corporate oversight and adequate internal control over financial reporting and disclosure controls and procedures. This will require that we incur substantial professional fees and internal costs to expand our accounting and finance functions and that we expend significant management efforts. We may experience difficulty in meeting these reporting requirements in a timely manner.

Our current controls and any new controls that we develop may become inadequate because of changes in conditions in our business. Further, weaknesses in our disclosure controls and internal control over financial reporting may be discovered in the future. Any failure to develop or maintain effective controls or any difficulties encountered in their implementation or improvement could harm our results of operations or cause us to fail to meet our reporting obligations and may result in a restatement of our consolidated financial statements for prior periods. Any failure to implement and maintain effective internal control over financial reporting could also adversely affect the results of periodic management evaluations and annual independent registered public accounting firm attestation reports regarding the effectiveness of our internal control over financial reporting that we will eventually be required to include in our periodic reports that will be filed with the SEC. Ineffective disclosure controls and procedures and internal control over financial reporting could also cause investors to lose confidence in our reported financial and other information, which would likely have a negative effect on the trading price of our common stock. In addition, if we are unable to continue to meet these requirements, we may not be able to remain listed on The Nasdaq Capital Market.

If we cannot provide reliable financial reports or prevent fraud, our business and results of operations could be harmed, investors could lose confidence in our reported financial information and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. Any failure to maintain effective disclosure controls and internal control over financial reporting could have a material and adverse effect on our business, results of operations and financial condition and could cause a decline in the trading price of our common stock.87

Table of Contents

Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.

We are subject to certain reporting requirements of the Exchange Act. Our disclosure controls and procedures are designed to reasonably assure that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to management, recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements or insufficient disclosures due to error or fraud may occur and not be detected.

We incur significant costs as a result of operating as a public company, and our management is required to devote substantial time to public company reporting and compliance initiatives.

As a public company listed on The Nasdaq Capital Market, we incur significant expenses for director and officer insurance, legal services, accounting services and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act, as well as rules subsequently implemented by the SEC, and The Nasdaq Capital Market have imposed various requirements on public companies. In July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, was enacted. There are significant corporate governance and executive compensation related provisions in the Dodd-Frank Act that required the SEC to adopt rules and regulations in these areas such as “say on pay” and proxy access. Recent legislation permits smaller “emerging growth companies” to implement many of these requirements over a longer period and up to five years from the pricing of our initial public offering. We intend to continue to take advantage of this legislation but cannot guarantee that we will not be required to implement these requirements sooner than budgeted or planned and thereby incur unexpected expenses. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations increase our legal and financial compliance costs and make some activities more time-consuming and costlier. For example, these rules and regulations make it more difficult and more expensive for us to obtain director and officer liability insurance and we are required to incur substantial costs to maintain our current levels of such coverage.

If securities or industry analysts publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.

The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. If only very few securities analysts commence coverage of us, or if industry analysts cease coverage of us, the trading price for our common stock would be negatively affected. If one or more of the analysts who cover us downgrade our common stock or publish inaccurate or unfavorable research about our business, our common stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, demand for our common stock could decrease, which might cause our common stock price and trading volume to decline.

9488

Table of Contents

If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected. *

Our research, development and manufacturing involve the use of hazardous and radioactive materials and various flammable and toxic chemicals. We are subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous and radioactive materials and waste products. Although we believe our procedures for storing, handling and disposing of these materials in our facilities comply with the relevant guidelines of the ~~Commonwealth of Pennsylvania, the~~ State of Washington and the Occupational Safety and Health Administration of the U.S. Department of Labor, the risk of accidental contamination or injury from these materials cannot be eliminated. If an accident occurs, we could be held liable for substantial resulting damages. We are also subject to numerous environmental, health and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and the handling of animals and biohazardous materials. Our workers’ compensation insurance may not provide adequate coverage against costs and expenses we may incur due to injuries to our employees resulting from the use of these materials. Our current environmental liability insurance covering certain of our facilities could be inadequate for all environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials and waste products. Additional federal, state and local laws and regulations affecting our operations may be adopted in the future. We may incur substantial costs to comply with, and substantial fines or penalties if we violate, any of these laws or regulations.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

OnIssuer ~~August 7,~~Purchases 2024, in connection with entering into the BMS License Agreement Amendment, we entered into a stock issuance agreement, or the BMS Stock Issuance Agreement, pursuant to which we issued BMS 230,415 shares of ~~our~~Equity ~~common stock as consideration for entering into the BMS License Agreement Amendment. The BMS License Agreement Amendment amends the BMS License Agreement.~~Securities

Pursuant to the BMS Stock Issuance Agreement, we filed a resale registration statement with the SEC on October 8, 2024, registering the shares issued to BMS for resale. Subject to complying with applicable securities laws, BMS is not subject to any restrictions with respect to the disposition of the shares. Additionally, BMS is not subject to any standstill restrictions.


	(a)	(b)
	Total number	Average price
	of shares (or units)	paid per share
Period	purchased	(or unit)
January 1, 2025 - January 31, 2025	—	$	—
February 1, 2025 - February 28, 2025	—		—
March 1, 2025 - March 31, 2025⁽¹⁾	19,093		9.22
Total	19,093	$	9.22

(1) The ~~securities~~number ~~issued~~of toshares ~~BMS~~reported ~~were~~reflects ~~sold~~a deemed surrender of shares in ~~reliance~~connection onwith ~~the~~a ~~exemption~~stock ~~from~~swap ~~registration~~transaction ~~requirements~~to ofcover the ~~Securities~~exercise ~~Act~~price ~~provided~~of byemployee ~~Section 4(a)(2) of~~stock ~~the~~options. ~~Securities~~The ~~Act~~deemed ~~and/or~~price ~~Regulation~~paid Dwas ~~promulgated~~the ~~thereunder~~closing asprice aof ~~transaction~~our bycommon anstock ~~issuer~~on ~~not~~the ~~involving~~Nasdaq aCapital ~~public~~Market ~~offering~~on the date of exercise.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine and Safety Disclosures

Not applicable.

Item 5. Other Information

None.

Table of Contents

Item 6. Exhibits

EXHIBIT INDEX

Exhibit No.		Description of Exhibit
2.1		Asset Purchase Agreement, by and between Immunome, Inc. and Ayala Pharmaceuticals, Inc., dated February 5, 2024 (incorporated by reference to Exhibit 2.1 to our Current Report on Form 8-K filed on February 6, 2024).

2.2+†		Asset Purchase Agreement, by and among Immunome, Inc., Zentalis Pharmaceuticals, Inc. and Zeno Management, Inc., dated October 25, 2024 (incorporated by reference to Exhibit 2.1 to our Current Report on Form 8-K filed October 29, 2024).

3.1		Amended and Restated Certificate of Incorporation of Immunome, Inc. (incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K filed October 6, 2020).

3.2		Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Immunome, Inc., dated October 2, 2023, to implement Officer Exculpation (incorporated by reference to Exhibit 3.3 to our Current Report on Form 8-K filed October 4, 2023).

3.3		Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Immunome, Inc., dated October 2, 2023, to implement Authorized Share Increase (incorporated by reference to Exhibit 3.4 to our Current Report on Form 8-K filed October 4, 2023).

3.4		Amended and Restated Bylaws of Immunome, Inc. (incorporated by reference to Exhibit 3.2 to our Current Report on Form 8-K filed October 6, 2020).

4.1		Form of Common Stock Certificate (incorporated by reference to Exhibit 4.2 to our Registration Statement on Form S-1 filed September 24, 2020).
10.1#		Relocation Offer Letter dated January 20, 2025, by and between the Company and Max Rosett (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on January 23, 2025).

4.2		Form of Subscription Agreement, dated June 29, 2023 (Incorporated by reference to Exhibit 10.4 to our Current Report on Form 8-K filed on June 29, 2023).

4.3		Stock Issuance Agreement, dated January 5, 2024, by and between Immunome, Inc. and Zentalis Pharmaceuticals, Inc. (incorporated by reference to Exhibit 4.3 to our Registration Statement on Form S-3 filed with the SEC on February 13, 2024).

4.4		Stock Issuance Agreement, dated August 7, 2024, by and between Immunome, Inc. and Bristol-Myers Squibb Company (incorporated by reference to Exhibit 4.7 to our Registration Statement on Form S-3 filed with the SEC on October 8, 2024).

4.5		Stock Issuance Agreement, by and between the Company and Zentalis Pharmaceuticals, Inc., dated October 25, 2024 (incorporated by reference to Exhibit 4.1 to our Current Report on Form 8-K filed with the SEC on October 29, 2024).

10.1#		Immunome, Inc. 2024 Inducement Plan and Forms of Stock Option Grant Notice, Option Agreement and Notice of Exercise thereunder (incorporated by reference to Exhibit 99.1 to our Current Report on Form 8-K filed with the SEC on October 7, 2024).

10.2†*		Amendment No. 2 to License Agreement, dated August 7, 2024, by and between Immunome, Inc. and Bristol-Myers Squibb Company.

31.1*		Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2*		Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1*		Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2*		Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101		Interactive Data File (Form 10-Q for the Quarterly Period ended ~~September~~March 3031, ~~2024~~2025 filed in XBRL). The financial information contained in the XBRL-related documents is “unaudited” and “unreviewed.” The instance document does not appear in the interactive file because its XBRL tags are embedded within the Inline XBRL document.

104		Cover Page Interactive File (embedded within the Inline XBRL document).

*	Filed or furnished herewith.

# Management contracts or compensatory plans or arrangements.

+ Schedules and exhibits to the agreement have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the Securities and Exchange Commission upon request.

† Certain portions of this exhibit (indicated by asterisks) have been omitted because they are not material and would likely cause competitive harm to Immunome, Inc. if publicly disclosed.

9690

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	IMMUNOME, INC.
	(Registrant)
Date: November 13, 2024	By:	/s/ Clay B. Siegall, Ph. D.
Date: May 12, 2025	By:	/s/ Clay B. Siegall, Ph. D.
	Name:	Clay B. Siegall, Ph. D.
	Title:	President and Chief Executive Officer
		(Principal Executive Officer)
Date: November 13, 2024	By:	/s/ Max Rosett
Date: May 12, 2025	By:	/s/ Max Rosett
	Name:	Max Rosett
	Title:	Chief Financial Officer
		(Principal Financial and Accounting Officer)

9791

Filing Compare · Immunome Inc.